



Review

Neuronal Cytoskeleton in Intellectual Disability: From Systems Biology and Modeling to Therapeutic Opportunities

Carla Liaci ¹, Mattia Camera ¹, Giovanni Caslini ¹, Simona Rando ¹, Salvatore Contino ²,
Valentino Romano ³ and Giorgio R. Merlo ^{1,*}

¹ Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy; carla.liaci@unito.it (C.L.); mattia.camera230@edu.unito.it (M.C.); giovanni.caslini@edu.unito.it (G.C.); simona.rando@edu.unito.it (S.R.)

² Department of Engineering, University of Palermo, Viale delle Scienze Ed. 8, 90128 Palermo, Italy; salvatore.contino01@community.unipa.it

³ Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Viale delle Scienze Ed. 16, 90128 Palermo, Italy; valentino.romano@unipa.it

* Correspondence: giorgioroberto.merlo@unito.it; Tel.: +39-0116706449; Fax: +39-0116706432

Abstract: Intellectual disability (ID) is a pathological condition characterized by limited intellectual functioning and adaptive behaviors. It affects 1–3% of the worldwide population, and no pharmacological therapies are currently available. More than 1000 genes have been found mutated in ID patients pointing out that, despite the common phenotype, the genetic bases are highly heterogeneous and apparently unrelated. Bibliomic analysis reveals that ID genes converge onto a few biological modules, including cytoskeleton dynamics, whose regulation depends on Rho GTPases transduction. Genetic variants exert their effects at different levels in a hierarchical arrangement, starting from the molecular level and moving toward higher levels of organization, i.e., cell compartment and functions, circuits, cognition, and behavior. Thus, cytoskeleton alterations that have an impact on cell processes such as neuronal migration, neurogenesis, and synaptic plasticity rebound on the overall establishment of an effective network and consequently on the cognitive phenotype. Systems biology (SB) approaches are more focused on the overall interconnected network rather than on individual genes, thus encouraging the design of therapies that aim to correct common dysregulated biological processes. This review summarizes current knowledge about cytoskeleton control in neurons and its relevance for the ID pathogenesis, exploiting in silico modeling and translating the implications of those findings into biomedical research.



Citation: Liaci, C.; Camera, M.; Caslini, G.; Rando, S.; Contino, S.; Romano, V.; Merlo, G.R. Neuronal Cytoskeleton in Intellectual Disability: From Systems Biology and Modeling to Therapeutic Opportunities. *Int. J. Mol. Sci.* **2021**, *22*, 6167. <https://doi.org/10.3390/ijms22116167>

Academic Editor: Thomas Fath

Received: 5 May 2021

Accepted: 4 June 2021

Published: 7 June 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: actin cytoskeleton; microtubules; GTPase signaling; small Rho GTPases; intellectual disability; neuronal networks; systems biology; Boolean modeling; protein:protein interaction network; pharmacological modulation

1. Introduction

ID is a heterogeneous group of neurodevelopmental disorders (NDDs), usually diagnosed before the age of 18, characterized by significant limitations in both intellectual functioning (IQ < 70) and adaptive behavior as expressed in conceptual, social, and practical adaptive skills [1]. It affects 1–3% of the worldwide population, depending on the inclusion criteria, with a higher prevalence among males [2–5]. Because of its high frequency, limited treatability, and required lifelong care, ID has a dramatic social and economic impact.

ID is manifested as both syndromic and non-syndromic forms, depending on whether the disability is associated with other symptoms, and it is clinically classified referring to severity (mild, moderate, and severe) and penetrance (partially to fully penetrant) [1]. A phenotype-based cluster analysis was made by Kochinke et al., establishing gene-phenotype relationships and revealing compromised molecular processes that underlie specific ID subgroups. For example, genes involved in growth factor signaling pathways,

such as the MAPK pathway, are enriched in comorbidities such as short stature and ectodermal anomalies as compared to all other ID-associated genes. Epilepsy, metabolic dysfunctions, and myopathy are instead co-occurring within a cluster of genes enriched with mitochondrial function. Microcephaly and behavioral abnormalities were linked to two clusters comprising genes enriched with chromatin-related functions.

ID mutations can be autosomal–recessive, autosomal–dominant (mostly de novo), or X-linked. The latter two are responsible for the higher prevalence of ID in males versus females.

The causes of ID are heterogeneous and still to be completely defined: it has been estimated that half of all cases are due to environmental factors such as intrauterine/neonatal insults (preterm-birth complications, intrapartum-related factors such as hypoxic-ischemic encephalopathy, and infections like meningitis and neonatal tetanus) and postnatal risk factors such as severe malnutrition during infancy. The other half of the cases are associated with genetic variants, highly heterogeneous, and only partially identified. According to the SysID database [1], 1454 ID genes (excluding 1224 annotated as low-confidence ID genes) have been identified, some of which code for proteins involved in the Rho GTPases signaling pathway, such as *OPHN1* (oligophrenin 1), *ARHGEF9* (Cdc42 guanine nucleotide exchange factor 9), *FGD1* (FYVE, RhoGEF, and PH domain-containing 1), *RAC1* (Rac family small GTPase 1), and *PAK3* (P21-activated kinase 3).

Based on a wealth of experimental data from animal models and cultured neurons, it is widely accepted that cognitive deficits in ID patients are linked to altered neuronal networking, impaired synaptic plasticity, and excitation/inhibition unbalance in the cerebral cortex and hippocampus, resulting in abnormal information processing [6–11].

2. From Genetics to Core Regulatory Modules

As genome-sequencing technologies improve and become accessible, more ID-causing mutations will surely be identified in patients. However, our mechanistic understanding of ID pathophysiology continues to lag behind the pace of gene discovery.

Considering the elevated number of risk genes and their heterogeneity, it is unlikely that each identified mutation represents an independent pathway that, when misregulated, causes a similar cognitive phenotype. On the contrary, it can be assumed that the identified mutations may converge to, or participate in, a limited number of core regulatory intracellular modules that are beginning to be identified, although they are not yet fully characterized. The dysfunction of different genes impacting the same process will result in analogous dysfunctions of the process itself. Thus, multiple genetic causes converge on a few common cellular outcomes and result in one overall phenotype. For this reason, an integrated approach that collects a large set of data but focuses on single biological processes is more suitable for furthering genetic diagnostics and developing treatment strategies to target shared pathways rather than single genes.

Three key questions arise: (i) What are the common core regulatory mechanisms dysregulated in ID? (ii) What are the key proteins (hubs; in gene network theory, hubs are defined as nodes with a high number of edges compared with other nodes) and/or posttranslational modifications at the basis of the cell endophenotype resulting in ID? (iii) Do we have adequate tools to identify and study such hubs and biological processes?

Integrative methods and data meta-analyses, protein::protein interaction (PPI) networks, and transcriptomics analysis coupled with gene ontology (GO) [12,13] have been successfully used to answer these questions, a general approach also known as SB. To reorganize the wealth of mutational data into biologically coherent modules, Kochinke et al. characterized the functional coherence and connectivity of a set of high-confidence ID genes using GO-based annotations and PPI databases. Eighty-six percent of these genes were found to be associated with at least one of 32 GO annotations, with the higher fold enrichment detected for transcription and chromatin regulation, metabolism, WNT, Hedgehog, MTOR, and MAPK signaling pathways, synaptic functioning, ubiquitination, cytoskeleton, and small GTPase signaling. Most ID proteins were also found to be co-expressed,

especially in the hippocampus, and to physically interact with each other. Similarly, Liu et al. [14] organized 63 prioritized high-confidence ID genes based on biological annotations and PPI networks, showing that they tightly converge onto two cellular mechanisms: chromatin modification/transcriptional regulation and synaptic function. Moreover, co-expression networks revealed that the same genes are enriched in the cortex from the early fetal to late mid-fetal stages.

A second approach used RNA-seq data derived from the blood of patients harboring mutations in the ID genes *CCNT2* (cyclin T2), *CDK9* (cyclin-dependent kinase 9), and *TAF2* (TATA-box binding protein associated factor 2), all encoding for transcription factors [15]. Differentially expressed genes were functionally enriched in the GO classes cytoskeleton dynamics, GTPase activity, axonogenesis, synaptic plasticity, neuronal differentiation, and chromatin regulation.

A third approach adopted a systematic analysis by building a highly stringent PPI network from genes previously related to ID and global developmental delay (GDD) in the Human Phenotype Ontology database [16]. This analysis identified six genes defined as hubs and 166 brain-expressed proteins that have not been previously associated with ID and GDD. The six hubs included *CDC42* (cell division cycle 42) and *RAC1*, two known cytoskeleton regulators, *APP* (amyloid β precursor protein), involved in proliferation, cell-cell adhesion, migration, and synaptogenesis, *EP300* (E1A binding protein p300), important for genomic stability through chromatin regulation, *TP53* (tumor protein p53), and *GNB1* (G protein subunit β 1).

Overall, the SB approaches reported above identified the following wide biological processes on which ID genes converge (Figure 1A).

2.1. Chromatin Modification and Transcriptional Regulation

Many chromatin-modifying enzymes and other epigenetic regulators have been genetically associated with ID and other syndromes in which ID is one of the major clinical outcomes [17,18]. A catalog of 519 ID genes was enriched 2.7-fold in the GO terms chromatin binding, chromatin remodeling, and chromatin modification [1]. Mutations in *EHMT1* (euchromatic histone lysine methyltransferase 1) and SWI/SNF chromatin remodeling complex were shown to have a role in Kleefstra syndrome and Coffin–Siris syndrome [19,20], respectively; mutations in *KDM5C* (lysine demethylase 5C), encoding an eraser enzyme for di-methylated and tri-methylated histone H3 lysine 4, account for 2% of X-linked ID (XLID) [21]; mutations in *DDX3X* (DEAD-box helicase 3 X-linked), coding for an RNA helicase involved in post-transcriptional modifications, were found to be relevant in ID because of its fundamental role in neurite outgrowth and dendritic spine formation via modulation of *RAC1* transcription [22]. Interestingly, analysis of co-expression networks and genetic structural variants suggested a role for long non-coding RNAs in ID [23].

2.2. Signal Transduction

WNT, MTOR, and MAPK signaling pathways have been shown to play a central role in brain development. Perturbations of these pathways have been implicated in multiple neuropsychiatric disorders, including autism spectrum disorder (ASD) and ID [23–25]. Mutations in elements of the MTOR signaling pathway can affect the synaptic transmission and dendritic spine density, as shown by mutation of *EIF4E* (eukaryotic translation initiation factor 4E), a regulator of MTOR (mechanistic target of rapamycin kinase) translation [26], while loss-of-function (LOF) of upstream components of the MTOR pathway like *PTEN* (phosphatase and tensin homolog) and *TSC1/2* (TSC complex subunit 1 and 2, also known as tuberous sclerosis 1 and 2) results in overactive MTOR signaling, causing dendritic and axonal overgrowth, neuronal hypertrophy, and ASD-like behavioral patterns [27,28]. Similarly, mutations in WNT pathway components, like *CTNNB1* (catenin β 1) and *CHD8* (chromodomain helicase DNA binding protein 8), are associated with ID, as *CTNNB1* is involved in synaptic function and its mutations are associated with deficits in intra-hemispheric connections, dendritic branching, long-term potentiation (LTP), and cognitive

functions [29]. MAPK pathway dysregulation has been implicated in several syndromic ID forms. For instance, mutations in *BRAF* (B-Raf proto-oncogene, serine/threonine kinase), *MAP2K1* (mitogen-activated protein kinase kinase 1, alias *MEK1*), *MAP2K2* (alias *MEK2*), and *KRAS* (*KRAS* proto-oncogene, GTPase) are associated with cardio-facio-cutaneous syndrome, in which ID is present in the majority of patients [30]. The constitutively active *KRAS*^{12V} expressed in both forebrain excitatory and inhibitory neurons cause decreased excitatory transmission, accompanied by reduced hippocampal LTP [31].

2.3. Ubiquitination System

Mutations in several ubiquitination system genes have been linked to ID. Gain and LOF mutations in *UBE3A* (ubiquitin protein ligase E3A) have been associated with increased risk of ASD and ID through dysregulation of WNT and MTOR pathways [32,33]; the X-linked E3 ubiquitin ligase *HUWE1* (HECT, UBA, and WWE domain containing E3 ubiquitin protein ligase 1), which regulates both CTNNB1 and EIF4E, was associated to ID and ASD [34,35]; *CUL4B* (cullin 4B) LOF mutations [36] cause defects in dendritic spines, affecting their morphogenesis and plasticity in the hippocampus via the accumulation of its target TSC1/2, and through the subsequent overactivation of the MTOR pathway [37].

2.4. Metabolism

The contribution of metabolic dysregulations to ID is highly dependent on the period in which the defect becomes relevant (prenatal, early or late infancy, adolescence). For example, alterations in oxidative phosphorylation during the prenatal period lead to abnormalities in brain formation [38]. Creatine deficiencies, like the one caused by *SLC6A8* (solute carrier family 6 member 8, alias *SLC6A*) mutations, cause a mild to moderate ID phenotype [39]. A mutation prevalence study in 288 male patients presenting mild to severe XLID found that 2.1% of them carried a *SLC6A8* pathogenic mutation [40]. Disorders of glycine, serine, and biogenic amine metabolism may produce severe mental and motor disturbances, having a connection with the molecular process of synaptic function [38], as seen in the succinic semialdehyde dehydrogenase deficiency, which causes γ -hydroxybutyric aciduria and disorder of GABA metabolism [41]. Finally, the excess or unavailability of substrates (urea cycle disorders, organic acidurias) can cause a varying severity of the ID phenotype [42].

2.5. Synaptic Function

Synaptic signaling pathways, such as the Rab and Arf pathways, are commonly altered in ID. Genome-wide weighted co-expression network analysis showed specific enrichment for synaptic functioning [14]. Mutations in genes coding for the GDI1 (Rab GDP dissociation inhibitor 1) regulator are known to be involved in ID [43]. The lack of GDI1 impairs synaptic vesicles' biogenesis and recycling in the hippocampus by defective endosomal-dependent recycling, leading to alterations in short-term plasticity [44]. Numerous genetic studies have shown that de novo missense variants of *CACNA1A* (calcium voltage-gated channel subunit α 1 A), coding the α -1A subunit of the P/Q-type voltage-dependent calcium channel, cause congenital ataxia and ID [45,46]. De novo mutations of SYNGAP1 (synaptic Ras GTPase activating protein 1) are found in non-syndromic ID patients [47]. In 2019, more than 50 individuals with SYNGAP1-related forms of ID showing behavioral abnormalities, including generalized epilepsy and ASD, have been reported [48]. Notably, most mutations affecting synaptic functioning are linked with the cytoskeleton regulation, in particular that of actin, required for the optimal trafficking of neurotransmitter vesicles (presynaptically) and receptor turnover (postsynaptically) [49,50].

2.6. Cytoskeleton Dynamics and Rho GTPases Signaling

The altered control of cytoskeleton dynamics within developing neurons is a core dysfunction in ID as well as in Down syndrome (DS), Rett syndrome, Fragile X syndrome (FXS), and ASD. *CDC42* and *WASP*, known regulators of actin filament polymerization and

branching, have been identified as hubs in PPI networks based on differentially expressed genes in DS [51]. Schizophrenia patients showed reduced actin polymerization in the brain, justifying the altered dendritic spine morphology and the reduced spine density [52].

Imbalance of actin cytoskeleton regulation has also been reported in FXS, a condition caused by an LOF mutation in FMR1 (FMRP translational regulator 1, also known as fragile mental retardation 1) [53]. Transcriptomic analysis on animal models of Rett syndrome revealed dysregulation of genes associated with cytoskeleton dynamics, actin polymerization, and focal adhesion [54]. Recent evidence suggests that dysfunction of Rho GTPases signaling contributes substantially to the pathogenesis of ASD: twenty genes encoding Rho GTPases regulators and effectors have been listed as ASD risk genes, representing 2.4% of the total [55]. Studies on the regulation of actin cytoskeleton dynamics in stem cells from ASD patients revealed altered dynamics of filament reconstruction upon activation of the Rho GTPases RAC1, CDC42, or RHOA (ras homolog family member A), showing shorter and less arborized neurites [56]. Expression and phosphorylation of cytoskeleton components were determined in the prefrontal cortex, hippocampus, and cerebellum of autistic-like C58/J mice. They revealed a region-dependent altered expression and phosphorylation patterns of Tau isoforms, associated with anomalous microtubule depolymerization and region-dependent changes in ADF/cofilin expression and phosphorylation associated, in turn, with abnormal actin filament depolymerizing dynamics [57].

Overall, strong evidence indicates that cytoskeleton dynamics is affected by mutations detected in ID (Figure 1B) and other NDDs; in this review, we focus on cytoskeleton regulation in physiological conditions and its dysregulation in the ID context.

A




Figure 1. Cont.

B




Figure 1. Core regulations in intellectual disability. (A). Deregulated biological processes identified in ID. The scheme illustrates the main intracellular processes identified via integrated analyses and their subcellular localization within hypothetical excitatory (in purple) and inhibitory (in blue) neurons. For each process, a few representative ID genes are reported. (B). GO terms [12,13] enrichment for ID-associated genes. The terms reported referring to biological processes linked to cytoskeleton activity and regulation. Four databases provided the list of ID-associated genes: HPO (Human Phenotype Ontology, in blue) [58], GEISINGER (in red) [59], OMIM (Online Mendelian Inheritance in Man, in green) [60], and SysID (in orange) [1]. *, **, and *** indicate $p < 0.05$, < 0.01 , and < 0.001 respectively. n.s., not significant.

3. Cytoskeleton Functions in Neuronal Development

During development, neurons migrate to find synaptic partners and establish the complexity of the neuronal wiring. Neurite extension and navigation are possible thanks to the formation of the growth cone, a sensory-motile structure at the tip of the growing axon directed by chemotaxis [61]. The structure of the growth cone is characterized by a dynamic periphery, in which actin filaments extend and retract to explore the surrounding environment, and by a more stable center that forms the axonal shaft [62]. The interplay between microtubule assembly and actin dynamics is then essential for axonal elongation. The polarity of microtubules, essential for the directional transport of proteins and organelles [63], allows the sliding movement that supports axon formation, as tubulin monomers are continuously transported at the leading edge of the growth cone [64].

Microtubules' and actin filaments' polymerization result from the addition of α/β -tubulin and glomerular actin (G-actin), respectively [65,66]. The rate of filament elongation and morphogenesis depends on the concentration and availability of monomers but also on the presence of proteins that regulate the assembly/disassembly kinetics and those responsible for increasing the level of complexity for higher-order network structures [67,68]. While microtubules are the stiffest components of the cytoskeleton and can switch between a stably growing state and a rapidly shrinking one [69], actin filaments are less rigid and more organized, supporting the overall structure and allowing the motility of the leading edge [70].

It is assumed that growth cones are already provided with all the proteins necessary for synaptogenesis during their searching for contacts [71]. The protrusion of filopodia finger-like structures retract upon contact with the postsynaptic cell to form a vestigial presynaptic terminal. These filopodia are characterized by a less tight bundle that is more dynamic compared to the architectural stability of conventional filopodia [72]. This dynamism is required to let the nascent spine be perfectly aligned between the presynaptic active zone and the postsynaptic density (PSD). The juxtaposition is possible thanks to the presence of cell adhesion molecules that provide perfect docking geometries between the two membranes in the synaptic cleft [73]. The actin cytoskeleton is involved in spine morphogenesis, as it controls changes in spine shapes. Immature dendritic spines show linear and thin-like structures, but, after making contact with the presynaptic terminal, actin filaments begin to cluster and enlarge the contact surface to form a mature spine with a mushroom-like shape [74]. This is conceivable thanks to actin-related proteins that generate branched filaments, such as the ARP2/3 complex, balanced with capping proteins, such as CAPZ, to restrict their elongation and actin severing proteins, such as ADF/cofilin, that enhance filament disassembly [75]. In addition, several scaffold proteins contribute to the maturation of dendritic spines controlling actin dynamics, e.g., PSD95, SHANK, and SRCIN1 (also known as p140Cap) [76–78].

Synapses are not static formations. They undergo changes in postnatal life, while carrying out specific activities, e.g., learning, and in specific periods, e.g., synaptic pruning during adolescence. In particular, synaptic plasticity takes place in an activity-dependent manner: LTP is the result of strengthened synapses after high-frequency stimulation from the presynaptic terminal, while long-term depression (LTD) is a decrease in synaptic activity after low-frequency signals [79]. For LTP, the presence of NMDA-type glutamate receptors in the membrane of the postsynaptic cells allows the insertion of new AMPA receptors in response to high-frequency stimuli. The localization of these ionotropic, excitatory glutamate receptors leads to an increase in the postsynaptic current and consequently to a stronger connection in a positive feedback loop. Both AMPA receptors' and NMDA receptors' trafficking relies on the actin cytoskeleton [80–83].

3.1. The Core Regulation of Actin Dynamics

Alterations in neurites and spine morphology, as well as in neuronal migration properties, have been consistently associated with ID and other NDDs that include ID as a main and recurrent phenotype [84]. These developmental features rely on the proper actin cytoskeleton dynamics, as neurite outgrowth, axonal migration, synaptogenesis, and synaptic plasticity are the result of three main processes: fibrous-actin (F-actin) dynamics (elongation/severing/branching), actin–myosin contractility, and F-actin coupling with the extracellular matrix [85,86]. All three processes are regulated by a complex protein network in which the Rho-family small GTPases RAC1, CDC42, and RHOA emerge as hubs (Figure 2A).

This section illustrates in detail the key components of the signaling pathway responsible for the control of the dynamics of the actin cytoskeleton, focusing on the biochemical and cellular role of each protein and its links with neurological and cognitive deficits in human and animal models.

3.1.1. Rho GTPases and Effectors

RAC1: RAC1 is a key regulator of neurite elongation, axon migration, synaptic function, and synaptic plasticity, as it promotes neurite outgrowth [85], spine formation and stabilization [87], and clustering of AMPA and NMDA receptors in the postsynaptic membrane [83,88], and it is essential for long-term synaptic plasticity in the hippocampus, which is the molecular mechanism at the base of learning and memory formation [89]. Formation and stabilization of integrin-dependent adhesion sites at membrane protrusion require local RAC1 activation followed by local RAC1 inactivation [90]. Moreover, the expression of constitutively active RAC1 inhibits NGF-induced neurite outgrowth [91],

indicating that tight spatiotemporal regulation of RAC1 signaling is required for optimal neurite outgrowth.

Seven de novo missense *RAC1* variants have been reported in patients with mild to severe ID [92,93]. Among them, two function as dominant-negative alleles (p.Cys18Tyr and p.Asn39Ser), while one is a constitutively active allele (p.Tyr64Asp) [93]. For the other mutations, it is not clear if they generate dominant-negative alleles or if they could result in a condition of haploinsufficiency. Interestingly, the p.Cys18Tyr variant prevented GTP-mediated activation of RAC1 and prevented overexpression of the mutated RAC1 from inhibiting the induction of LTP in the hippocampus [94].

In mice, the deletion of *Rac1* in the ventricular zone of the telencephalon resulted in ventricles enlargement, impaired migration of median ganglionic eminence-derived interneurons, and impaired projection of commissural and corticothalamic axons. Interestingly, primary *Rac1*-deficient neurons had increased neurites formation and branching, indicating that RAC1 may be dispensable for neuritogenesis per se [95].

CDC42: CDC42 plays a critical role in neurite outgrowth [91], neuronal migration, and dendritic spines formation and maturation [96]. It is also essential for the establishment of neural polarity, as it promotes axon formation and elongation by regulating ADF/cofilin activity at the growth cone and by promoting microtubules stability through DPYSL2 (dihydropyrimidinase-like 2) [97,98].

Eight *CDC42* de novo missense mutations have been reported in 13 unrelated patients showing several developmental abnormalities, including ID and dysmorphic facial features [99–102]. In vitro studies and experiments involving *C. elegans* showed that these mutations result in proteins with altered activity and/or impaired target interactions, with some mutations acting as a gain of function and others acting as hypomorphs [101]. Notably, one missense mutation of *CDC42*, which has been described as a de novo mutation in one individual and inherited mutation in three related individuals, resulted in a hypomorphic allele associated with several developmental phenotypes, but not with ID [101]. Overall, the complex and heterogeneous set of developmental abnormalities associated with *CDC42* mutations may reflect different functional consequences of the single mutations.

Brain-specific *Cdc42*-KO mice die soon after birth and show a reduced cortical mass and a widespread loss of axonal tracts [97]. The effects of *CDC42* depletion in the postnatal brain have been assessed using *Cdc42^{flox/flox}*, *Camk2a*-CRE mice, in which CRE recombinase is expressed in cortical pyramidal neurons and hippocampus starting from P16-P19. These mice showed reduced spine density and LTP in the hippocampus, together with memory deficits [103].

RHOA: Broadly speaking, the effects of RAC1 and CDC42 signaling on neurite outgrowth and dendritic spine formation are antagonized by RHOA signaling [85,90,104]. In particular, RHOA activity inhibits the formation of integrin-dependent adhesions [8], promotes neurite retraction by activating myosin 2a [105–107], and negatively regulates spine formation and maintenance [108].

Interestingly, *KCTD13* (potassium channel tetramerization domain containing 13) and *CUL3* (cullin 3), two genes linked to NDDs, are involved in RHOA ubiquitination [109–111], and RHOA inhibition rescues synaptic transmission, learning, and memory defects in *Kctd13*-KO mice [112,113]. These findings are consistent with the notion that RHOA dysregulation itself is linked to NDDs.

PAK1: Six PAK proteins have been identified in mammals. Based on their sequence homology, PAKs are classified into two groups, the first including PAK1, PAK2, and PAK3 and the second including PAK4, PAK5, and PAK6. All six PAKs are expressed in the nervous system with a different spatio-temporal pattern, with PAK1 and 3 being the most studied in the context of neuronal function [114]. Active RAC1 and CDC42 bind to the CRIB region of PAK1, relieving its autoinhibition and promoting its kinase activity [115–117].

PAK1 plays a critical role in both synaptic function and axon migration. *Pak1*-KO mice show impaired LTP at hippocampal CA1 synapses, reduced enrichment of F-actin

at dendritic spines, and impaired NMDA-dependent ADF/cofilin phosphorylation [118]. Both overexpression and inhibition of PAK1 in the mouse developing brain led to profound defects in the migration of cortical neurons [119].

In humans, gain of function missense variants in *PAK1* have been associated with ID, macrocephaly, and seizures [120,121]. Interestingly, deficits in the PAK1 pathway may partially explain the impaired migration of GABAergic neurons in DS patients [122].

PAK3: Differently from PAK1, which is activated by both RAC1 and CDC42, PAK3 is mainly activated by CDC42 [123].

Mutations of *PAK3* are associated with XLID [124,125]. Two *PAK3* variants responsible for severe ID and corpus callosum agenesis (G424R and K389N) were shown to suppress kinase activity, increase the interaction between PAK3 and the guanine exchange factor ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6, also known as α -PIX), and inhibit cell migration [124]. Another variant (R67C) inhibits the binding of PAK3 to CDC42, impairing PAK3 activation [123].

In mice, the latter variant impacts cognitive functions and adult hippocampal neurogenesis [126]. Likewise, *Pak3*-KO mice have no apparent defects in the actin cytoskeleton, but showed impaired hippocampal LTP, together with learning and memory deficits [127].

LIMK1: LIMK1 (LIM domain kinase 1) is a serine–threonine kinase that possesses two LIM domains, a PDZ domain, and a C-terminal kinase catalytic domain [128]. LIMK1 is a key downstream target of RAC1 signaling and is activated by PAK1 by phosphorylation at the Thr-508 residue [129]. Dominant-negative LIMK1 inhibits RAC1-stimulated lamellipodial protrusion [130], CDC42-induced filopodia formation, and RHOA-mediated stress fibers formation in Cos-7 cells [131].

Neurons of *Limk1*-KO mice showed reduced growth cone size and altered dendritic spine morphology [127].

In humans, heterozygous deletion of 27 genes, including *LIMK1*, results in Williams syndrome, a complex developmental disorder characterized by ID and impaired long-term memory [132]. Interestingly, *Limk1*^{+/-} mice also showed impaired long-term memory, together with reduced late-LTP in the hippocampus [133], indicating the LIMK1 haploinsufficiency in Williams syndrome patients may be causally related to memory defects. Unlike LIMK1, which is specifically expressed in the nervous system and enriched at mature synapses, LIMK2 is ubiquitously expressed [134,135], although it has been less studied. In the neuronal context, there is evidence for the role of LIMK2 in neurite outgrowth and neuronal migration [136,137].

ROCK: ROCK (Rho-associated coiled-coil containing protein kinase) is activated by active RHOA [138,139]. Two ROCK isoforms exist: ROCK1, which is prominently expressed in non-neuronal tissues such as liver and testis, and ROCK2, which is mainly expressed in brain and skeletal muscle [140]. ROCK activity stabilizes actin filaments by activating LIMK, which in turn inactivates ADF/cofilin [141,142]; on the other hand, ROCK promotes actomyosin contractility and stress fibers formation by phosphorylating MLC9 (myosin light chain 9) at Ser19, the same residue phosphorylated by MLCK (myosin light chain kinase) [143], and by phosphorylating MBS, the regulatory subunit of myosin light chain phosphatase [144,145]. A nonsense variant of *ROCK* was identified in an ID patient [146].

The pharmacological inhibition of actomyosin contractility inhibits actin retrograde flow and actin filaments' severing, and promotes neurite outgrowth in the early stages of neuronal polarization [147,148], indicating that RHOA opposes neurite elongation by stimulating actomyosin contractility.

Notably, PAK1 inhibits MLCK [149], suggesting that RAC1 and RHOA act antagonistically on actomyosin contractility.

Cdk5-p35: CDK5 (cyclin-dependent kinase 5) is activated by binding with the specific protein partners CDK5R1 (cyclin-dependent kinase 5 regulatory subunit 1, also known as p35) and CDK5R2 (also known as p39) [150,151]. CDK5 is important for neuronal migration, neurite outgrowth, axon guidance, and synaptogenesis during brain development and for

synaptic plasticity during adulthood [152,153]. CDK5 controls cytoskeleton remodeling by regulating Rho GTPases and by stabilizing actin filaments through p35-mediated-binding to F-actin [154]. CDK5 functions as a balance factor, as it can both facilitate RHOA-mediated growth cone collapse or dendritic spine retraction through phosphorylation of NGEF (neuronal guanine nucleotide exchange factor, also known as ARHGEF27) [155] or inhibit these processes by phosphorylating CDKN1B (cyclin-dependent kinase inhibitor 1B), and prevents RHOA activation by guanine exchange factors (GEFs) [156,157].

Similarly, CDK5 activates RAC1 via phosphorylation of KALRN (kalirin RhoGEF kinase) to promote dendritic spine stabilization [158] or inhibits RAC1 activation via phosphorylation of a RASGRF2 (Ras protein-specific guanine nucleotide releasing factor 2) or PPP1R9A (protein phosphatase 1 regulatory subunit 9A, also known as neurabin-I) [159,160]. CDK5 can also indirectly regulate CDC42-mediated dendrite outgrowth and extension via phosphorylation of NTR (neurotrophic receptor tyrosine kinase 2) [161].

In a mutation screening, novel silent mutations in *CDK5* and *p35* were identified: three intronic variations and four heterozygous variations in a cohort of 360 patients with non-syndromic ID, suggesting that these mutations and polymorphisms may contribute to ID phenotype [162].

3.1.2. GAPs and GEFs

Small GTPases cycle between a GTP-bound active state and a GDP-bound inactive state. The most important regulators of small GTPases are GTPase-activating proteins (GAPs), which promote GTP hydrolysis, GEFs, which promote activation by inducing the release of GDP and the binding of GTP, and guanine dissociation inhibitors, which prevent GDP dissociation [163].

OPHN1: OPHN1 is an F-actin binding protein ubiquitously expressed in the central nervous system in both glial cells and neurons, where it mainly localizes at the tip of growing neurites, growth cones, and dendritic spines [164,165]. It shows GAP activity towards RHOA, and, to a lesser extent, towards RAC1 and CDC42 [164,166].

In humans, LOF mutations in *OPHN1* cause syndromic XLID, in which ID is associated with epilepsy, ventriculomegaly, and cerebellar hypoplasia [167–169].

Ophn1-KO mice recapitulate some aspects of the human phenotype, such as social, behavioral, and cognitive impairments, as well as ventricular enlargement and susceptibility to seizures [165,170]. At the cellular level, *Ophn1*-KO mice show hyperexcitability of the hippocampal network, associated with a reduced number of hippocampal GABAergic interneurons, impaired dendritic spine maturation, and short-term synaptic plasticity [165,170]. Moreover, *OPHN1*-deficient human iPSCs showed decreased neurogenic potential and impaired neurite elongation [171].

ARHGAP15: ARHGAP15 (Rho GTPase activating protein 15) is a RAC-specific GAP protein, expressed in both excitatory and inhibitory neurons of the adult hippocampus and cortex. It is a negative regulator of RAC1/RAC3 activity, and its loss results in the hyperactivation of the RAC1 pathway [172]. ARHGAP15 comprises a pleckstrin homology domain, which mediates its membrane localization and consequent activation via binding to the PI3K product phosphatidylinositol 3,4,5-trisphosphate [172].

Arhgap15-KO mice showed altered neuritogenesis and synaptic density, resulting in increased spike frequency and bursts, accompanied by poor synchronization. Its loss mainly impacts interneuron-dependent inhibition. Adult *Arhgap15*-KO mice showed defective hippocampus-dependent functions such as working and associative memories [172].

In humans, the loss of ARHGAP15 has been reported in a rare variant of Mowat–Wilson disease, which is characterized by severe neurological deficits, severe ID, speech impairment, and ASD [173,174].

NOMA-GAP: ARHGAP33 (Rho GTPase activating protein 33, also known as NOMA-GAP) is a multi-adaptor protein with GAP activity, and it is a major negative regulator of CDC42 [175]. NOMA-GAP has been shown to be essential for NGF-stimulated neuronal differentiation through the inhibition of CDC42 signaling and regulation of the ERK5-

MAPK signaling [175]. *Noma-gap*-KO mice showed hyperactivity of CDC42 and reduced complexity of dendritic arborization [176].

TRIO: TRIO (trio Rho guanine nucleotide exchange factor) is a conserved Rho GTPase regulator that is highly expressed during brain development [177,178]. It contains two functional GEF domains: GEFD1, which regulates RAC1 and RHOG activity, and GEFD2, which regulates RHOA activity. It is involved in actin remodeling and it is necessary for cell migration and growth. TRIO controls, through RAC1 activation, cytokinesis, axon outgrowth, and guidance and modulates excitatory synaptic transmission [7,179]. In the developing hippocampal neurons, it limits dendrite formation without affecting the establishment of axon polarity. While *Trio*-KO has been shown to be embryonically lethal [180], hippocampus- and cortex-specific *Trio*-KO and heterozygous mice show progressive defects in learning ability, sociability, and motor coordination [178,181]. Whole-exome sequencing studies identified *TRIO* de novo mutations in several patients affected by NDDs in which ID appears as a prominent phenotype [182].

ARHGEF6 and ARHGEF7: ARHGEF6 and ARHGEF7 (Rho guanine nucleotide exchange factor 7, also known as β PIX) are GEFs of the Rho GTPases. ARHGEF6 has been shown to be specific for RAC1, activating and targeting it to membrane ruffles and focal adhesions [183]. On the other hand, *Arhgef6*-KO mice showed a significant reduction in the activity of both RAC1 and CDC42, but only at the hippocampal level [184].

Both proteins share an SH3 domain, a prerequisite for the binding with PAK1, PAK2, and PAK3 [185]. Santiago-Medina et al. [186] stressed the importance of the subtle regulation exerted on adhesion dynamics and membrane protrusions by PAK–ARHGEF6 and PAK–ARHGEF7 interactions during neurite outgrowth, as the partial inhibition of the interaction robustly stimulates neurite outgrowth and growth cone point contacts' turnover, whereas the complete inhibition freezes it stabilizing adhesions.

Both ARHGEF6 and ARHGEF7 present the Dbl homology and pleckstrin domains, which possess RhoGEF activity. Moreover, an ARHGEF7 transcriptional isoform presents a PDZ target at the C-terminal, functional to the binding with PDZ protein, e.g., SHANKs (SH3 and multiple ankyrin repeat domains), at the excitatory synaptic sites [187].

Mutation screening of 119 patients with nonspecific ID revealed a T > C variant in the first intron of *ARHGEF6* (c.166-11T > C) [188,189], although the pathogenicity of this specific variant was then questioned [190]. In addition, a male patient with severe ID, carrying a molecularly unbalanced translocation (X;21) disrupting *ARHGEF6*, was then identified [188].

Arhgef6-KO mice showed an increased dendritic length of hippocampal pyramidal neurons, reduced spine synapses, an overall reduction in early-phase LTP, and an increase in LTD, together with impaired spatial and complex learning and less behavioral control in mildly stressful situations, resembling the human ID phenotype, thus validating *Arhgef6*-KO mice as a proper ID animal model [184].

For what concerns ARHGEF7, the case of two siblings presenting generalized epilepsy and ID was reported, consequently to the 13q34 deletion. This genomic locus contains two protein-coding genes, SOX1 (SRY-box transcription factor 1) and ARHGEF7, thereby supporting the possible contribution of ARHGEF7 haploinsufficiency to the pathogenic phenotype [191].

Arhgef7-KO mice showed embryonic lethality at E9.5; for this reason, the in vivo role of ARHGEF7 was investigated through heterozygous or cortex-specific KO mice [192,193]. These models demonstrated that ARHGEF7 is essential in both neuritogenesis and synaptogenesis during cortical and hippocampal development, since its loss results in extensive loss of axons and reduced dendritic complexity, as well as in a decrease of synaptic density. Furthermore, *Arhgef7* heterozygous mice exhibited impaired social interactions [192].

ARHGEF9: ARHGEF9 is a brain-specific GEF that specifically activates CDC42 [194]. It regulates, through the recruitment and activation of CDC42, the clustering of GPHN (gephyrin) at postsynaptic sites [195]. GPHN clusters, in turn, promote postsynaptic clustering of glycine receptors and GABA_A receptors [196].

Arhgef9-KO mice showed reduced GABA_A receptor clusters at dendritic spines, enhanced LTP, increased levels of anxiety, and impaired spatial learning [197].

In humans, *ARHGEF9* mutations cause an XLID syndrome associated with seizures and facial dysmorphism [198–200].

TIAM1: TIAM1 (TIAM Rac1 associated GEF 1) is a GEF protein highly expressed in the developing nervous system that activates RAC1 and, to a lesser extent, CDC42 and RHOA [201,202]. RAC1 activation by TIAM1 is required for neurite outgrowth induced by NGF/NTRK1, BDNF/NTRK2, and Ephrin/Eph signaling [203,204]. Moreover, suppression of TIAM1 activity leads to defects in axonogenesis and radial migration [205,206]. TIAM1 is also required for spine formation and morphogenesis in response to various extracellular signals. In particular, Ephrin-B1/EphB2 signaling promotes spine development by activating RAC1 through TIAM1, while NMDA-mediated calcium influx at glutamatergic synapses activates a CAMK2 (calcium/calmodulin-dependent protein kinase II)-TIAM1 complex that persistently activates RAC1, leading to LTP and spine enlargement [207,208]; interestingly, knock-in mice harboring a mutation that inhibits the formation of the CAMK2–TIAM1 complex showed reduced RAC1 activity and memory deficits [209].

TIAM1 activity seems to be exquisitely relevant for granule neurons of the dentate gyrus, as TIAM1 knock-down (KD) in these cells led to a decreased number of glutamatergic synapses expressing AMPA receptor and to an increased spine length, while no effect was observed upon TIAM1 KD in CA1 neurons [210].

Consistent with this finding, *Tiam1*-KO mice showed defective maintenance of the dendritic arborization and impaired stabilization of dendritic spines in the granule neurons [211]. Strikingly, these mice showed enhanced contextual learning and memory [211]. For this reason, and considering that TIAM1 is overexpressed in DS patients, the authors of this study speculated that elevated levels of TIAM1 contribute to the learning and memory deficits associated with DS.

3.1.3. Actin Binding Proteins

The effects of RAC1, CDC42, and RHOA on actin dynamics are mediated by actin-binding proteins (ABPs), which are classified according to their activity: actin depolymerization, such as ADF/cofilin, branching, such as ARP2/3, severing, such as GSN (gelsolin), bundling, such as fascin family proteins, and nucleotide exchanging, such as profilin family proteins [68].

ADF/cofilin: LIMK1 inhibits ADF/cofilin proteins by phosphorylation at the Ser3 residue [212,213].

This protein family is composed of three isoforms: DSTN (destrin, actin depolymerizing factor, also known as ADF), CFL1 (cofilin 1), which is the most expressed in the central nervous system, and CFL2, which is specifically expressed in muscle tissue [214,215]. Since most studies addressing the roles of ADF/cofilin do not specify the isoform and most antibodies do not differentiate between these isoforms, this protein family is referred to simply as ADF/cofilin.

ADF/cofilin binds to ADP-actin, increasing the depolymerization rate of the pointed end and causing the severing of actin filaments [131,216]. This leads to an increase in G-actin availability and the number of barbed ends, resulting, at physiological ATP-actin concentrations, in actin reorganization and promoting axon elongation [97,217,218]. Importantly, not only the balance but also the cycling between the active and inactive forms of ADF/cofilin plays a role in modulating actin dynamics [97,219,220].

SSH: Proteins of the Slingshot family (SSH1–3 in mammals) dephosphorylate ADF/cofilin at Ser3 [221], thereby controlling actin dynamics and reorganization. SSH proteins mediate NGF-induced neurite extension. SSH1 and SSH2 KD suppress neurite extension by increasing the concentration of the non-phosphorylated form of ADF/cofilin [222].

YWHAZ: YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta, also known as 14-3-3 ζ) is an adaptor protein that affects actin dynamics via the stabilization of phospho-ADF/cofilin [223] and the regulation of SSH and

LIMK1 [224]. Additionally, it has been shown that 14-3-3 ζ inhibits the ubiquitin-mediated degradation of δ -catenin [225], a component of the cadherin–catenin cell adhesion complex, which in turn inhibits RHOA and activates CDC42 and RAC1 [226–228].

14-3-3 ζ -KO mice present reduced spine density, stressing the importance of this protein in the regulation of the actin cytoskeleton [229].

ARP2/3: The ARP2/3 complex is a heptameric complex formed by ACTR2 (actin-related protein 2, also known as ARP2), ACTR3 (also known as ARP3), and ARPC1-5 (actin-related protein complex 1–5) [230]. It binds existing actin filaments and initiates the formation of new filaments that branch off the existing filaments at an angle of about 70° [231]. The axon guidance molecules VEGF and SEMA3A affect actin dynamics at the growth cone by increasing and decreasing ARP2/3 activity, respectively [232,233]. Thus, ARP2/3 is essential for neuronal migration [74] but also for spine formation, maturation, and maintenance [234,235].

The postnatal loss of ARPC3 in forebrain excitatory neurons leads to progressive spine loss and defective LTP-induced spine volume expansion [235]. Moreover, ARP2/3 activity is required for the maturation of filopodia into spines and for the recruitment at the postsynaptic membrane of AMPA receptors, a process that is essential for the functional maturation of excitatory synapses [236]. The activity of ARP2/3 is also controlled by PAK1, which can phosphorylate ARPC1 promoting F-actin polymerization and branching [237].

NPFs: The activity of nucleation-promoting factors (NPFs) is required to activate the nucleation and branching activity of the ARP2/3 complex. These factors include WASP (Wiskott–Aldrich syndrome protein), N-WASP (neural WASP), the WAVE regulatory complex (WRC) formed by WASF1 (WASP family member 1), CYFIP1 (cytoplasmic FMR1 interacting protein 1), ABI2 (abl interactor 2), NCKAP1 (NCK associated protein 1), and BRIK (BRICK1 subunit of SCAR/WAVE actin nucleating complex), or paralogues of these, and the WASH complex, formed by WASHC1-5 (WASH complex subunit 1–5) [230,238]. The activity of NPFs is controlled by Rho GTPases; in particular, active RAC1 and CDC42 activate N-WASP and WASP, respectively, by binding to their CRIB region [239,240]. Active RAC1 has also been shown to activate WRC [241]. Notably, dominant-negative WASF1 abolishes the formation of RAC1-dependent lamellipodia and RAC1-dependent neurite extension [242].

Strong genetic evidence indicates that alterations in the NPFs-ARP2/3 signaling module may lead to ID: copy number variants of the chromosomal region 15q11-q13, encompassing *CYFIP1*, were identified in patients with ASD and ID [243], with several studies indicating a pathogenic role for both increased and decreased *CYFIP1* dosage [244–246]; 21 de novo missense *CYFIP2* variants, most of which were shown to impact on WRC-mediated actin remodeling, have been reported in 37 ID patients [247,248]; *WASHC4* has been identified as an autosomal recessive ID gene [249,250]; *NCKAP1* variants predicted to be deleterious for protein function have been associated with ID [251]; *ABI2* is a candidate autosomal recessive ID gene [252]; de novo splice site mutations of *WASHC5* were shown to cause Ritscher–Schinzel/3C syndrome, a disorder characterized by several phenotypes, among which ID [253].

GSN: GSN (gelsolin) acts by severing actin filaments and capping free barbed ends [254]. Its depletion in hippocampal neurons increases the number of filopodia by reducing their retraction [255]. GSN is recruited to dendritic spines following LTD [256], presumably by the increase in calcium concentration [257], suggesting its involvement in synaptic plasticity.

FMN2: FMN2 (formin 2) is an ABP that belongs to the family of formin homology (FH) domain proteins. Since it is involved in the maturation of tip adhesion, it is essential for the generation of traction forces by filopodia and the stabilization of the growth cone [258]. By binding to the actin cytoskeleton, it functions as a clutch with the extracellular matrix at adhesion sites. FMN2 was found localized to ventral actin stress fibers in fibroblasts [258] and *punctae* along dendrites in neurons [259].

Notably, *FMN2* truncating mutations in two consanguineous families lead to decreased spine density and non-syndromic autosomal-recessive ID [259].

Profilins: Profilin family proteins (PFN1-4) promote the conversion of ADP-actin into ATP-actin, thus providing the actin monomers necessary to sustain barbed end elongation [260]. In striking contrast, low levels of profilin can also inhibit actin polymerization by sequestering actin monomers [261–263]. Profilins may have a role in the stabilization of spine morphology [264], and it is involved in the regulation of actin polymerization in growing neurites, as both overexpression and expression of dominant-negative profilin lead to impaired neurite outgrowth [265].

SHTN1: PAK1 phosphorylates SHTN1 (shootin 1), promoting its interaction with F-actin [266]. SHTN1 physically interacts with L1-CAM and F-actin, thus allowing the force generated by actin retrograde flow to be transmitted to the extracellular matrix and coupling actin polymerization with neurite elongation [267,268].

Interestingly, SHTN1 mRNA was found to be consistently down-regulated in blood samples of ID patients harboring mutations in the transcription factors CCNT2, CDK9, and TAF2 [15].




Figure 2. Cont.




Figure 2. Proteins involved in the regulation of neurite elongation. (A). PPI network of the best-characterized components of the Rho GTPase signaling RAC1, RHOA, and CDC42 realized with Cytoscape [269]. Boxes represent the nodes (proteins), while the arrows indicate the edges (interactions). GTPases are reported in green, their GEFs and GAPs in red, their effectors in blue, and actin-binding or actin-modifying proteins in purple. Edges can be either “activatory” (arrowheads) or “inhibitory” (blunted lines). The “neurite elongation” node represents the phenotypic outcome. Acronyms are spelled out in the text. (B,C). Expression trajectories of ID-related genes in the human dorsolateral prefrontal cortex (B) and hippocampus (C). Quantile normalized gene-level expression values (log₂ transformed) inferred from Human Brain Transcriptome database [270] were plotted against logarithmic age in days. The pattern was summarized by the smoothed curves of the expression values. Dashed lines divide periods of development and the solid line separates prenatal from postnatal periods. Individual genes are color-coded, legend in panel (C).

3.2. Synaptogenesis and Synaptic Plasticity

A set of mutations identified in ID specifically affect spine development and morphological changes during maturation. In this section, we summarize the most relevant findings.

KALRN: KALRN (kalirin) is a GEF for RAC1 [271]. In mice, KALRN expression increases at two weeks of age, a key time for synaptogenesis [272]. *Kalrn*-KO mice showed decreased synaptic density in the apical dendrites of CA1 hippocampal neurons, along with learning deficits [273].

PPP1R9A and PPP1R9B: PPP1R9A (neurabin -I) and PPP1R9B (also called neurabin-II or spinophilin) show F-actin cross-linking and phosphatase activity. They are enriched in dendritic spines [274] and are likely to influence dendritic spine morphology and function through their interaction with F-actin [275].

Ppp1r9b-KO mice have a reduced number of filopodia and an increase in spine density [276].

ARHGEF2: Neurabin-I and Neurabin-II interact with the Rho GEF ARHGEF2 (also known as Lfc). This interaction selectively regulates Rho-dependent organization of F-actin in spines; ARHGEF2 is maintained inactive/sequestered through the interaction with microtubules and targeted to dendritic spines as a result of the interaction with Neurabin-I and Neurabin-II [277].

ARHGEF2 mutation leads to reduced activity of the RHOA pathway. A homozygous frameshift mutation in the *ARHGEF2* is associated with ID, midbrain–hindbrain malformation, and mild microcephaly in a consanguineous family of Kurdish–Turkish descent [278].

SHANK: SHANK family proteins are higher-order organizing scaffold proteins of the PSD. They are known to interact with the ABP DBNL (drebrin like) in the PSD to promote the reorganization of actin after stimulation [279]. SHANK proteins activate RAC1 signaling at the PSD by recruiting ARHGEF7 through its PDZ C-terminal domain [187].

Indeed, heterozygous mice lacking a SHANK3 C-terminus have an impaired actin polymerization and a consequent decrease of NMDA receptor delivery to the postsynaptic plasma membrane [280]. SHANK3 can also directly interact with the ARP2/3 complex to increase F-actin level by decapping the barbed ends of actin filaments, thus promoting filament extension [281]. A large variety of alterations in SHANK proteins are grouped as “shankopathies” and are linked with NDDs characterized by alterations in the actin cytoskeleton network [282].

It has been proposed that in the 22q13 deletion syndrome, an NDD characterized by ID, the disruption of *SHANK3* is responsible for the clinical disorder [283–285].

CAMK2: The activity of CAMK2, which is stimulated upon the increase in intracellular calcium concentration, is essential for AMPA receptor delivery to the membrane of silent synapses and SYNGAP activation [48,286]. Whole-exome sequencing identified 19 rare de novo variants of CAMK2A and CAMK2B in 24 unrelated ID patients [287].

3.3. The Role of Microtubules in ID

Microtubules are basic elements of the cytoskeleton and actively participate in most neurodevelopmental processes. Neurons depend on microtubule dynamics for cell division, axon guidance, intracellular trafficking, and synapse formation [288]. They are constituted by heterodimers of α - and β -tubulin that associate to form a hollow cylinder. The stable to dynamic microtubules ratio is significantly higher in the neurite that is meant to form the axon as compared to the other neurites, indicating that stable microtubules are essential for axon specification [289,290]. Microtubules' polarity is required to deliver various cargoes to the correct location within the cell to assure axonal trafficking and to maintain the correct neuronal morphology. Microtubules also play a crucial role in spinogenesis, as dynamic microtubules penetrate dendritic spines to modulate their morphology by interacting with a large variety of microtubule-associated proteins [291–293]. Some of them act directly on microtubules to affect their assembly or stability, while others act indirectly by modulating tubulin level or intracellular transport; for example, severing proteins are essential to increase tubulin monomers' availability and to reorganize microtubules' scaffold architecture [294], while microtubule plus-end tracking proteins (+TIPs) are responsible for the regulation of microtubules by interacting with the plus ends and by functioning as a scaffold for other regulatory proteins [295,296]. Cytoplasmic linker proteins (CLIPs), a subgroup of +TIPs, are fundamental for microtubule invasion into the growth cone leading edge and into nascent dendritic spines [297,298].

Many microtubule-associated genes are linked to ID and to other NDDs in which ID appears as a prominent and recurrent phenotype: *ADNP* mutations are associated with ASD; *ASPM*, *MCPH1*, *STIL*, *CDK5RAP2*, *CENPJ*, *PRUNE1*, and *KIF20* mutations are associated with microcephaly; *TUBB2B* mutations are associated with polymicrogyria; *LIS1*, *DCX*, and *TUBA1A* are linked to lissencephaly [288].

KIF1A, KIF4A, KIF5C, and KIF7: Kinesins are motor proteins that move along microtubules in an anterograde fashion, transporting their cargo towards microtubules' plus end. KIF1A (kinesin family member 1A) is selectively expressed in neurons, and its partial or total depletion results in the disruption of axonal and dendritic transports [299]. A dominant de novo missense mutation in *KIF1A* was found in a patient with non-syndromic ID [300], and other de novo mutations were found in six patients affected by severe early-infantile neurodegenerative syndrome [301]. Next-generation sequencing revealed mutations in other kinesin family members such as *KIF4A* and *KIF5C* for which the causative role in ID is supported by evidence obtained using KO models [302]. Mutations in *KIF2A* and *KIF5C* were reported in patients with malformations of cortical development presenting ID [303], and homozygous mutations in *KIF7* were found in patients with ciliary disorders in which ID is part of the phenotype [304].

KIFBP: KIFBP (kinesin family binding protein) is a modulator of kinesins activity. Homozygous nonsense mutations of KIFBP are associated with Goldberg–Shprintzen syndrome, which is a form of syndromic ID [305].

CHAMP1: CHAMP1 (chromosome alignment maintaining phosphoprotein 1) is a zinc finger protein that regulates chromosome segregation during mitosis. De novo *CHAMP1* mutations are associated with GDD and ID [306–308].

CLIP1: CLIP1 (CAP-Gly Domain Containing Linker Protein 1) is a +TIP that regulates microtubule growth and bundling. Next-generation sequencing revealed an autosomal recessive form of ID associated with a nonsense variant in *CLIP1* in an Iranian consanguineous family [309].

KATNAL1: KATNAL1 (katanin catalytic subunit A1 like 1) is one of the two major catalytic subunits of the microtubule-severing enzyme Katanin, together with KATNAL2. Three unrelated patients with heterozygous de novo deletions encompassing 13q12.3 presented moderate ID phenotype; since this region contains *KATNAL1*, this gene has been proposed as a candidate ID gene [310].

MID1 and MID2: MID1 (midline 1) and MID2 are E3 ubiquitin ligases that have a role in microtubule stability and organization. *MID1* mutations are associated with Opitz G/BBB syndrome, in which mild to severe ID can appear [311]. A *MID2* missense mutation that disrupts its interaction with microtubules is associated with XLID [312].

CDKL5: CDKL5 (cyclin-dependent kinase-like 5) is a kinase protein essential for brain development. CDKL5 interacts with IQGAP1 (IQ motif containing GTPase activating protein 1), through which it forms a functional complex with its effectors RAC1 and CLIP1, MAPRE2 (microtubule-associated protein RP/EB family member 2), MAP1S (microtubule-associated protein 1S), ARHGEF2, and SHTN1 [313–315], thus stressing its regulation over cytoskeleton dynamics, in particular over microtubules. *CDKL5* mutations cause the so-called CDKL5 deficiency disorder in which severe ID is one of the most important clinical manifestations [316].

4. Cytoskeleton in Non-Neuronal Cells and ID

Astrocytes, oligodendrocytes, and microglia cells express a fair fraction of ID genes, including those involved in Rho GTPases signaling and cytoskeleton organization (Figure 3). For this reason, and considering that these cells contribute to cognitive functions, it is reasonable to hypothesize that mutations in these genes might lead to ID not only by affecting neuron functions but also in a non-neuron autonomous manner. In the following section, we will review some of the literature on this subject.

Astrocytes: It is well established that astrocytes play a role in learning and memory formation [317,318]. For example, inhibition of lactate release by astrocytes impairs long-term memory formation [319], while chemogenetic or optogenetic activation of astrocytes in the CA1 region of the hippocampus during learning enhances memory formation [320].

The actin cytoskeleton is involved in many aspects of astrocyte physiology and function, such as the plasticity of the perisynaptic astrocytic processes [321], small membrane protrusions that contact synapses and regulate synaptic transmission [322], glial scar formation [323,324], and vesicle trafficking [325].

Therefore, one might speculate that defects in cytoskeleton dynamics may lead to ID by affecting astrocyte functions. In line with this hypothesis, astrocytes of *Ophn1*-KO mice are less ramified and show altered migration and glial scar formation [326]. Moreover, mice deficient for ARNTL (aryl hydrocarbon receptor nuclear translocator like, also known as Bmal1), an essential component of the molecular clockwork driving circadian rhythms, showed severe cognitive deficits, associated with a reduction of perisynaptic astrocytic processes covering hippocampal mossy fiber synapses, which is probably due to a reduction of RHOA activity in *Arntl*-deficient astrocytes [327].

The generation of astrocyte-specific *Ophn1*-KO and *Arntl*-KO mice may elucidate the non-neuron autonomous contribution of these proteins.

Oligodendrocytes: Oligodendrocytes, the myelin-forming cells of the central nervous system, are essential to establish neuronal networks with proper functions [328,329]. Myelination of newborn synapses is a key process during learning and memory formation, indicating a role for oligodendrocytes in cognitive functions [330,331]. The actin

cytoskeleton participates in myelination in two steps: first, actin filaments' assembly drives oligodendrocytes' branching, and second, their depolymerization induces myelin wrapping [332]. This regulation underlies the importance of actin dynamics in oligodendrocytes, with actin-depolymerizing proteins like GSN and ADF/cofilin being among the most abundant transcripts in oligodendrocytes [333,334]. Myelin defects have been reported in DS patients [335,336] and non-syndromic XLID patients with mutations in *PAK3* [337,338]. *PAK3* is highly expressed in oligodendrocyte progenitor cells, and it is essential for their differentiation into mature oligodendrocytes [339–341]. Notably, P14 (but not P60) *Pak3*-KO mice showed myelination defects of the axons of corpus callosum [341], a phenotype that is reminiscent of corpus callosum agenesis observed in ID patients harboring *PAK3* mutations.

Microglia: Microglia cells, the resident innate immune cells of the brain, are involved in the regulation of brain development by promoting both synaptic pruning and synapse formation [342]. Interestingly, mice with autophagy-deficient microglia showed impaired synaptic pruning and, consequently, altered brain connectivity, leading to social and behavioral defects [343]. Since microglia engulf synapses during pruning [342,344] and considering that engulfment requires cytoskeleton rearrangements, it would be interesting to investigate the role of cytoskeleton dynamics in synaptic pruning.




Figure 3. Cytoskeleton-related ID gene expression in non-neuronal cells. Venn diagrams created with the multiple list comparator tool by molbiotools [345] showing the intersections between the lists of primary ID genes reported in the SysID database (red) [1], genes associated to the GO terms [12,13] “regulation of GTPase activity” and “cytoskeleton organization” (blue), and genes expressed in astrocytes (on the left), oligodendrocytes (at the center), and microglia (on the right) (green). The list of genes expressed in non-neuronal cell types was obtained from an RNA-seq dataset [346].

5. In Silico Modeling of Cytoskeleton Regulation

SB approaches complement the wealth of experimental and mutational data derived from small-scale studies and high-throughput methods with computational and mathematical modeling to reconstruct the dynamic organization of a specific cellular regulatory network, a task that is often out of reach of molecular technologies. Moreover, computational models can be implemented with existing data to raise predictions of how the biological system would behave in particular conditions. Our ability to model a complex regulation of connected elements in silico has largely improved, allowing us to:

- simultaneously consider a large number of interacting proteins and link their relationships with emerging phenotypes
- elaborate hypotheses and design new experiments
- search for biomarkers and druggable targets for translational purposes

SB studies are performed with bottom-up (dynamic models such as Boolean models) or top-down (statistical analyses and static networks) procedures. A Boolean model was implemented to study the molecular dynamics underlying the behavior of the neuronal growth cone during axon growth and guidance. Interestingly, simulations performed with mutant networks suggest that many mutations underlying ID and ASD affect the motility of the growth cone and in particular the formation of filopodia and lamellipodia [347].

To our knowledge, no studies have currently applied this type of modeling to study the regulatory module underlying neurite elongation.

Bottom-up pipelines start with a survey and manual curation of the scientific literature and databases looking for key genes, proteins, and interactions regulating the process under investigation, e.g., neurite extension, in order to derive a graphical depiction of the network in which nodes are genes/proteins and edges are the interactions among them. Here, we provide an example of a protein regulatory network for neurite elongation centered on GTPases (Figure 2A). The graphical map can be translated into a computational and/or mathematical model for dynamic simulations of the biochemical network in different contexts.

There are different frameworks for mathematical/computational modeling (ODEs, Boolean, agent-based), which differ in their trade-off in terms of biological complexity, scalability, or simulation reliability. Referring to Boolean models, there are only two mutually exclusive states for each node, the logic 1 and 0. The initial graphical map is rewritten converting the interactions between proteins/genes to Boolean functions by using the three logical operators: AND, OR, and NOT. As an example, in Table 1, we show the Boolean model corresponding to the network of Figure 2A rewritten with the >syntax of the 'BoolNet' R package [348] and simplified by removing nodes that lack downstream targets in our reconstruction of the network (i.e., PAK3) or that exert a redundant effect with other nodes (i.e., Gelsolin and ArhGEF9), thus reducing the computational cost.

Table 1. Boolean model of the GTPases network for neurite elongation.

Targets, Factors (1)	Reference
neuro_elo, f_actin	[68]
f_actin, (profilin formin arp2_3 shootin1) & !cfl	[266,349–353]
arp2_3, wave	[351,354]
wave, (rac1 cdc42) & !cdk5_p35	[351,355,356]
cdc42, (arhgef6 arhgef7) & !(noma_gap ophn1)	[166,176,184,193,357]
rhoa, trio !(ophn1 tiam1)	[164,358,359]
rac1, (tiam1 arhgef6 arhgef7 trio) & !(arhgap15 ophn1)	[164,172,184,193,205,358]
rock, rhoa	[360]
pak1, (rac1 cdc42 arhgef6 arhgef7) & !(arhgap15 cdk5_p35)	[186,361–364]
arhgap15, !pak1	[363]
shootin1, pak1	[266]
cdk5_p35, f_actin	[154]
limk2, rock	[360]
cfl, ssh1 & !(limk2 limk1)	[222,365]
limk1, pak1 !ssh1	[129,224]
ssh1, f_actin	[222,366]

(1) Targets and factors refer to the components (nodes and edges) indicated in Figure 2A rewritten with the BoolNet R package syntax.

Simulations can be run by choosing the initial conditions to be used (exhaustive, chosen, random), i.e., selecting which node is set as active (1) or inactive (0). During the simulation, the nodes state can be either synchronous or asynchronous: in the synchronous type, the state is updated simultaneously, while in the asynchronous type, only one transition function—randomly chosen—is updated at each simulation.

The simulation aims to identify the steady states reached by the system, named “attractors”, corresponding to particularly stable configurations of activity for each node of the network (Figure 4B). Attractors are thought to correspond to cell phenotypes [367]; consequently, it is a good practice to add in the network one or more “abstract” nodes whose meaning refers to a particular phenotype, like the one named “neurite extension” in Figure 2A, facilitating the identification of attractors that correspond to the activation (or inactivation) of the phenotypic node.

The simulation performed on the neurite elongation Boolean network using the exhaustive method and the synchronous type yielded 2155 attractors (five relevant examples

are shown in Figure 4B) in which the phenotypic node is active in 12.4% of attractors (Figure 3C). This preliminary simulation suggests that the system has a low propensity to promote neurite elongation in its default condition. As a validation, we performed an *in silico* mutagenesis analysis using published experimental data on KO/KD models for all the proteins of the network (Table 2).

Table 2. Proteins involved in the regulation of neurite elongation with the corresponding KO/KD phenotypes.

Protein	Gene Mutation (1)	Phenotype	Reference
Rac1	Forebrain-specific KO	Increased number of primary neurites and secondary branches	[95]
RhoA	KO	Increased axon length (significantly greater actin retrograde flow, fewer actin arcs, and substantially longer F-actin bundles)	[368]
Cdc42	KO	Defective axon formation (disrupted cytoskeletal organization, enlargement of the growth cones, and inhibition of filopodia dynamics)	[97]
WAVE1	KO	No effect on neurite growth	[369]
Cdk5	Dominant-negative	Inhibition of neurite outgrowth	[370]
p35	KD	Inhibition of neurite outgrowth	[370]
Arp2/3	KD	Increased number of irregular, shorter, and broader neurites	[371]
PAK1	Dominant-negative	Decreased number of dendrites	[361]
PAK2	Dominant-negative	No effect on the neurite growth	[372]
PAK3	KD	Increased elongation of neuronal processes	[373]
LIMK2	KD	Reduced number of neurite-bearing cells and the mean neurite length	[222]
LIMK1	KD	Reduced number of neurite-bearing cells and the mean neurite length	[222]
ROCK1	Haploinsufficiency	Increased basal and apical dendritic length and dendritic intersections	[374]
ROCK2	Haploinsufficiency	No effect on the neurite growth	[374]
SSH1/SSH2	KD	Decreased neurite extension	[222]
ArhGEF6	KO	Increased neurite length	[184]
ArhGEF7	Cortex-specific KO	Impaired axon formation	[193]
ArhGAP15	KO	Decreased neurite length and branching	[172,375]
TRIO	Neuron-specific KO	Decreased axon length	[376]
Tiam1	KO	Decreased neurite length	[211]
NOMA-GAP	KO	Decreased dendritic branching	[176]
OPHN1	KO	Decreased dendritic tree complexity, i.e., branching	[377]
Cofilin	KO	Inhibited neurite outgrowth	[378]
Profilin1	KD	Impaired axon elongation	[349]
Profilin1	Mutation of the actin-binding domain	Decreased of neurite length	[265]
Formin	KO	Impaired axon elongation	[379]
Shootin1	KD	Inhibited polarization	[380]

(1) Gene mutations referred to in *in vitro* and *in vivo* models.

The *in silico* KO is achieved by fixing the state of a particular node to 0 throughout the simulation. The results of these analyses show that, in all cases, the effects of KO observed in real models were confirmed *in silico* (Figure 4C).

Despite the apparent oversimplification of the Boolean models, they have been successfully used to analyze the dynamics of various biological networks, especially in reverse engineering of regulatory networks and in analyzing complex mutant expression data [62,381–383], improving the design of bench experiments.




Figure 4. Boolean network. (A). Flow chart of the procedure to follow in order to construct a Boolean model. (B). Attractor analysis of the Boolean network for the study of neurite extension (Table 1). Comparison of five representative attractor profiles: (1) fixed-point attractor of the WT network (active phenotypic node); (2) fixed-point attractor of the WT network (inactive phenotypic node); (3) multi-state cyclic attractor of the WT network (inactive phenotypic node); (4) fixed-point attractor of the RHOA-KO network (active phenotypic node); (5) fixed-point attractor of the Cofilin-KO network (inactive phenotypic node). Red boxes correspond to inactive nodes and green boxes to active nodes. (C). In silico mutagenesis for the validation of the Boolean network (Table 1) using published experimental data from KO models (Table 2). Red bars refer to the total number of attractors obtained. The green part of each bar corresponds to the number of attractors with an active phenotypic node computed over all attractors obtained in each simulation.

6. Therapeutic Opportunities for Cytoskeleton-Related Forms of ID and Related Conditions

Cognitive deficits in ID are the results of alterations in many cellular processes including neurogenesis, migration, and, consequently, neuronal connectivity. This pathology has its onset during brain development, as high-confidence ID genes are preferentially expressed from early fetal to late mid-fetal stages [14]. Although their expression has a big impact during neuronal development, most of them continue to be expressed during adulthood (e.g., the ones mutated in cytoskeleton-related forms of ID, Figure 2B,C), thus suggesting that they may continue to contribute to the pathological phenotype.

For many years, ID and the other cognitive disorders were thought to be irreversible, especially in adults, and treatments were focused only on personalized educational plans and co-morbidity alleviation, except for a few syndromic forms of ID, for which specific treatments, like enzyme replacement therapy, are used and result in intellectual improvements [384]. Nonetheless, recent studies on specific forms of ID and other NDDs provide evidence that neurological impairments can be reversed, even in postnatal life, thanks to the retained ability of local neuronal circuitries to undergo plastic reorganization and balance excitatory vs. inhibitory synaptic density. Notable examples of targeted treatments on models of NDDs are provided:

- (1) Starting from the hypothesis that learning deficits in NF1 (neurofibromatosis 1) are caused by an excess of RAS activity and by the consequent increase in GABA-mediated inhibition, *Nf1*^{+/-} mice (a model of NF1) were treated with both farnesyl-transferase and HMG-CoA reductase inhibitors to decrease RAS activity; the treatment was successful in rescuing spatial memory and attention deficits [385,386].
- (2) The observation that the hippocampal signaling through postsynaptic GABA receptors was significantly increased in Ts65Dn mice (a model of DS) prompted the testing of selective GABA_B and GABA_A receptor antagonists; both treatments rescued memory in novel place and object recognition tests and contextual fear conditioning tasks [387–389]. It was later shown that GABA_A receptor signaling is excitatory rather than inhibitory in Ts65Dn mice and DS patients, because of an increased hippocampal expression of the cation chloride cotransporter SLC12A2 (solute carrier family 12 member 2). Its inhibitor, bumetanide, a common diuretic, was able to restore synaptic plasticity and hippocampus-dependent memory in adult Ts65Dn mice [390]. Recently, the discovery that the over-activation of microglia plays a role in the DS phenotype widened our knowledge about this pathology, as it has resulted in successful testing of anti-inflammatory drugs to rescue cognitive impairments [391].
- (3) As the mutation in *CREBBP* (CREB-binding protein) is considered the most significant mutation in Rubinstein–Taybi syndrome, pharmacological strategies to enhance CREBBP-dependent gene expression were investigated. *Crebbp*^{+/-} mice (a model of Rubinstein–Taybi syndrome) treated with either PDE4 inhibitor (to enhance cAMP signaling) or HDAC inhibitor (to halt the counterpart of the histone acetylation function of CREBBP) were rescued for long-term memory deficit [392,393]. Similarly, *Kmt2d*^{+/ β Geo} mice (a model of Kabuki syndrome) were rescued by the treatment with HDAC inhibitors [394].
- (4) Hyperactivity of MTOR signaling is observed in several neurodevelopmental disorders, the so-called “mTORopathies”; therefore, it is not surprising that MTOR inhibitors were extensively tested. Heterozygous mutations in either *TSC1* or *TSC2* that form an MTOR-inhibiting complex can cause tuberous sclerosis by hyperactivating MTOR signaling. *Tsc2*^{+/-} and *Tsc1* homozygous mutant mice (a model of tuberous sclerosis), were treated with rapamycin, rescuing spatial learning and context discrimination deficits together with neurological findings [395,396]. Rapamycin prevented seizures and rescued defective cortical lamination and heterotopia in *Strada*-KO model, an upstream inhibitor of MTORC1, in a rare NDD called Pretzel syndrome [397]. Interestingly, MTOR inhibitors are currently in clinical trials as antiepileptic agents [398]. This class of drugs was also tested to revert neuronal hypertrophy caused by PTEN deficiency in Lhermitte–Duclose and Cowden syndromes [27] and is seen as a promising approach for the treatment of ASD [399].
- (5) *Fmr1*^{-/-} mice (a model of FXS) were used to study the GABA_Aergic deficit that underlies FXS; treatment with a mGluR5 antagonist rescued associative learning [400], as well as treatments with positive allosteric modulators of GABA_A receptors in animal models [401] and GABA_B receptor agonists, which, in patients, seemed to rescue behavioral functions [20]. Additionally, the antibiotic minocycline, a metalloproteinase inhibitor, appeared to be effective in patients [402].

Although ID genetic heterogeneity sets a limit on individual treatment, these studies have the merit to demonstrate that ID is potentially responsive to therapeutic interventions. The identification of common disrupted molecular and cellular mechanisms will help in finding flexible therapies, targeting central nodes more than individual genes. One of these nodes is represented by the cytoskeleton under the control of Rho GTPases signaling.

6.1. Pharmacological Stabilization of Microtubules

Several genes associated with ID code for proteins acting on microtubules' formation and regulation [288]. Likewise, alterations of the microtubule cytoskeleton have been linked to ASD, schizophrenia, DS, and major depression disorders [403,404].

Microtubule stabilizers were mostly studied in neurodegenerative disorders characterized by compromised MAPT (microtubule-associated protein tau, or simply tau) functions. According to the hypothesis that microtubule-stabilizing drugs could offset the loss of normal tau functions [405], taxane microtubule stabilizers were tested. Paclitaxel was tested on a mouse model presenting tau pathology in spinal motor neurons [406], restoring fast axonal transport and ameliorating motor impairments. Another taxol, Epothilone D, able to cross the blood–brain barrier, was tested in mouse models of both tauopathy and schizophrenia [407,408], reducing axonal dysfunction, cognitive deficits, and synaptic transmission. Indeed, although taxanes are well-known chemotherapy medications [409], at nanomolar concentrations they appeared safe, eliciting only beneficial effects [407].

Microtubule stabilization can be achieved also by targeting microtubule-binding proteins. The neurosteroid pregnenolone (PREG) was shown to induce CLIP1 active conformation and to restore its association with microtubules in *Cdk15*-deficient neurons rescuing morphological defects [313].

Another solution was provided by small peptides able to act out the activity of microtubule-associated proteins. NAP (NAPVSIPQ), alias Davunetide, is a neuroprotective peptide snipped by ADNP (activity-dependent neuroprotector homeobox). *ADNP* haploinsufficiency results in increased tau phosphorylation and memory impairments in neurodegenerative diseases, including Alzheimer's disease [410]. *ADNP* mutations have been linked also to ASD and ID [411]. In preclinical studies, NAP was found to reduce tau hyperphosphorylation and to interact with MAPRE1-3, enhancing microtubule assembly [412]. Interestingly, Risperidone, an atypical antipsychotic, interacts with MAPRE1-3, competing with NAP. Risperidone treatment in schizophrenia and ASD patients improved their cognitive functions and mitigated their disruptive behavior [413,414].

Several other compounds are under investigation for their activity over microtubules and microtubule-related proteins, e.g., blood–brain barrier-penetrant heterocyclic molecules able to stabilize microtubules, and calpain inhibitors, which, by protecting the protein LIS1 (platelet-activating factor acetylhydrolase 1b regulatory subunit 1) against proteolysis, are able to recover retrograde transport and network formation in *LIS1*^{+/-} mice (a model of lissencephaly) [415,416].

6.2. Pharmacological Modulation of Actin Dynamics

Altered actin polymerization kinetics features most of the ID models presenting mutations on genes involved in actin-reorganizing signaling pathways. Yet, the phenomenon was characterized only in ASD and schizophrenia patients, in which a defective actin polymerization was observed [52,56].

Because of its ubiquitous expression, directly targeting actin raises many concerns. Conversely, a more appealing possibility is ABPs' or upstream regulators' targeting, which are largely brain-specific, e.g., CTTNBP2 (cortactin binding protein 2) [417], particularly enriched in specific brain areas, e.g., PAK1 in the prefrontal cortex (Figure 2B) or KALRN in the cortex and hippocampus [418], or specific to neuronal compartments, e.g., KLHL17 (kelch-like family member 17, also known as actinfillin) at the PSD [419].

The validity of such an approach was demonstrated in a study on a *Shank3*-deficient mouse model [280]. First, this study correlated the NMDA receptor hypofunction to an impaired actin polymerization caused by the increased level of active ADF/cofilin, which was in turn caused by the decreased RAC1/PAK1/LIMK1 signaling. Then, it showed how the inhibition of ADF/cofilin through a competitor peptide rescued ASD-like behaviors, improving the F-actin/G-actin ratio and restoring NMDA receptor function in mice.

Actin dissociation/association rate can also be affected by the presence of other natural actin ligands, fungal and bacterial toxins, and cytotoxic macrolides derived from marine sponges. As for ABPs, actin ligands are classified according to their activities and roughly divided into actin stabilizers, e.g., phalloidin, jasplakinolide, and miurenamide A, and destabilizers, e.g., latrunculin, cytochalasin D, and kabiramide C. Both stabilizing and destabilizing agents are intended in their proper meaning only in vitro, while in vivo

they are expected to affect the cytoskeleton dynamics only by delaying or accelerating them. These compounds have been largely used as a cell biology tool, like phalloidin in conjugation with fluorophores, overlooking their ability to compete with specific ABPs in a biomimetic mode. Trisoxazole macrolides, e.g., kabiramide C, are small biomimetic molecules promoting actin filament severing and capping by competing specifically with Gelsolin [420]. Analogously, the myxobacterial compound miuraenamides A binds to and stabilizes F-actin by competing with ADF/cofilin for its binding site [421]. Interestingly, low-dose treatment of SKOV3 and HUVECs cells with miuraenamides A showed no effects on cell viability and proliferation, while actin structure was initially subtly changed, but recovered subsequently [422].

Since the reorganization of the cell cytoskeleton is an essential process during metastasis formation, this class of molecules has always been seen as a good candidate for anticancer drug development. However, they could be a starting point in the creation of new compounds that do not influence actin polymerization per se but selectively antagonize specific ABPs.

6.3. Modulation of Small GTPases Activity

Several forms of ID are caused by mutations that either increase or decrease Rho GTPases' signaling. However, it is important to note that both hyper- and hypo-activation of these signaling pathways led to similar phenotypes. A good example is provided by the mouse model bearing RAC1 conditional inactivation at the hippocampal level, which resembles the phenotypic abnormalities reported for the FXS model, which in contrast shows a massive activation of RAC1 [10,423]. This comparison stresses the importance of tight control on GTPases functioning and encourages the research of both positive and negative pharmaceutical modulators.

Several compounds were characterized for their inhibitory activity toward RAC1, which is of particular interest in cancer research. Most of them act by interfering with RAC1-GEF PPI, such as NSC23766 and EHOp-016 (which interfere with TRIO and TIAM1) [424,425] and AZA1 (which inhibits both CDC42 and RAC1) [426], or by promoting GTP unloading, such as EHT1864 [427]. Peptide-based approaches have also shown early promise [428].

A striking example of such a pharmacological treatment is provided by the *Ophn1*-KO model of ID, which exhibits hyperactive RHOA signaling. In these mice, the administration of the ROCK/PKA inhibitor Fasudil rescued spine density, hippocampal hyperexcitability, ventricular enlargement, and behavioral abnormalities [170,429]. Fasudil was also able to rescue the decreased neurogenic potential and impaired neurite elongation in *OPHN1*-deficient human iPSCs [171].

In other cases, the opposite approach is required, i.e., positive modulation of the GTPase activity. Hyper-activation of RAC1 through the inoculation of the bacterial toxin CNF1 has been shown to improve the behavioral phenotype of a mouse model of Rett syndrome and to reverse the astrocytic deficits, which were assumed to have an impact on dendritic maturation [430]. CNF1 activates Rho GTPases through a single glutamine deamidation [431,432], allowing the reshape of the actin cytoskeleton and consequently promoting neurotransmission and synaptic plasticity. CNF1 was shown to enhance working memory for object location and discrimination also in WT mice [433,434].

7. Concluding Remarks

Current treatments of ID are largely based on psychosocial measures, environmental enrichment, dedicated educational plans, and motor activity, while pharmacotherapies are lagging. Recent evidence suggests that some phenotypes associated with cognitive disabilities can be reversed, through either genetic approaches [435] or pharmacotherapy. At present, whether these provide a realistic opportunity for treatment remains to be defined.

One obstacle is represented by the high genetic variability observed in ID. SB approaches and integrative tools are beginning to deconvolute and model the core biological

processes responsible for the altered circuitry and synaptic dysfunctions in ID. One of these processes is the regulation of cytoskeleton dynamics, whose hubs are the small GTPases of the Rho class. A relevant outcome of our current knowledge is the possibility to leverage the wealth of experimental and mutational data to derive a computational model, through which we will learn more about the behavior of the system.

Rho class GTPases are promising targets for pharmacological intervention and can be positively or negatively modulated by acting upstream, on the regulatory partners, or downstream, on actin stability. To achieve a brain-specific, GTPase-specific, modest, and controlled remodulation, a full characterization of the PPI between GTPases and their regulatory partners is required. Current knowledge led to the identification of several potentially valid compounds, some of which are well characterized for their biological activity, while others still need a proper characterization.

Future efforts should focus on completing our knowledge about the cytoskeleton core regulatory network, considering that relevant elements might still be missing or have been overlooked. Proteomic analyses focused on the human neuronal cytoskeleton are needed, intending to identify novel druggable elements participating in the GTPase regulatory network or neurodevelopmental processes, i.e., neurite elongation, neuronal migration, and adhesion.

Since most of the current knowledge is based on animal models, an area of strong interest is the generation and validation of cellular models of ID based on human neurons. Such models should recapitulate the cortical and hippocampal endophenotype of human ID and offer the possibility to examine the excitatory/inhibitory balance. In light of these observations, human iPSCs offer a valid model to identify new valuable readouts and to start screening compounds able to alleviate ID [436].

Author Contributions: C.L., M.C., G.C., S.R., S.C., V.R., and G.R.M. wrote parts of the original text and assisted in figure design and drawing. G.R.M. and C.L. coordinated the work and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by Telethon Foundation (Italy, GGP20039) and Univ. of Torino (RiLO ex 60%).

Data Availability Statement: SysID database (<https://www.sysid.dbmr.unibe.ch/>, accessed on 6 June 2021); Online Mendelian Inheritance in Man (OMIM) (<https://www.omim.org/>, accessed on 6 June 2021); The Human Phenotype Ontology (HPO) (<https://hpo.jax.org/app/>, accessed on 6 June 2021); Gene Ontology Resource (GO) (<http://geneontology.org/>, accessed on 6 June 2021); Human Brain Transcriptome (HBT) (<https://hbatlas.org/>, accessed on 6 June 2021); non-neuronal cell types RNA-seq data are available in the NCBI GEO database as GEO: GSE73721.

Acknowledgments: We thank Emilio Hirsch (Univ. of Torino, Italy) for helpful comments on the manuscript and Federico Torelli (Univ. of Freiburg, Germany) for graphic assistance.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

ID	Intellectual Disability
SB	Systems Biology
NDD	Neurodevelopmental Disorder
XLID	X-linked Intellectual Disability
PPI	Protein::Protein Interaction
GO	Gene Ontology
GDD	Global Developmental Delay
ASD	Autism Spectrum Disorder

LTD	Long Term Depression,
DS	Down syndrome
G-actin	Glomerular actin
F-actin	Fibrous actin
GAP	GTPase Activating Protein
GEF	Guanine Exchange Factor
KD	Knock-Down
ABP	Actin Binding Protein
NPF	Nucleation Promoting Factor
WRC	WAVE Regulatory Complex
PSD	Postsynaptic Density
+TIP	Microtubule Plus End Tracking Protein
CLIP	Cytoplasmic Linker Protein

References

- Kochinke, K.; Zweier, C.; Nijhof, B.; Fenckova, M.; Cizek, P.; Honti, F.; Keerthikumar, S.; Oortveld, M.A.; Kleefstra, T.; Kramer, J.; et al. Systematic Phenomics Analysis Deconvolutes Genes Mutated in Intellectual Disability into Biologically Coherent Modules. *Am. J. Hum. Genet.* **2016**, *98*, 149–164. [[CrossRef](#)] [[PubMed](#)]
- Mir, Y.R.; Kuchay, R.A.H. Advances in identification of genes involved in autosomal recessive intellectual disability: A brief review. *J. Med. Genet.* **2019**, *56*, 567–573. [[CrossRef](#)]
- Van Bokhoven, H. Genetic and Epigenetic Networks in Intellectual Disabilities. *Annu. Rev. Genet.* **2011**, *45*, 81–104. [[CrossRef](#)]
- Srivastava, A.K.; Schwartz, C.E. Intellectual disability and autism spectrum disorders: Causal genes and molecular mechanisms. *Neurosci. Biobehav. Rev.* **2014**, *46*, 161–174. [[CrossRef](#)]
- McKenzie, K.; Milton, M.; Smith, G.; Ouellette-Kuntz, H. Systematic Review of the Prevalence and Incidence of Intellectual Disabilities: Current Trends and Issues. *Curr. Dev. Disord. Rep.* **2016**, *3*, 104–115. [[CrossRef](#)]
- Mottron, L.; Belleville, S.; Rouleau, G.A.; Collignon, O. Linking neocortical, cognitive, and genetic variability in autism with alterations of brain plasticity: The Trigger-Threshold-Target model. *Neurosci. Biobehav. Rev.* **2014**, *47*, 735–752. [[CrossRef](#)]
- Ba, W.; van der Raadt, J.; Kasri, N.N. Rho GTPase signaling at the synapse: Implications for intellectual disability. *Exp. Cell Res.* **2013**, *319*, 2368–2374. [[CrossRef](#)] [[PubMed](#)]
- Penzes, P.; Buonanno, A.; Passafarro, M.; Sala, C.; Sweet, R.A. Developmental vulnerability of synapses and circuits associated with neuropsychiatric disorders. *J. Neurochem.* **2013**, *126*, 165–182. [[CrossRef](#)]
- Murakoshi, H.; Wang, H.; Yasuda, R. Local, persistent activation of Rho GTPases during plasticity of single dendritic spines. *Nat. Cell Biol.* **2011**, *472*, 100–104. [[CrossRef](#)]
- Tejada-Simon, M.V. Modulation of actin dynamics by Rac1 to target cognitive function. *J. Neurochem.* **2015**, *133*, 767–779. [[CrossRef](#)]
- De Filippis, B.; Valenti, D.; Chiodi, V.; Ferrante, A.; de Bari, L.; Fiorentini, C.; Domenici, M.R.; Ricceri, L.; Vacca, R.A.; Fabbri, A.; et al. Modulation of Rho GTPases rescues brain mitochondrial dysfunction, cognitive deficits and aberrant synaptic plasticity in female mice modeling Rett syndrome. *Eur. Neuropsychopharmacol.* **2015**, *25*, 889–901. [[CrossRef](#)]
- Ashburner, M.; Ball, C.A.; Blake, J.A.; Botstein, D.; Butler, H.; Cherry, J.M.; Davis, A.P.; Dolinski, K.; Dwight, S.S.; Eppig, J.T.; et al. Gene Ontology: Tool for the unification of biology. *Nat. Genet.* **2000**, *25*, 25–29. [[CrossRef](#)]
- Carbon, S.; Douglass, E.; Good, B.M.; Unni, D.R.; Harris, N.L.; Mungall, C.J.; Basu, S.; Chisholm, R.L.; Dodson, R.J.; Hartline, E.; et al. The Gene Ontology resource: Enriching a Gold mine. *Nucleic Acids Res.* **2021**, *49*, D325–D334. [[CrossRef](#)]
- Liu, Z.; Zhang, N.; Zhang, Y.; Du, Y.; Zhang, T.; Li, Z.; Wu, J.; Wang, X. Prioritized High-Confidence Risk Genes for Intellectual Disability Reveal Molecular Convergence During Brain Development. *Front. Genet.* **2018**, *9*, 349. [[CrossRef](#)] [[PubMed](#)]
- InanlooRahatloo, K.; Peymani, F.; Kahrizi, K.; Najmabadi, H. Whole-Transcriptome Analysis Reveals Dysregulation of Actin-Cytoskeleton Pathway in Intellectual Disability Patients. *Neuroscience* **2019**, *404*, 423–444. [[CrossRef](#)] [[PubMed](#)]
- Piergiorgio, R.M.; De Vasconcelos, A.T.R.; Pimentel, M.M.G.; Santos-Rebouças, C.B. Strict network analysis of evolutionary conserved and brain-expressed genes reveals new putative candidates implicated in Intellectual Disability and in Global Development Delay. *World J. Biol. Psychiatry* **2020**, *1*–11. [[CrossRef](#)] [[PubMed](#)]
- Gupta, S.; Kim, S.Y.; Artis, S.; Molfese, D.; Schumacher, A.; Sweatt, J.D.; Paylor, R.E.; Lubin, F.D. Histone Methylation Regulates Memory Formation. *J. Neurosci.* **2010**, *30*, 3589–3599. [[CrossRef](#)]
- Baker-Andresen, D.; Ratnu, V.S.; Bredy, T.W. Dynamic DNA methylation: A prime candidate for genomic metaplasticity and behavioral adaptation. *Trends Neurosci.* **2013**, *36*, 3–13. [[CrossRef](#)]
- Santen, G.W.E.; Aten, E.; Sun, Y.; Almomani, R.; Gilissen, C.; Nielsen, M.; Kant, S.G.; Snoeck, I.N.; Peeters, E.A.J.; Hilhorst-Hofstee, Y.; et al. Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat. Genet.* **2012**, *44*, 379–380. [[CrossRef](#)]
- Willemsen, M.; Silfhout, A.V.-V.; Nillesen, W.; Wissink-Lindhout, W.; Van Bokhoven, H.; Philip, N.; Berry-Kravis, E.; Kini, U.; Van Ravenswaaij-Arts, C.; Chiaie, B.D.; et al. Update on Kleefstra Syndrome. *Mol. Syndr.* **2012**, *2*, 202–212. [[CrossRef](#)]

21. Iwase, S.; Lan, F.; Bayliss, P.; De La Torre-Ubieta, L.; Huarte, M.; Qi, H.H.; Whetstine, J.R.; Bonni, A.; Roberts, T.M.; Shi, Y. The X-Linked Mental Retardation Gene SMCX/JARID1C Defines a Family of Histone H3 Lysine 4 Demethylases. *Cell* **2007**, *128*, 1077–1088. [[CrossRef](#)] [[PubMed](#)]
22. Chen, H.-H.; Yu, H.-I.; Tarn, W.-Y. DDX3 Modulates Neurite Development via Translationally Activating an RNA Regulator Involved in Rac1 Activation. *J. Neurosci.* **2016**, *36*, 9792–9804. [[CrossRef](#)]
23. Gudenäs, B.L.; Wang, L. Gene Coexpression Networks in Human Brain Developmental Transcriptomes Implicate the Association of Long Noncoding RNAs with Intellectual Disability. *Bioinform. Biol. Insights* **2015**, *9*, BBI-S29435. [[CrossRef](#)] [[PubMed](#)]
24. Kuechler, A.; Willemsen, M.H.; Albrecht, B.; Bacino, C.A.; Bartholomew, D.W.; Van Bokhoven, H.; Boogaard, M.J.H.V.D.; Bramswig, N.; Buettner, C.; Cremer, K.; et al. De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: Expanding the mutational and clinical spectrum. *Hum. Genet.* **2015**, *134*, 97–109. [[CrossRef](#)]
25. O’Roak, B.J.; Vives, L.; Fu, W.; Egertson, J.D.; Stanaway, I.B.; Phelps, I.G.; Carvill, G.; Kumar, A.; Lee, C.; Ankenman, K.; et al. Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders. *Science* **2012**, *338*, 1619–1622. [[CrossRef](#)]
26. Santini, E.; Huynh, T.; MacAskill, A.F.; Carter, A.G.; Pierre, P.; Ruggero, D.; Kaphzan, H.; Klann, E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. *Nature* **2013**, *493*, 411–415. [[CrossRef](#)]
27. Kwon, C.-H.; Zhu, X.; Zhang, J.; Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 12923–12928. [[CrossRef](#)]
28. Magdalon, J.; Sánchez-Sánchez, S.M.; Griese-Oliveira, K.; Sertié, A.L. Dysfunctional mTORC1 Signaling: A Convergent Mechanism between Syndromic and Nonsyndromic Forms of Autism Spectrum Disorder? *Int. J. Mol. Sci.* **2017**, *18*, 659. [[CrossRef](#)] [[PubMed](#)]
29. Tucci, V.; Kleefstra, T.; Hardy, A.; Heise, I.; Maggi, S.; Willemsen, M.H.; Hilton, H.; Esapa, C.; Simon, M.; Buenavista, M.-T.; et al. Dominant β -catenin mutations cause intellectual disability with recognizable syndromic features. *J. Clin. Investig.* **2014**, *124*, 1468–1482. [[CrossRef](#)] [[PubMed](#)]
30. Pierpont, M.E.M.; Magoulas, P.L.; Adi, S.; Kavamura, M.I.; Neri, G.; Noonan, J.; Pierpont, E.I.; Reinker, K.; Roberts, A.E.; Shankar, S.; et al. Cardio-Facio-Cutaneous Syndrome: Clinical Features, Diagnosis, and Management Guidelines. *Pediatrics* **2014**, *134*, e1149–e1162. [[CrossRef](#)]
31. Papale, A.; D’Isa, R.; Menna, E.; Cerovic, M.; Solari, N.; Hardingham, N.; Cambiaghi, M.; Cursi, M.; Barbacid, M.; Leocani, L.; et al. Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. *Biol. Psychiatry* **2017**, *81*, 179–192. [[CrossRef](#)]
32. Yi, J.J.; Berrios, J.; Newbern, J.; Snider, W.D.; Philpot, B.D.; Hahn, K.M.; Zylka, M.J. An Autism-Linked Mutation Disables Phosphorylation Control of UBE3A. *Cell* **2015**, *162*, 795–807. [[CrossRef](#)]
33. Zheng, L.; Ding, H.; Lu, Z.; Li, Y.; Pan, Y.; Ning, T.; Ke, Y. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. *Genes Cells* **2008**, *13*, 285–294. [[CrossRef](#)]
34. Moortgat, S.; Berland, S.; Aukrust, I.; Maystadt, I.; Baker, L.; Benoit, V.; Caro-Llopis, A.; Cooper, N.S.; Debray, F.-G.; Faivre, L.; et al. HUWE1 variants cause dominant X-linked intellectual disability: A clinical study of 21 patients. *Eur. J. Hum. Genet.* **2018**, *26*, 64–74. [[CrossRef](#)]
35. D’Arca, D.; Zhao, X.; Xu, W.; Ramirez-Martinez, N.C.; Iavarone, A.; Lasorella, A. Huwe1 ubiquitin ligase is essential to synchronize neuronal and glial differentiation in the developing cerebellum. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 5875–5880. [[CrossRef](#)]
36. Londin, E.R.; Adjianto, J.; Philp, N.; Novelli, A.; Vitale, E.; Perria, C.; Serra, G.; Alesi, V.; Surrey, S.; Fortina, P. Donor splice-site mutation in CUL4Bis likely cause of X-linked intellectual disability. *Am. J. Med. Genet. Part A* **2014**, *164*, 2294–2299. [[CrossRef](#)]
37. Chen, C.-Y.; Tsai, M.-S.; Lin, C.-Y.; Yu, I.-S.; Chen, Y.-T.; Lin, S.-R.; Juan, L.-W.; Chen, Y.-T.; Hsu, H.-M.; Lee, L.-J.; et al. Rescue of the genetically engineered *Cul4b* mutant mouse as a potential model for human X-linked mental retardation. *Hum. Mol. Genet.* **2012**, *21*, 4270–4285. [[CrossRef](#)]
38. García-Cazorla, A.; Wolf, N.I.; Serrano, M.; Pérez-Dueñas, B.; Pineda, M.; Campistol, J.; Fernández-Alvarez, E.; Colomer, J.; DiMauro, S.; Hoffmann, G.F. Inborn errors of metabolism and motor disturbances in children. *J. Inherit. Metab. Dis.* **2009**, *32*, 618–629. [[CrossRef](#)] [[PubMed](#)]
39. Salomons, G.S.; van Dooren, S.J.; Verhoeven, N.M.; Cecil, K.M.; Ball, W.S.; Degrauw, T.J.; Jakobs, C. X-Linked Creatine-Transporter Gene (*SLC6A8*) Defect: A New Creatine-Deficiency Syndrome. *Am. J. Hum. Genet.* **2001**, *68*, 1497–1500. [[CrossRef](#)] [[PubMed](#)]
40. Rosenberg, E.H.; Almeida, L.S.; Kleefstra, T.; Degrauw, R.S.; Yntema, H.G.; Bahi, N.; Moraine, C.; Ropers, H.-H.; Fryns, J.-P.; Degrauw, T.J.; et al. High Prevalence of SLC6A8 Deficiency in X-Linked Mental Retardation. *Am. J. Hum. Genet.* **2004**, *75*, 97–105. [[CrossRef](#)] [[PubMed](#)]
41. Knerr, I.; Gibson, K.M.; Jakobs, C.; Pearl, P.L. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. *CNS Spectr.* **2008**, *13*, 598–605. [[CrossRef](#)]
42. Nicolaidis, P.; Liebsch, D.; Dale, N.; Leonard, J.; Surtees, R. Neurological outcome of patients with ornithine carbamoyltransferase deficiency. *Arch. Dis. Child.* **2002**, *86*, 54–56. [[CrossRef](#)] [[PubMed](#)]
43. D’Adamo, P.; Menegon, A.; Nigro, C.L.; Grasso, M.; Gulisano, M.; Tamanini, F.; Bienvenu, T.; Gedeon, A.K.; Oostra, B.; Wu, S.-K.; et al. Mutations in *GDI1* are responsible for X-linked non-specific mental retardation. *Nat. Genet.* **1998**, *19*, 134–139. [[CrossRef](#)]
44. Bianchi, V.; Farisello, P.; Baldelli, P.; Meskenaite, V.; Milanese, M.; Vecellio, M.; Mühlemann, S.; Lipp, H.P.; Bonanno, G.; Benfenati, F.; et al. Cognitive impairment in *Gdi1*-deficient mice is associated with altered synaptic vesicle pools and short-term synaptic plasticity, and can be corrected by appropriate learning training. *Hum. Mol. Genet.* **2008**, *18*, 105–117. [[CrossRef](#)]

45. Blumkin, L.; Michelson, M.; Leshinsky-Silver, E.; Kivity, S.; Lev, D.; Lerman-Sagie, T. Congenital Ataxia, Mental Retardation, and Dyskinesia Associated with a Novel CACNA1A Mutation. *J. Child Neurol.* **2010**, *25*, 892–897. [[CrossRef](#)]
46. Luo, X.; Rosenfeld, J.A.; Yamamoto, S.; Harel, T.; Zuo, Z.; Hall, M.; Wierenga, K.J.; Pastore, M.T.; Bartholomew, D.; Delgado, M.R.; et al. Clinically severe CACNA1A alleles affect synaptic function and neurodegeneration differentially. *PLoS Genet.* **2017**, *13*, e1006905. [[CrossRef](#)] [[PubMed](#)]
47. Hamdan, F.F.; Daoud, H.; Piton, A.; Gauthier, J.; Dobrzyniecka, S.; Krebs, M.-O.; Joobar, R.; Lacaille, J.-C.; Nadeau, A.; Milunsky, J.M.; et al. De Novo SYNGAP1 Mutations in Nonsyndromic Intellectual Disability and Autism. *Biol. Psychiatry* **2011**, *69*, 898–901. [[CrossRef](#)]
48. Holder, J.L., Jr.; Hamdan, F.F.; Michaud, J.L. *SYNGAP1-Related Intellectual Disability*; University of Washington: Seattle, WA, USA, 1993.
49. Hotulainen, P.; Hoogenraad, C. Actin in dendritic spines: Connecting dynamics to function. *J. Cell Biol.* **2010**, *189*, 619–629. [[CrossRef](#)]
50. Gu, J.; Lee, C.W.; Fan, Y.; Komlos, D.; Tang, X.; Sun, C.; Yu, K.; Hartzell, H.C.; Chen, G.; Bamburg, J.R.; et al. ADF/cofilin-mediated actin dynamics regulate AMPA receptor trafficking during synaptic plasticity. *Nat. Neurosci.* **2010**, *13*, 1208–1215. [[CrossRef](#)] [[PubMed](#)]
51. Sriroopreddy, R.; Sajeed, R.; Raghuraman, P.; Sudandiradoss, C. Differentially expressed gene (DEG) based protein-protein interaction (PPI) network identifies a spectrum of gene interactome, transcriptome and correlated miRNA in nondisjunction Down syndrome. *Int. J. Biol. Macromol.* **2019**, *122*, 1080–1089. [[CrossRef](#)]
52. Bhambhani, H.P.; Mueller, T.M.; Simmons, M.S.; Meador-Woodruff, J.H. Actin polymerization is reduced in the anterior cingulate cortex of elderly patients with schizophrenia. *Transl. Psychiatry* **2017**, *7*, 1278. [[CrossRef](#)]
53. Michaelsen-Preusse, K.; Feuge, J.; Korte, M. Imbalance of synaptic actin dynamics as a key to fragile X syndrome? *J. Physiol.* **2018**, *596*, 2773–2782. [[CrossRef](#)]
54. Bhattacharjee, A.; Mu, Y.; Winter, M.K.; Knapp, J.R.; Eggmann, L.S.; Gunewardena, S.S.; Kobayashi, K.; Kato, S.; Krizsan-Agbas, D.; Smith, P.G. Neuronal cytoskeletal gene dysregulation and mechanical hypersensitivity in a rat model of Rett syndrome. *Proc. Natl. Acad. Sci. USA* **2017**, *114*, E6952–E6961. [[CrossRef](#)]
55. Guo, D.; Yang, X.; Shi, L. Rho GTPase Regulators and Effectors in Autism Spectrum Disorders: Animal Models and Insights for Therapeutics. *Cells* **2020**, *9*, 835. [[CrossRef](#)] [[PubMed](#)]
56. Griesi-Oliveira, K.; Suzuki, A.M.; Alves, A.Y.; Mafra, A.C.C.N.; Yamamoto, G.L.; Ezquina, S.; Magalhães, Y.T.; Forti, F.L.; Sertie, A.L.; Zachi, E.C.; et al. Actin cytoskeleton dynamics in stem cells from autistic individuals. *Sci. Rep.* **2018**, *8*, 11138. [[CrossRef](#)]
57. Barón-Mendoza, I.; Garcia, O.; Calvo-Ochoa, E.; Rebollar-García, J.O.; Garzón-Cortés, D.; Haro, R.; González-Arenas, A. Alterations in neuronal cytoskeletal and astrocytic proteins content in the brain of the autistic-like mouse strain C58/J. *Neurosci. Lett.* **2018**, *682*, 32–38. [[CrossRef](#)] [[PubMed](#)]
58. Köhler, S.; Gargano, M.; Matentzoglou, N.; Carmody, L.C.; Lewis-Smith, D.; Vasilevsky, N.A.; Danis, D.; Balagura, G.; Baynam, G.; Brower, A.M.; et al. The Human Phenotype Ontology in 2021. *Nucleic Acids Res.* **2021**, *49*, D1207–D1217. [[CrossRef](#)] [[PubMed](#)]
59. Gonzalez-Mantilla, A.J.; Moreno-De-Luca, A.; Ledbetter, D.H.; Martin, C.L. A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders. *JAMA Psychiatry* **2016**, *73*, 275–283. [[CrossRef](#)]
60. Amberger, J.S.; Bocchini, C.A.; Scott, A.F.; Hamosh, A. McKusick's Online Mendelian Inheritance in Man (OMIM®). *Nucleic Acids Res.* **2009**, *37*, D793–D796. [[CrossRef](#)] [[PubMed](#)]
61. Kahn, O.I.; Baas, P.W. Microtubules and Growth Cones: Motors Drive the Turn. *Trends Neurosci.* **2016**, *39*, 433–440. [[CrossRef](#)]
62. Lowery, L.A.; Van Vactor, D. The trip of the tip: Understanding the growth cone machinery. *Nat. Rev. Mol. Cell Biol.* **2009**, *10*, 332–343. [[CrossRef](#)]
63. Maday, S.; Twelvetrees, A.E.; Moughamian, A.J.; Holzbaur, E.L. Axonal Transport: Cargo-Specific Mechanisms of Motility and Regulation. *Neuron* **2014**, *84*, 292–309. [[CrossRef](#)]
64. Tanaka, E.; Sabry, J. Making the connection: Cytoskeletal rearrangements during growth cone guidance. *Cell* **1995**, *83*, 171–176. [[CrossRef](#)]
65. Lewis, S.A.; Tian, G.; Cowan, N.J. The α - and β -tubulin folding pathways. *Trends Cell Biol.* **1997**, *7*, 479–484. [[CrossRef](#)]
66. Kunze, D.; Rüstow, B. Pathobiochemical Aspects of Cytoskeleton Components. *Clin. Chem. Lab. Med.* **1993**, *31*, 477–490. [[CrossRef](#)] [[PubMed](#)]
67. Johnson, G.V.W.; Jope, R.S. The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. *J. Neurosci. Res.* **1992**, *33*, 505–512. [[CrossRef](#)]
68. Winder, S.J.; Ayscough, K.R. Actin-binding proteins. *J. Cell Sci.* **2005**, *118*, 651–654. [[CrossRef](#)]
69. Mitchison, T.J.; Kirschner, M.W. Dynamic instability of microtubule growth. *Nat. Cell Biol.* **1984**, *312*, 237–242. [[CrossRef](#)] [[PubMed](#)]
70. Pollard, T.D.; Borisy, G.G. Cellular Motility Driven by Assembly and Disassembly of Actin Filaments. *Cell* **2003**, *112*, 453–465. [[CrossRef](#)]
71. Haydon, P.G.; Drapeau, P. From contact to connection: Early events during synaptogenesis. *Trends Neurosci.* **1995**, *18*, 196–201. [[CrossRef](#)]
72. Korobova, F.; Svitkina, T. Molecular Architecture of Synaptic Actin Cytoskeleton in Hippocampal Neurons Reveals a Mechanism of Dendritic Spine Morphogenesis. *Mol. Biol. Cell* **2010**, *21*, 165–176. [[CrossRef](#)]

73. Südhof, T.C. Towards an Understanding of Synapse Formation. *Neuron* **2018**, *100*, 276–293. [[CrossRef](#)]
74. Yoshihara, Y.; De Roo, M.; Muller, D. Dendritic spine formation and stabilization. *Curr. Opin. Neurobiol.* **2009**, *19*, 146–153. [[CrossRef](#)] [[PubMed](#)]
75. Spence, E.F.; Soderling, S.H. Actin Out: Regulation of the Synaptic Cytoskeleton. *J. Biol. Chem.* **2015**, *290*, 28613–28622. [[CrossRef](#)] [[PubMed](#)]
76. Yusifov, R.; Tippmann, A.; Staiger, J.F.; Schlüter, O.M.; Löwel, S. Spine dynamics of PSD-95-deficient neurons in the visual cortex link silent synapses to structural cortical plasticity. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2022701118. [[CrossRef](#)]
77. Sala, C.; Piëch, V.; Wilson, N.R.; Passafaro, M.; Liu, G.; Sheng, M. Regulation of Dendritic Spine Morphology and Synaptic Function by Shank and Homer. *Neuron* **2001**, *31*, 115–130. [[CrossRef](#)]
78. Repetto, D.; Camera, P.; Melani, R.; Morello, N.; Russo, I.; Calcagno, E.; Tomasoni, R.; Bianchi, F.T.; Berto, G.; Giustetto, M.; et al. P140cap Regulates Memory and Synaptic Plasticity through Src-Mediated and Citron-N-Mediated Actin Reorganization. *J. Neurosci.* **2014**, *34*, 1542–1553. [[CrossRef](#)]
79. Huganir, R.L.; Nicoll, R.A. AMPARs and Synaptic Plasticity: The Last 25 Years. *Neuron* **2013**, *80*, 704–717. [[CrossRef](#)]
80. Allison, D.W.; Gelfand, V.I.; Spector, I.; Craig, A.M. Role of Actin in Anchoring Postsynaptic Receptors in Cultured Hippocampal Neurons: Differential Attachment of NMDA versus AMPA Receptors. *J. Neurosci.* **1998**, *18*, 2423–2436. [[CrossRef](#)]
81. Kim, C.-H.; Lisman, J.E. A Role of Actin Filament in Synaptic Transmission and Long-Term Potentiation. *J. Neurosci.* **1999**, *19*, 4314–4324. [[CrossRef](#)]
82. Zhou, Q.; Xiao, M.-Y.; Nicoll, R.A. Contribution of cytoskeleton to the internalization of AMPA receptors. *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 1261–1266. [[CrossRef](#)]
83. Duffney, L.J.; Wei, J.; Cheng, J.; Liu, W.; Smith, K.R.; Kittler, J.T.; Yan, Z. Shank3 Deficiency Induces NMDA Receptor Hypofunction via an Actin-Dependent Mechanism. *J. Neurosci.* **2013**, *33*, 15767–15778. [[CrossRef](#)]
84. Irwin, S.A.; Galvez, R.; Greenough, W.T. Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome. *Cereb. Cortex* **2000**, *10*, 1038–1044. [[CrossRef](#)]
85. Kozma, R.; Sarner, S.; Ahmed, S.; Lim, L. Rho family GTPases and neuronal growth cone remodelling: Relationship between increased complexity induced by Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and lysophosphatidic acid. *Mol. Cell. Biol.* **1997**, *17*, 1201–1211. [[CrossRef](#)] [[PubMed](#)]
86. Smith, C.L. Cytoskeletal movements and substrate interactions during initiation of neurite outgrowth by sympathetic neurons in vitro. *J. Neurosci.* **1994**, *14*, 384–398. [[CrossRef](#)] [[PubMed](#)]
87. Tashiro, A.; Minden, A.; Yuste, R. Regulation of dendritic spine morphology by the rho family of small GTPases: Antagonistic roles of Rac and Rho. *Cereb. Cortex* **2000**, *10*, 927–938. [[CrossRef](#)] [[PubMed](#)]
88. Wiens, K.M.; Lin, H.; Liao, D. Rac1 Induces the Clustering of AMPA Receptors during Spinogenesis. *J. Neurosci.* **2005**, *25*, 10627–10636. [[CrossRef](#)]
89. Martinez, L.A.; Tejada-Simon, M.V. Pharmacological inactivation of the small GTPase Rac1 impairs long-term plasticity in the mouse hippocampus. *Neuropharmacology* **2011**, *61*, 305–312. [[CrossRef](#)] [[PubMed](#)]
90. Woo, S.; Gomez, T.M. Rac1 and RhoA Promote Neurite Outgrowth through Formation and Stabilization of Growth Cone Point Contacts. *J. Neurosci.* **2006**, *26*, 1418–1428. [[CrossRef](#)]
91. Aoki, K.; Nakamura, T.; Matsuda, M. Spatio-temporal Regulation of Rac1 and Cdc42 Activity during Nerve Growth Factor-induced Neurite Outgrowth in PC12 Cells. *J. Biol. Chem.* **2004**, *279*, 713–719. [[CrossRef](#)]
92. Lelieveld, S.H.; Reijnders, M.R.F.; Pfundt, R.; Yntema, H.G.; Kamsteeg, E.-J.; De Vries, P.; De Vries, B.B.A.; Willemsen, M.H.; Kleefstra, T.; Löhner, K.; et al. Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disability. *Nat. Neurosci.* **2016**, *19*, 1194–1196. [[CrossRef](#)]
93. Reijnders, M.R.; Ansor, N.M.; Kousi, M.; Yue, W.W.; Tan, P.L.; Clarkson, K.; Clayton-Smith, J.; Corning, K.; Jones, J.R.; Lam, W.W.; et al. RAC1 Missense Mutations in Developmental Disorders with Diverse Phenotypes. *Am. J. Hum. Genet.* **2017**, *101*, 466–477. [[CrossRef](#)] [[PubMed](#)]
94. Tian, C.; Kay, Y.; Sadybekov, A.; Rao, S.; Katritch, V.; Herring, B.E. An Intellectual Disability-Related Missense Mutation in Rac1 Prevents LTP Induction. *Front. Mol. Neurosci.* **2018**, *11*, 223. [[CrossRef](#)] [[PubMed](#)]
95. Chen, L.; Liao, G.; Waclaw, R.R.; Burns, K.A.; Linnquist, D.; Campbell, K.; Zheng, Y.; Kuan, C.-Y. Rac1 Controls the Formation of Midline Commissures and the Competency of Tangential Migration in Ventral Telencephalic Neurons. *J. Neurosci.* **2007**, *27*, 3884–3893. [[CrossRef](#)] [[PubMed](#)]
96. Wong, K.; Ren, X.-R.; Huang, Y.-Z.; Xie, Y.; Liu, G.; Saito, H.; Tang, H.; Wen, L.; Brady-Kalnay, S.M.; Mei, L.; et al. Signal Transduction in Neuronal Migration. *Cell* **2001**, *107*, 209–221. [[CrossRef](#)]
97. Garvalov, B.K.; Flynn, K.C.; Neukirchen, D.; Meyn, L.; Teusch, N.; Wu, X.; Brakebusch, C.; Bamberg, J.R.; Bradke, F. Cdc42 Regulates Cofilin during the Establishment of Neuronal Polarity. *J. Neurosci.* **2007**, *27*, 13117–13129. [[CrossRef](#)]
98. Li, A.; Zhu, H.-M.; Chen, Y.; Yan, F.; Liu, Z.-Y.; Li, Z.-L.; Dong, W.-R.; Zhang, L.; Wang, H.-H. Cdc42 Facilitates Axonogenesis by Enhancing Microtubule Stabilization in Primary Hippocampal Neurons. *Cell. Mol. Neurobiol.* **2021**, 1–12. [[CrossRef](#)]
99. Takenouchi, T.; Okamoto, N.; Ida, S.; Uehara, T.; Kosaki, K. Further evidence of a mutation in CDC42 as a cause of a recognizable syndromic form of thrombocytopenia. *Am. J. Med. Genet. Part A* **2015**, *170*, 852–855. [[CrossRef](#)]

100. Takenouchi, T.; Kosaki, R.; Niizuma, T.; Hata, K.; Kosaki, K. Macrothrombocytopenia and developmental delay with a *de novo* CDC42 mutation: Yet another locus for thrombocytopenia and developmental delay. *Am. J. Med. Genet. Part A* **2015**, *167*, 2822–2825. [[CrossRef](#)]
101. Martinelli, S.; Krumbach, O.H.; Pantaleoni, F.; Coppola, S.; Amin, E.; Pannone, L.; Nouri, K.; Farina, L.; Dvorsky, R.; Lepri, F.; et al. Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. *Am. J. Hum. Genet.* **2018**, *102*, 309–320. [[CrossRef](#)]
102. Motokawa, M.; Watanabe, S.; Nakatomi, A.; Kondoh, T.; Matsumoto, T.; Morifuji, K.; Sawada, H.; Nishimura, T.; Nunoi, H.; Yoshiura, K.I.; et al. A hot-spot mutation in CDC42 (p.Tyr64Cys) and novel phenotypes in the third patient with Takenouchi-Kosaki syndrome. *J. Hum. Genet.* **2018**, *63*, 387–390. [[CrossRef](#)]
103. Kim, I.H.; Wang, H.; Soderling, S.H.; Yasuda, R. Loss of Cdc42 leads to defects in synaptic plasticity and remote memory recall. *Elife* **2014**, *3*, e02839. [[CrossRef](#)] [[PubMed](#)]
104. Yamaguchi, Y.; Kato, H.; Yasui, H.; Mori, K.; Negishi, M. RhoA Inhibits the Nerve Growth Factor-induced Rac1 Activation through Rho-associated Kinase-dependent Pathway. *J. Biol. Chem.* **2001**, *276*, 18977–18983. [[CrossRef](#)] [[PubMed](#)]
105. Jalink, K.; Van Corven, E.J.; Hengeveld, T.; Morii, N.; Narumiya, S.; Moolenaar, W.H. Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. *J. Cell Biol.* **1994**, *126*, 801–810. [[CrossRef](#)]
106. Hirose, M.; Ishizaki, T.; Watanabe, N.; Uehata, M.; Kranenburg, O.; Moolenaar, W.H.; Matsumura, F.; Maekawa, M.; Bito, H.; Narumiya, S. Molecular dissection of the Rho-associated protein kinase (p160ROCK)- regulated neurite remodeling in neuroblastoma N1E-115 cells. *J. Cell Biol.* **1998**, *141*, 1625–1636. [[CrossRef](#)]
107. Kubo, T.; Endo, M.; Hata, K.; Taniguchi, J.; Kitajo, K.; Tomura, S.; Yamaguchi, A.; Mueller, B.K.; Yamashita, T. Myosin IIA is required for neurite outgrowth inhibition produced by repulsive guidance molecule. *J. Neurochem.* **2008**, *105*, 113–126. [[CrossRef](#)] [[PubMed](#)]
108. Pilpel, Y.; Segal, M. Activation of PKC induces rapid morphological plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms. *Eur. J. Neurosci.* **2004**, *19*, 3151–3164. [[CrossRef](#)] [[PubMed](#)]
109. Chen, Y.; Yang, Z.; Meng, M.; Zhao, Y.; Dong, N.; Yan, H.; Liu, L.; Ding, M.; Peng, H.B.; Shao, F. Cullin Mediates Degradation of RhoA through Evolutionarily Conserved BTB Adaptors to Control Actin Cytoskeleton Structure and Cell Movement. *Mol. Cell* **2009**, *35*, 841–855. [[CrossRef](#)]
110. Wang, T.; Guo, H.; Xiong, B.; Stessman, H.A.F.; Wu, H.; Coe, B.P.; Turner, T.N.; Liu, Y.; Zhao, W.; Hoekzema, K.; et al. De novo genic mutations among a Chinese autism spectrum disorder cohort. *Nat. Commun.* **2016**, *7*, 13316. [[CrossRef](#)]
111. Lin, G.N.; Corominas, R.; Lemmens, I.; Yang, X.; Tavernier, J.; Hill, D.E.; Vidal, M.; Sebat, J.; Iakoucheva, L.M. Spatiotemporal 16p11.2 Protein Network Implicates Cortical Late Mid-Fetal Brain Development and KCTD13-Cul3-RhoA Pathway in Psychiatric Diseases. *Neuron* **2015**, *85*, 742–754. [[CrossRef](#)] [[PubMed](#)]
112. Escamilla, C.O.; Filonova, I.; Walker, A.K.; Xuan, Z.X.; Holehonnur, R.; Espinosa, F.; Liu, S.; Thyme, S.; López-García, I.A.; Mendoza, D.B.; et al. Kctd13 deletion reduces synaptic transmission via increased RhoA. *Nature* **2017**, *551*, 227–231. [[CrossRef](#)] [[PubMed](#)]
113. Martin Lorenzo, S.; Nalesso, V.; Chevalier, C.; Birling, M.C.; Herault, Y. Targeting the RHOA pathway improves learning and memory in adult Kctd13 and 16p11.2 deletion mouse models. *Mol. Autism* **2021**, *12*, 1. [[CrossRef](#)] [[PubMed](#)]
114. Zhang, K.; Wang, Y.; Fan, T.; Zeng, C.; Sun, Z.S. The p21-activated kinases in neural cytoskeletal remodeling and related neurological disorders. *Protein Cell* **2020**. [[CrossRef](#)]
115. Manser, E.; Leung, T.; Salihuddin, H.; Zhao, Z.S.; Lim, L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. *Nature* **1994**, *367*, 40–46. [[CrossRef](#)] [[PubMed](#)]
116. Buchwald, G.; Hostinova, E.; Rudolph, M.G.; Kraemer, A.; Sickmann, A.; Meyer, H.E.; Scheffzek, K.; Wittinghofer, A. Conformational Switch and Role of Phosphorylation in PAK Activation. *Mol. Cell Biol.* **2001**, *21*, 5179–5189. [[CrossRef](#)]
117. Reeder, M.K.; Serebriiskii, I.G.; Golemis, E.A.; Chernoff, J. Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants that Selectively Couple to Cdc42. *J. Biol. Chem.* **2001**, *276*, 40606–40613. [[CrossRef](#)]
118. Asrar, S.; Meng, Y.; Zhou, Z.; Todorovski, Z.; Huang, W.W.; Jia, Z. Regulation of hippocampal long-term potentiation by p21-activated protein kinase 1 (PAK1). *Neuropharmacology* **2009**, *56*, 73–80. [[CrossRef](#)]
119. Causeret, F.; Terao, M.; Jacobs, T.; Nishimura, Y.V.; Yanagawa, Y.; Obata, K.; Hoshino, M.; Nikolić, M. The p21-activated kinase is required for neuronal migration in the cerebral cortex. *Cereb. Cortex* **2009**, *19*, 861–875. [[CrossRef](#)]
120. Horn, S.; Au, M.; Basel-Salmon, L.; Bayrak-Toydemir, P.; Chapin, A.; Cohen, L.; Elting, M.W.; Graham, J.M.; Gonzaga-Jauregui, C.; Konen, O.; et al. De novo variants in PAK1 lead to intellectual disability with macrocephaly and seizures. *Brain* **2019**, *142*, 3351–3359. [[CrossRef](#)]
121. Otori, S.; Mitsuhashi, S.; Ben-Haim, R.; Heyman, E.; Sengoku, T.; Ogata, K.; Matsumoto, N. A novel PAK1 variant causative of neurodevelopmental disorder with postnatal macrocephaly. *J. Hum. Genet.* **2020**, *65*, 481–485. [[CrossRef](#)]
122. Huo, H.Q.; Qu, Z.Y.; Yuan, F.; Ma, L.; Yao, L.; Xu, M.; Hu, Y.; Ji, J.; Bhattacharyya, A.; Zhang, S.C.; et al. Modeling Down Syndrome with Patient iPSCs Reveals Cellular and Migration Deficits of GABAergic Neurons. *Stem Cell Rep.* **2018**, *10*, 1251–1266. [[CrossRef](#)]
123. Kreis, P.; Thévenot, E.; Rousseau, V.; Boda, B.; Muller, D.; Barnier, J.V. The p21-activated kinase 3 implicated in mental retardation regulates spine morphogenesis through a Cdc42-dependent pathway. *J. Biol. Chem.* **2007**, *282*, 21497–21506. [[CrossRef](#)]

124. Duarte, K.; Heide, S.; Poëa-Guyon, S.; Rousseau, V.; Depienne, C.; Rastetter, A.; Nava, C.; Attié-Bitach, T.; Razavi, F.; Martinovic, J.; et al. PAK3 mutations responsible for severe intellectual disability and callosal agenesis inhibit cell migration. *Neurobiol. Dis.* **2020**, *136*, 104709. [[CrossRef](#)] [[PubMed](#)]
125. Qian, Y.; Wu, B.; Lu, Y.; Zhou, W.; Wang, S.; Wang, H. Novel PAK3 gene missense variant associated with two Chinese siblings with intellectual disability: A case report. *BMC Med. Genet.* **2020**, *21*, 31. [[CrossRef](#)] [[PubMed](#)]
126. Castillon, C.; Gonzalez, L.; Domenichini, F.; Guyon, S.; Da Silva, K.; Durand, C.; Lestaavel, P.; Vaillend, C.; Laroche, S.; Barnier, J.V.; et al. The intellectual disability PAK3 R67C mutation impacts cognitive functions and adult hippocampal neurogenesis. *Hum. Mol. Genet.* **2020**, *29*, 1950–1968. [[CrossRef](#)] [[PubMed](#)]
127. Meng, J.; Meng, Y.; Hanna, A.; Janus, C.; Jia, Z. Abnormal long-lasting synaptic plasticity and cognition in mice lacking the mental retardation gene Pak3. *J. Neurosci.* **2005**, *25*, 6641–6650. [[CrossRef](#)]
128. Okano, I.; Hiraoka, J.; Otera, H.; Nunoue, K.; Ohashi, K.; Iwashita, S.; Hirai, M.; Mizuno, K. Identification and characterization of a novel family of serine/threonine kinases containing two N-terminal LIM motifs. *J. Biol. Chem.* **1995**, *270*, 31321–31330. [[CrossRef](#)]
129. Edwards, D.C.; Sanders, L.C.; Bokoch, G.M.; Gill, G.N. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. *Nat. Cell Biol.* **1999**, *1*, 253–259. [[CrossRef](#)]
130. Yang, N.; Higuchi, O.; Ohashi, K.; Nagata, K.; Wada, A.; Kangawa, K.; Nishida, E.; Mizuno, K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. *Nature* **1998**, *393*, 809–812. [[CrossRef](#)] [[PubMed](#)]
131. Sumi, T.; Matsumoto, K.; Takai, Y.; Nakamura, T. Cofilin phosphorylation and actin cytoskeletal dynamics regulated by Rho- and Cdc42-activated LIM-kinase 2. *J. Cell Biol.* **1999**, *147*, 1519–1532. [[CrossRef](#)]
132. Hoogenraad, C.C.; Akhmanova, A.; Galjart, N.; De Zeeuw, C.I. LIMK1 and CLIP-115: Linking cytoskeletal defects to Williams Syndrome. *BioEssays* **2004**, *26*, 141–150. [[CrossRef](#)]
133. Todorovski, Z.; Asrar, S.; Liu, J.; Saw, N.M.N.; Joshi, K.; Cortez, M.A.; Snead, O.C.; Xie, W.; Jia, Z. LIMK1 Regulates Long-Term Memory and Synaptic Plasticity via the Transcriptional Factor CREB. *Mol. Cell. Biol.* **2015**, *35*, 1316–1328. [[CrossRef](#)]
134. Proschel, C.; Blouin, M.J.; Gutowski, N.J.; Ludwig, R.; Noble, M. Limk1 is predominantly expressed in neural tissues and phosphorylates serine, threonine and tyrosine residues in vitro. *Oncogene* **1995**, *11*, 1271–1281.
135. Wang, J.Y.; Wigston, D.J.; Rees, H.D.; Levey, A.I.; Falls, D.L. LIM kinase 1 accumulates in presynaptic terminals during synapse maturation. *J. Comp. Neurol.* **2000**, *416*, 319–334. [[CrossRef](#)]
136. Tastet, J.; Vourc'h, P.; Laumonier, F.; Vallée, B.; Michelle, C.; Duittoz, A.; Bénédicti, H.; Andres, C.R. LIMK2d, a truncated isoform of Lim kinase 2 regulates neurite growth in absence of the LIM kinase domain. *Biochem. Biophys. Res. Commun.* **2012**, *420*, 247–252. [[CrossRef](#)]
137. Andrews, W.D.; Zito, A.; Memi, F.; Jones, G.; Tamamaki, N.; Parnavelas, J.G. Limk2 mediates semaphorin signalling in cortical interneurons migrating through the subpallium. *Biol. Open* **2013**, *2*, 277–282. [[CrossRef](#)]
138. Matsui, T.; Amano, M.; Yamamoto, T.; Chihara, K.; Nakafuku, M.; Ito, M.; Nakano, T.; Okawa, K.; Iwamatsu, A.; Kaibuchi, K. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for the small GTP binding protein Rho. *EMBO J.* **1996**, *15*, 2208–2216. [[CrossRef](#)]
139. Ishizaki, T.; Maekawa, M.; Fujisawa, K.; Okawa, K.; Iwamatsu, A.; Fujita, A.; Watanabe, N.; Saito, Y.; Kakizuka, A.; Morii, N.; et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. *EMBO J.* **1996**, *15*, 1885–1893. [[CrossRef](#)] [[PubMed](#)]
140. Nakagawa, O.; Fujisawa, K.; Ishizaki, T.; Saito, Y.; Nakao, K.; Narumiya, S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. *FEBS Lett.* **1996**, *392*, 189–193. [[CrossRef](#)]
141. Ohashi, K.; Nagata, K.; Maekawa, M.; Ishizaki, T.; Narumiya, S.; Mizuno, K. Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. *J. Biol. Chem.* **2000**, *275*, 3577–3582. [[CrossRef](#)]
142. Maekawa, M.; Ishizaki, T.; Boku, S.; Watanabe, N.; Fujita, A.; Iwamatsu, A.; Obinata, T.; Ohashi, K.; Mizuno, K.; Narumiya, S. Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. *Science* **1999**, *285*, 895–898. [[CrossRef](#)] [[PubMed](#)]
143. Amano, M.; Ito, M.; Kimura, K.; Fukata, Y.; Chihara, K.; Nakano, T.; Matsuura, Y.; Kaibuchi, K. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *J. Biol. Chem.* **1996**, *271*, 20246–20249. [[CrossRef](#)] [[PubMed](#)]
144. Kimura, K.; Ito, M.; Amano, M.; Chihara, K.; Fukata, Y.; Nakafuku, M.; Yamamori, B.; Feng, J.; Nakano, T.; Okawa, K.; et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* **1996**, *273*, 245–248. [[CrossRef](#)]
145. Katoh, K.; Kano, Y.; Amano, M.; Kaibuchi, K.; Fujiwara, K. Stress fiber organization regulated by MLCK and Rho-kinase in cultured human fibroblasts. *Am. J. Physiol. Cell Physiol.* **2001**, *280*. [[CrossRef](#)]
146. Bowling, K.M.; Thompson, M.L.; Amaral, M.D.; Finnila, C.R.; Hiatt, S.M.; Engel, K.L.; Cochran, J.N.; Brothers, K.B.; East, K.M.; Gray, D.E.; et al. Genomic diagnosis for children with intellectual disability and/or developmental delay. *Genome Med.* **2017**, *9*, 43. [[CrossRef](#)]
147. Kollins, K.M.; Hy, J.; Bridgman, P.C.; Hyang, Y.Q.; Gallo, G. Myosin-II negatively regulates minor process extension and the temporal development of neuronal polarity. *Dev. Neurobiol.* **2009**, *69*, 279–298. [[CrossRef](#)]
148. Medeiros, N.A.; Burnette, D.T.; Forscher, P. Myosin II functions in actin-bundle turnover in neuronal growth cones. *Nat. Cell Biol.* **2006**, *8*, 215–226. [[CrossRef](#)]

149. Sanders, L.C.; Matsumura, F.; Bokoch, G.M.; De Lanerolle, P. Inhibition of myosin light chain kinase by p21-activated kinase. *Science* **1999**, *283*, 2083–2085. [[CrossRef](#)] [[PubMed](#)]
150. Tsai, L.H.; Delalle, I.; Caviness, V.S.; Chae, T.; Harlow, E. P35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5. *Nature* **1994**, *371*, 419–423. [[CrossRef](#)]
151. Tang, D.; Yeung, J.; Lee, K.Y.; Matsushita, M.; Matsui, H.; Tomizawa, K.; Hatase, O.; Wang, J.H. An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator. *J. Biol. Chem.* **1995**, *270*, 26897–26903. [[CrossRef](#)]
152. Hisanaga, S.I.; Endo, R. Regulation and role of cyclin-dependent kinase activity in neuronal survival and death. *J. Neurochem.* **2010**, *115*, 1309–1321. [[CrossRef](#)]
153. Hawasli, A.H.; Benavides, D.R.; Nguyen, C.; Kansy, J.W.; Hayashi, K.; Chambon, P.; Greengard, P.; Powell, C.M.; Cooper, D.C.; Bibb, J.A. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. *Nat. Neurosci.* **2007**, *10*, 880–886. [[CrossRef](#)]
154. He, L.; Zhang, Z.; Yu, Y.; Ahmed, S.; Cheung, N.S.; Qi, R.Z. The neuronal p35 activator of Cdk5 is a novel F-actin binding and bundling protein. *Cell. Mol. Life Sci.* **2011**, *68*, 1633–1643. [[CrossRef](#)]
155. Fu, W.Y.; Chen, Y.; Sahin, M.; Zhao, X.S.; Shi, L.; Bikoff, J.B.; Lai, K.O.; Yung, W.H.; Fu, A.K.Y.; Greenberg, M.E.; et al. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. *Nat. Neurosci.* **2007**, *10*, 67–76. [[CrossRef](#)]
156. Kawachi, T.; Chihama, K.; Nabeshima, Y.I.; Hoshino, M. Cdk5 phosphorylates and stabilizes p27^{kip1} contributing to actin organization and cortical neuronal migration. *Nat. Cell Biol.* **2006**, *8*, 17–26. [[CrossRef](#)] [[PubMed](#)]
157. Besson, A.; Gurian-West, M.; Schmidt, A.; Hall, A.; Roberts, J.M. p27Kip1 modulates cell migration through the regulation of RhoA activation. *Genes Dev.* **2004**, *18*, 862–876. [[CrossRef](#)] [[PubMed](#)]
158. Xin, X.; Wang, Y.; Ma, X.M.; Rompolas, P.; Keutmann, H.T.; Mains, R.E.; Eipper, B.A. Regulation of Kalirin by Cdk5. *J. Cell Sci.* **2008**, *121*, 2601–2611. [[CrossRef](#)]
159. Kesavapany, S.; Amin, N.; Zheng, Y.L.; Nijhara, R.; Jaffe, H.; Sihag, R.; Gutkind, J.S.; Takahashi, S.; Kulkarni, A.; Grant, P.; et al. p35/Cyclin-Dependent Kinase 5 Phosphorylation of Ras Guanine Nucleotide Releasing Factor 2 (RasGRF2) Mediates Rac-Dependent Extracellular Signal-Regulated Kinase 1/2 Activity, Altering RasGRF2 and Microtubule-Associated Protein 1b Distribution in Neurons. *J. Neurosci.* **2004**, *24*, 4421–4431. [[CrossRef](#)] [[PubMed](#)]
160. Causeret, F.; Jacobs, T.; Terao, M.; Heath, O.; Hoshino, M.; Nikolić, M. Neurabin-I is phosphorylated by Cdk5: Implications for neuronal morphogenesis and cortical migration. *Mol. Biol. Cell* **2007**, *18*, 4327–4342. [[CrossRef](#)] [[PubMed](#)]
161. Cheung, Z.H.; Chin, W.H.; Chen, Y.; Ng, Y.P.; Ip, N.Y. Cdk5 is involved in BDNF-stimulated dendritic growth in hippocampal neurons. *PLoS Biol.* **2007**, *5*, 865–877. [[CrossRef](#)]
162. Moncini, S.; Castronovo, P.; Murgia, A.; Russo, S.; Bedeschi, M.F.; Lunghi, M.; Selicorni, A.; Bonati, M.T.; Riva, P.; Venturin, M. Functional characterization of CDK5 and CDK5R1 mutations identified in patients with non-syndromic intellectual disability. *J. Hum. Genet.* **2016**, *61*, 283–293. [[CrossRef](#)]
163. Cherfils, J.; Zeghouf, M. Regulation of small GTPases by GEFs, GAPs, and GDIs. *Physiol. Rev.* **2013**, *93*, 269–309. [[CrossRef](#)]
164. Fauchereau, F.; Herbrand, U.; Chafey, P.; Eberth, A.; Koulakoff, A.; Vinet, M.C.; Ahmadian, M.R.; Chelly, J.; Billuart, P. The RhoGAP activity of OPHN1, a new F-actin-binding protein, is negatively controlled by its amino-terminal domain. *Mol. Cell. Neurosci.* **2003**, *23*, 574–586. [[CrossRef](#)]
165. Khelifaoui, M.; Denis, C.; Van Galen, E.; De Bock, F.; Schmitt, A.; Houbron, C.; Morice, E.; Giros, B.; Ramakers, G.; Fagni, L.; et al. Loss of X-linked mental retardation gene oligophrenin1 in mice impairs spatial memory and leads to ventricular enlargement and dendritic spine immaturity. *J. Neurosci.* **2007**, *27*, 9439–9450. [[CrossRef](#)]
166. Billuart, P.; Bienvenu, T.; Roncet, N.; Des Portes, V.; Vinet, M.C.; Zemni, R.; Crollius, H.R.; Carrié, A.; Fauchereau, F.; Cherry, M.; et al. Oligophrenin-1 encodes a rhoGAP protein involved in X-linked mental retardation. *Nature* **1998**, *392*, 923–926. [[CrossRef](#)] [[PubMed](#)]
167. Nuovo, S.; Brankovic, V.; Caputi, C.; Casella, A.; Nigro, V.; Leuzzi, V.; Valente, E.M. Novel unconventional variants expand the allelic spectrum of OPHN1 gene. *Am. J. Med. Genet. Part A* **2021**, *185*, 1575–1581. [[CrossRef](#)] [[PubMed](#)]
168. Bergmann, C.; Zerres, K.; Senderek, J.; Rudnik-Schöneborn, S.; Eggermann, T.; Häusler, M.; Mull, M.; Ramaekers, V.T. Oligophrenin 1 (OPHN1) gene mutation causes syndromic X-linked mental retardation with epilepsy, rostral ventricular enlargement and cerebellar hypoplasia. *Brain* **2003**, *126*, 1537–1544. [[CrossRef](#)] [[PubMed](#)]
169. Bogliş, A.; Cosma, A.S.; Tripon, F.; Bănescu, C. Exon 21 deletion in the *OPHN1* gene in a family with syndromic X-linked intellectual disability: Case report. *Medicine* **2020**, *99*, e21632. [[CrossRef](#)]
170. Busti, I.; Allegra, M.; Spalletti, C.; Panzi, C.; Restani, L.; Billuart, P.; Caleo, M. ROCK/PKA inhibition rescues hippocampal hyperexcitability and GABAergic neuron alterations in a oligophrenin-1 knock-out mouse model of X-linked intellectual disability. *J. Neurosci.* **2020**, *40*, 2776–2788. [[CrossRef](#)]
171. Compagnucci, C.; Barresi, S.; Petri, S.; Billuart, P.; Piccini, G.; Chiurazzi, P.; Alfieri, P.; Bertini, E.; Zanni, G. Rho Kinase Inhibition Is Essential During In Vitro Neurogenesis and Promotes Phenotypic Rescue of Human Induced Pluripotent Stem Cell-Derived Neurons With Oligophrenin-1 Loss of Function. *Stem Cells Transl. Med.* **2016**, *5*, 860–869. [[CrossRef](#)]
172. Zamboni, V.; Armentano, M.; Saró, G.; Ciraolo, E.; Ghigo, A.; Germena, G.; Umbach, A.; Valnegri, P.; Passafaro, M.; Carabelli, V.; et al. Disruption of ArhGAP15 results in hyperactive Rac1, affects the architecture and function of hippocampal inhibitory neurons and causes cognitive deficits. *Sci. Rep.* **2016**, *6*, 34877. [[CrossRef](#)] [[PubMed](#)]

173. Mulatinho, M.V.; De Carvalho Serao, C.L.; Scalco, F.; Hardekopf, D.; Pekova, S.; Mrasek, K.; Liehr, T.; Weise, A.; Rao, N.; Llerena, J.C. Severe intellectual disability, omphalocele, hypospadias and high blood pressure associated to a deletion at 2q22.1q22.3: Case report. *Mol. Cytogenet.* **2012**, *5*, 30. [[CrossRef](#)]
174. Smigiel, R.; Szafranska, A.; Czyzewska, M.; Rauch, A.; Zweier, C.; Patkowski, D. Severe clinical course of Hirschsprung disease in a Mowat-Wilson syndrome patient. *J. Appl. Genet.* **2010**, *51*, 111–113. [[CrossRef](#)]
175. Rosário, M.; Franke, R.; Bednarski, C.; Birchmeier, W. The neurite outgrowth multiadapter RhoGAP, NOMA-GAP, regulates neurite extension through SHP2 and Cdc42. *J. Cell Biol.* **2007**, *178*, 503–516. [[CrossRef](#)] [[PubMed](#)]
176. Rosário, M.; Schuster, S.; Jüttner, R.; Parthasarathy, S.; Tarabykin, V.; Birchmeier, W. Neocortical dendritic complexity is controlled during development by NOMA-GAP-dependent inhibition of Cdc42 and activation of cofilin. *Genes Dev.* **2012**, *26*, 1743–1757. [[CrossRef](#)] [[PubMed](#)]
177. Debant, A.; Serra-Pagès, C.; Seipel, K.; O'Brien, S.; Tang, M.; Park, S.H.; Streuli, M. The multidomain protein Trio binds the LAR transmembrane tyrosine phosphatase, contains a protein kinase domain, and has separate rac-specific and rho-specific guanine nucleotide exchange factor domains. *Proc. Natl. Acad. Sci. USA* **1996**, *93*, 5466–5471. [[CrossRef](#)]
178. Pengelly, R.J.; Greville-Heygate, S.; Schmidt, S.; Seaby, E.G.; Jabalameli, M.R.; Mehta, S.G.; Parker, M.J.; Goudie, D.; Fagotto-Kaufmann, C.; Mercer, C.; et al. Mutations specific to the Rac-GEF domain of TRIO cause intellectual disability and microcephaly. *J. Med. Genet.* **2016**, *53*, 735–742. [[CrossRef](#)] [[PubMed](#)]
179. Schmidt, S.; Debant, A. Function and regulation of the Rho guanine nucleotide exchange factor Trio. *Small GTPases* **2014**, *5*, e983880. [[CrossRef](#)]
180. O'Brien, S.P.; Seipel, K.; Medley, Q.G.; Bronson, R.; Segal, R.; Streuli, M. Skeletal muscle deformity and neuroanatomical disorder in Trio exchange factor-deficient mouse embryos. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 12074–12078. [[CrossRef](#)]
181. Katranča, S.M.; Shaw, J.E.; Zhao, A.Y.; Myers, S.A.; Cocco, A.R.; Jeng, A.T.; Zhu, M.; Pittenger, C.; Greer, C.A.; Carr, S.A.; et al. Trio Haploinsufficiency Causes Neurodevelopmental Disease-Associated Deficits. *Cell Rep.* **2019**, *26*, 2805–2817. [[CrossRef](#)]
182. Ba, W.; Yan, Y.; Reijnders, M.R.F.; Schuur-Hoeijmakers, J.H.M.; Feenstra, I.; Bongers, E.M.H.F.; Bosch, D.G.M.; De Leeuw, N.; Pfundt, R.; Gilissen, C.; et al. TRIO loss of function is associated with mild intellectual disability and affects dendritic branching and synapse function. *Hum. Mol. Genet.* **2016**, *25*, 892–902. [[CrossRef](#)]
183. Ten Klooster, J.P.; Jaffer, Z.M.; Chernoff, J.; Hordijk, P.L. Targeting and activation of Rac1 are mediated by the exchange factor β -Pix. *J. Cell Biol.* **2006**, *172*, 759–769. [[CrossRef](#)] [[PubMed](#)]
184. Ramakers, G.J.A.; Wolfer, D.; Rosenberger, G.; Kuchenbecker, K.; Kreienkamp, H.J.; Prange-kiel, J.; Rune, G.; Richter, K.; Langnaese, K.; Masneuf, S.; et al. Dysregulation of Rho GTPases in the α Pix/Arhgef6 mouse model of X-linked intellectual disability is paralleled by impaired structural and synaptic plasticity and cognitive deficits. *Hum. Mol. Genet.* **2012**, *21*, 268–286. [[CrossRef](#)] [[PubMed](#)]
185. Manser, E.; Loo, T.H.; Koh, C.G.; Zhao, Z.S.; Chen, X.Q.; Tan, L.; Tan, I.; Leung, T.; Lim, L. PAK kinases are directly coupled to the PIX family of nucleotide exchange factors. *Mol. Cell* **1998**, *1*, 183–192. [[CrossRef](#)]
186. Santiago-Medina, M.; Gregus, K.A.; Gomez, T.M. PAK-PIX interactions regulate adhesion dynamics and membrane protrusion to control neurite outgrowth. *J. Cell Sci.* **2013**, *126*, 1122–1133. [[CrossRef](#)] [[PubMed](#)]
187. Park, E.; Na, M.; Choi, J.; Kim, S.; Lee, J.R.; Yoon, J.; Park, D.; Sheng, M.; Kim, E. The Shank family of postsynaptic density proteins interacts with and promotes synaptic accumulation of the β PIX guanine nucleotide exchange factor for Rac1 and Cdc42. *J. Biol. Chem.* **2003**, *278*, 19220–19229. [[CrossRef](#)]
188. Kutsche, K.; Yntema, H.; Brandt, A.; Jantke, I.; Nothwang, H.G.; Orth, U.; Boavida, M.G.; David, D.; Chelly, J.; Fryns, J.P.; et al. Mutations in ARHGEF6, encoding a guanine nucleotide exchange factor for Rho GTPases, in patients with X-linked mental retardation. *Nat. Genet.* **2000**, *26*, 247–250. [[CrossRef](#)]
189. Yntema, H.G.; Hamel, B.C.J.; Smits, A.P.T.; Van Roosmalen, T.; Van Den Helm, B.; Kremer, H.; Ropers, H.H.; Smeets, D.F.C.M.; Van Bokhoven, H. Localisation of a gene for non-specific X linked mental retardation (MRX46) to Xq25-q26. *J. Med. Genet.* **1998**, *35*, 801–805. [[CrossRef](#)]
190. Piton, A.; Redin, C.; Mandel, J.L. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. *Am. J. Hum. Genet.* **2013**, *93*, 368–383. [[CrossRef](#)]
191. Orsini, A.; Bonuccelli, A.; Striano, P.; Azzara, A.; Costagliola, G.; Consolini, R.; Peroni, D.G.; Valetto, A.; Bertini, V. Generalized epilepsy and mild intellectual disability associated with 13q34 deletion: A potential role for SOX1 and ARHGEF7. *Seizure* **2018**, *59*, 38–40. [[CrossRef](#)]
192. Kwon, Y.; Lee, S.J.; Lee, E.; Kim, D.; Park, D. β Pix heterozygous mice have defects in neuronal morphology and social interaction. *Biochem. Biophys. Res. Commun.* **2019**, *516*, 1204–1210. [[CrossRef](#)]
193. López Tobón, A.; Suresh, M.; Jin, J.; Vitriolo, A.; Pietralla, T.; Tedford, K.; Bossenz, M.; Mahnken, K.; Kiefer, F.; Testa, G.; et al. The guanine nucleotide exchange factor Arhgef7/ β Pix promotes axon formation upstream of TC10. *Sci. Rep.* **2018**, *8*, 8811. [[CrossRef](#)] [[PubMed](#)]
194. Reid, T.; Bathoorn, A.; Ahmadian, M.R.; Collard, J.G. Identification and characterization of hPEM-2, a guanine nucleotide exchange factor specific for Cdc42. *J. Biol. Chem.* **1999**, *274*, 33587–33593. [[CrossRef](#)] [[PubMed](#)]
195. Tyagarajan, S.K.; Ghosh, H.; Harvey, K.; Fritschy, J.M. Collybistin splice variants differentially interact with gephyrin and Cdc42 to regulate gephyrin clustering at GABAergic synapses. *J. Cell Sci.* **2011**, *124*, 2786–2796. [[CrossRef](#)] [[PubMed](#)]

196. Pizzarelli, R.; Griguoli, M.; Zacchi, P.; Petrini, E.M.; Barberis, A.; Cattaneo, A.; Cherubini, E. Tuning GABAergic Inhibition: Gephyrin Molecular Organization and Functions. *Neuroscience* **2020**, *439*, 125–136. [[CrossRef](#)] [[PubMed](#)]
197. Papadopoulos, T.; Korte, M.; Eulenburg, V.; Kubota, H.; Retiounskaia, M.; Harvey, R.J.; Harvey, K.; O'Sullivan, G.A.; Laube, B.; Hülsmann, S.; et al. Impaired GABAergic transmission and altered hippocampal synaptic plasticity in collybistin-deficient mice. *EMBO J.* **2007**, *26*, 3888–3899. [[CrossRef](#)]
198. Alber, M.; Kalscheuer, V.M.; Marco, E.; Sherr, E.; Lesca, G.; Till, M.; Gradek, G.; Wiesener, A.; Korenke, C.; Mercier, S.; et al. *ARHGEF9* disease. *Neurol. Genet.* **2017**, *3*. [[CrossRef](#)] [[PubMed](#)]
199. Wang, J.Y.; Zhou, P.; Wang, J.; Tang, B.; Su, T.; Liu, X.R.; Li, B.M.; Meng, H.; Shi, Y.W.; Yi, Y.H.; et al. *ARHGEF9* mutations in epileptic encephalopathy/intellectual disability: Toward understanding the mechanism underlying phenotypic variation. *Neurogenetics* **2018**, *19*, 9–16. [[CrossRef](#)] [[PubMed](#)]
200. Yao, R.; Zhang, Y.; Liu, J.; Wang, J.; Xu, Y.; Li, N.; Wang, J.; Yu, T. Clinical and Molecular Characterization of Three Novel *ARHGEF9* Mutations in Patients with Developmental Delay and Epilepsy. *J. Mol. Neurosci.* **2020**, *70*, 908–915. [[CrossRef](#)]
201. Michiels, F.; Habets, G.G.M.M.; Stam, J.C.; Habets, G.G.M.; Van Der Kammen, R.A.; Collard, J.G. A role for Rac in Tiam1-induced membrane ruffling and invasion. *Nature* **1995**, *375*, 338–340. [[CrossRef](#)]
202. Ehler, E.; Van Leeuwen, F.; Collard, J.G.; Salinas, P.C. Expression of Tiam-1 in the developing brain suggests a role for the Tiam-1-Rac signaling pathway in cell migration and neurite outgrowth. *Mol. Cell. Neurosci.* **1997**, *9*, 1–12. [[CrossRef](#)]
203. Van Leeuwen, F.N.; Kain, H.E.T.; Van Der Kammen, R.A.; Michiels, F.; Kranenburg, O.W.; Collard, J.G. The guanine nucleotide exchange factor Tiam1 affects neuronal morphology; opposing roles for the small GTPases Rac and Rho. *J. Cell Biol.* **1997**, *139*, 797–807. [[CrossRef](#)]
204. Miyamoto, Y.; Yamauchi, J.; Tanoue, A.; Wu, C.; Mobley, W.C. TrkB binds and tyrosine-phosphorylates Tiam1, leading to activation of Rac1 and induction of changes in cellular morphology. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 10444–10449. [[CrossRef](#)] [[PubMed](#)]
205. Kunda, P.; Paglini, G.; Quiroga, S.; Kosik, K.; Cáceres, A. Evidence for the involvement of Tiam1 in axon formation. *J. Neurosci.* **2001**, *21*, 2361–2372. [[CrossRef](#)]
206. Kawauchi, T.; Chihama, K.; Nabeshima, Y.I.; Hoshino, M. The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. *EMBO J.* **2003**, *22*, 4190–4201. [[CrossRef](#)]
207. Tolia, K.F.; Bikoff, J.B.; Kane, C.G.; Tolia, C.S.; Hu, L.; Greenberg, M.E. The Rac1 guanine nucleotide exchange factor Tiam1 mediates EphB receptor-dependent dendritic spine development. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 7265–7270. [[CrossRef](#)] [[PubMed](#)]
208. Saneyoshi, T.; Matsuno, H.; Suzuki, A.; Murakoshi, H.; Hedrick, N.G.; Agnello, E.; O'Connell, R.; Stratton, M.M.; Yasuda, R.; Hayashi, Y. Reciprocal Activation within a Kinase-Effector Complex Underlying Persistence of Structural LTP. *Neuron* **2019**, *102*, 1199–1210. [[CrossRef](#)] [[PubMed](#)]
209. Kojima, H.; Rosendale, M.; Sugiyama, Y.; Hayashi, M.; Horiguchi, Y.; Yoshihara, T.; Ikegaya, Y.; Saneyoshi, T.; Hayashi, Y. The role of CaMKII-Tiam1 complex on learning and memory. *Neurobiol. Learn. Mem.* **2019**, *166*, 107070. [[CrossRef](#)]
210. Rao, S.; Kay, Y.; Herring, B.E. Tiam1 is Critical for Glutamatergic Synapse Structure and Function in the Hippocampus. *J. Neurosci.* **2019**, *39*, 9306–9315. [[CrossRef](#)] [[PubMed](#)]
211. Cheng, J.; Scala, F.; Blanco, F.A.; Niu, S.; Firozi, K.; Keehan, L.; Mulherkar, S.; Froudarakis, E.; Li, L.; Duman, J.G.; et al. The Rac-GEF Tiam1 Promotes Dendrite and Synapse Stabilization of Dentate Granule Cells and Restricts Hippocampal-Dependent Memory Functions. *J. Neurosci.* **2021**, *41*, 1191–1206. [[CrossRef](#)] [[PubMed](#)]
212. Arber, S.; Barbayannis, F.A.; Hanser, H.; Schnelder, C.; Stanyon, C.A.; Bernardis, O.; Caroni, P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. *Nature* **1998**, *393*, 805–809. [[CrossRef](#)]
213. Lappalainen, P.; Drubin, D.G. Cofilin promotes rapid actin filament turnover in vivo. *Nature* **1997**, *388*, 78–82. [[CrossRef](#)]
214. Maciver, S.K.; Hussey, P.J. The ADF/cofilin family: Actin-remodeling proteins. *Genome Biol.* **2002**, *3*, 1–12. [[CrossRef](#)] [[PubMed](#)]
215. Agnew, B.J.; Minamide, L.S.; Bamburg, J.R. Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site. *J. Biol. Chem.* **1995**, *270*, 17582–17587. [[CrossRef](#)] [[PubMed](#)]
216. Svitkina, T.M.; Borisy, G.G. Arp2/3 complex and actin depolymerizing factor/cofilin in dendritic organization and treadmilling of actin filament array in lamellipodia. *J. Cell Biol.* **1999**, *145*, 1009–1026. [[CrossRef](#)]
217. Bravo-Cordero, J.J.; Magalhaes, M.A.O.; Eddy, R.J.; Hodgson, L.; Condeelis, J. Functions of cofilin in cell locomotion and invasion. *Nat. Rev. Mol. Cell Biol.* **2013**, *14*, 405–417. [[CrossRef](#)]
218. Meberg, P.J.; Bamburg, J.R. Increase in neurite outgrowth mediated by overexpression of actin depolymerizing factor. *J. Neurosci.* **2000**, *20*, 2459–2469. [[CrossRef](#)] [[PubMed](#)]
219. Wen, Z.; Han, L.; Bamburg, J.R.; Shim, S.; Ming, G.L.; Zheng, J.Q. BMP gradients steer nerve growth cones by a balancing act of LIM kinase and Slingshot phosphatase on ADF/cofilin. *J. Cell Biol.* **2007**, *178*, 107–119. [[CrossRef](#)] [[PubMed](#)]
220. Meberg, P.J.; Ono, S.; Minamide, L.S.; Takahashi, M.; Bamburg, J.R. Actin depolymerizing factor and cofilin phosphorylation dynamics: Response to signals that regulate neurite extension. *Cell Motil. Cytoskeleton.* **1998**, *39*, 172–190. [[CrossRef](#)]
221. Niwa, R.; Nagata-Ohashi, K.; Takeichi, M.; Mizuno, K.; Uemura, T. Control of actin reorganization by slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. *Cell* **2002**, *108*, 233–246. [[CrossRef](#)]
222. Endo, M.; Ohashi, K.; Mizuno, K. LIM kinase and slingshot are critical for neurite extension. *J. Biol. Chem.* **2007**, *282*, 13692–13702. [[CrossRef](#)] [[PubMed](#)]

223. Gohla, A.; Bokoch, G.M. 14-3-3 Regulates actin dynamics by stabilizing phosphorylated cofilin. *Curr. Biol.* **2002**, *12*, 1704–1710. [[CrossRef](#)]
224. Soosairajah, J.; Maiti, S.; Wiggan, O.; Sarmiere, P.; Moussi, N.; Sarcevic, B.; Sampath, R.; Bamburg, J.R.; Bernard, O. Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. *EMBO J.* **2005**, *24*, 473–486. [[CrossRef](#)]
225. Toyo-Oka, K.; Wachi, T.; Hunt, R.F.; Baraban, S.C.; Taya, S.; Ramshaw, H.; Kaibuchi, K.; Schwarz, Q.P.; Lopez, A.F.; Wynshaw-Boris, A. 14-3-3 ϵ and ζ regulate neurogenesis and differentiation of neuronal progenitor cells in the developing brain. *J. Neurosci.* **2014**, *34*, 12168–12181. [[CrossRef](#)]
226. Taniuchi, K.; Nakagawa, H.; Hosokawa, M.; Nakamura, T.; Eguchi, H.; Ohigashi, H.; Ishikawa, O.; Katagiri, T.; Nakamura, Y. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating Rho-family GTPases. *Cancer Res.* **2005**, *65*, 3092–3099. [[CrossRef](#)]
227. Noren, N.K.; Liu, B.P.; Burrige, K.; Kreft, B. p120 Catenin regulates the actin cytoskeleton via RHO family GTPases. *J. Cell Biol.* **2000**, *150*, 567–579. [[CrossRef](#)]
228. Anastasiadis, P.Z.; Moon, S.Y.; Thoreson, M.A.; Mariner, D.J.; Crawford, H.C.; Zheng, Y.; Reynolds, A.B. Inhibition of RhoA by p120 catenin. *Nat. Cell Biol.* **2000**, *2*, 637–644. [[CrossRef](#)] [[PubMed](#)]
229. Xu, X.; Jaehne, E.J.; Greenberg, Z.; McCarthy, P.; Saleh, E.; Parish, C.L.; Camera, D.; Heng, J.; Haas, M.; Baune, B.T.; et al. 14-3-3 ζ deficient mice in the BALB/c background display behavioural and anatomical defects associated with neurodevelopmental disorders. *Sci. Rep.* **2015**, *5*, 12434. [[CrossRef](#)] [[PubMed](#)]
230. Rotty, J.D.; Wu, C.; Bear, J.E. New insights into the regulation and cellular functions of the ARP2/3 complex. *Nat. Rev. Mol. Cell Biol.* **2013**, *14*, 7–12. [[CrossRef](#)]
231. Pollard, T.D. Regulation of actin filament assembly by Arp2/3 complex and formins. *Annu. Rev. Biophys. Biomol. Struct.* **2007**, *36*, 451–477. [[CrossRef](#)] [[PubMed](#)]
232. Schlau, M.; Terheyden-Keighley, D.; Theis, V.; Mannherz, H.G.; Theiss, C. VEGF triggers the activation of cofilin and the Arp2/3 complex within the growth cone. *Int. J. Mol. Sci.* **2018**, *19*, 384. [[CrossRef](#)]
233. Brown, J.A.; Bridgman, P.C. Disruption of the cytoskeleton during Semaphorin 3A induced growth cone collapse correlates with differences in actin organization and associated binding proteins. *Dev. Neurobiol.* **2009**, *69*, 633–646. [[CrossRef](#)]
234. Chou, F.-S.; Wang, P.-S. The Arp2/3 complex is essential at multiple stages of neural development. *Neurogenesis* **2016**, *3*, e1261653. [[CrossRef](#)] [[PubMed](#)]
235. Kim, I.H.; Racz, B.; Wang, H.; Burianek, L.; Weinberg, R.; Yasuda, R.; Wetsel, W.C.; Soderling, S.H. Disruption of Arp2/3 results in asymmetric structural plasticity of dendritic spines and progressive synaptic and behavioral abnormalities. *J. Neurosci.* **2013**, *33*, 6081–6092. [[CrossRef](#)] [[PubMed](#)]
236. Spence, E.F.; Kanak, D.J.; Carlson, B.R.; Soderling, S.H. The Arp2/3 complex is essential for distinct stages of spine synapse maturation, including synapse unsilencing. *J. Neurosci.* **2016**, *36*, 9696–9709. [[CrossRef](#)] [[PubMed](#)]
237. Vadlamudi, R.K.; Li, F.; Barnes, C.J.; Bagheri-Yarmand, R.; Kumar, R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. *EMBO Rep.* **2004**, *5*, 154–160. [[CrossRef](#)] [[PubMed](#)]
238. Chen, Z.; Borek, D.; Padrick, S.B.; Gomez, T.S.; Metlagel, Z.; Ismail, A.M.; Umetani, J.; Billadeau, D.D.; Otwinowski, Z.; Rosen, M.K. Structure and control of the actin regulatory WAVE complex. *Nature* **2010**, *468*, 533–538. [[CrossRef](#)]
239. Kim, A.S.; Kakalis, L.T.; Abdul-Manan, N.; Liu, G.A.; Rosen, M.K. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. *Nature* **2000**, *404*, 151–158. [[CrossRef](#)]
240. Tomasevic, N.; Jia, Z.; Russell, A.; Fujii, T.; Hartman, J.J.; Clancy, S.; Wang, M.; Beraud, C.; Wood, K.W.; Sakowicz, R. Differential regulation of WASP and N-WASP by Cdc42, Rac1, Nck, and PI(4,5)P2. *Biochemistry* **2007**, *46*, 3494–3502. [[CrossRef](#)]
241. Eden, S.; Rohatgi, R.; Podtelejnikov, A.V.; Mann, M.; Kirschner, M.W. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. *Nature* **2002**, *418*, 790–793. [[CrossRef](#)]
242. Miki, H.; Suetsugu, S.; Takenawa, T. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. *EMBO J.* **1998**, *17*, 6932–6941. [[CrossRef](#)]
243. Abekhouk, S.; Bardoni, B. CYFIP family proteins between autism and intellectual disability: Links with fragile X syndrome. *Front. Cell. Neurosci.* **2014**, *8*, 81. [[CrossRef](#)]
244. Davenport, E.C.; Szulc, B.R.; Drew, J.; Taylor, J.; Morgan, T.; Higgs, N.F.; López-Doménech, G.; Kittler, J.T. Autism and Schizophrenia-Associated CYFIP1 Regulates the Balance of Synaptic Excitation and Inhibition. *Cell Rep.* **2019**, *26*, 2037–2051. [[CrossRef](#)]
245. Oguro-Ando, A.; Rosensweig, C.; Herman, E.; Nishimura, Y.; Werling, D.; Bill, B.R.; Berg, J.M.; Gao, F.; Coppola, G.; Abrahams, B.S.; et al. Increased CYFIP1 dosage alters cellular and dendritic morphology and dysregulates mTOR. *Mol. Psychiatry* **2015**, *20*, 1069–1078. [[CrossRef](#)]
246. Bozdagi, O.; Sakurai, T.; Dorr, N.; Pilorge, M.; Takahashi, N.; Buxbaum, J.D. Haploinsufficiency of Cyfip1 produces fragile X-like phenotypes in mice. *PLoS ONE* **2012**, *7*, e42422. [[CrossRef](#)] [[PubMed](#)]
247. Begemann, A.; Sticht, H.; Begtrup, A.; Vitobello, A.; Faivre, L.; Banka, S.; Alhaddad, B.; Asadollahi, R.; Becker, J.; Bierhals, T.; et al. New insights into the clinical and molecular spectrum of the novel CYFIP2-related neurodevelopmental disorder and impairment of the WRC-mediated actin dynamics. *Genet. Med.* **2020**, *23*, 534–554. [[CrossRef](#)] [[PubMed](#)]

248. Schaks, M.; Reinke, M.; Witke, W.; Rottner, K. Molecular Dissection of Neurodevelopmental Disorder-Causing Mutations in CYFIP2. *Cells* **2020**, *9*, 1355. [[CrossRef](#)] [[PubMed](#)]
249. Ropers, F.; Derivery, E.; Hu, H.; Garshasbi, M.; Karbasiyan, M.; Herold, M.; Nürnberg, G.; Ullmann, R.; Gautreau, A.; Sperling, K.; et al. Identification of a novel candidate gene for non-syndromic autosomal recessive intellectual disability: The WASH complex member swip. *Hum. Mol. Genet.* **2011**, *20*, 2585–2590. [[CrossRef](#)]
250. Assoum, M.; Bruel, A.L.; Crenshaw, M.L.; Delanne, J.; Wentzensen, I.M.; McWalter, K.; Dent, K.M.; Vitobello, A.; Kuentz, P.; Thevenon, J.; et al. Novel KIAA1033/WASHC4 mutations in three patients with syndromic intellectual disability and a review of the literature. *Am. J. Med. Genet. Part A* **2020**, *182*, 792–797. [[CrossRef](#)]
251. Guo, H.; Zhang, Q.; Dai, R.; Yu, B.; Hoekzema, K.; Tan, J.; Tan, S.; Jia, X.; Chung, W.K.; Hernan, R.; et al. NCKAP1 Disruptive Variants Lead to a Neurodevelopmental Disorder with Core Features of Autism. *Am. J. Hum. Genet.* **2020**, *107*, 963–976. [[CrossRef](#)]
252. Harripaul, R.; Vasli, N.; Mikhailov, A.; Rafiq, M.A.; Mittal, K.; Windpassinger, C.; Sheikh, T.I.; Noor, A.; Mahmood, H.; Downey, S.; et al. Mapping autosomal recessive intellectual disability: Combined microarray and exome sequencing identifies 26 novel candidate genes in 192 consanguineous families. *Mol. Psychiatry* **2018**, *23*, 973–984. [[CrossRef](#)]
253. Elliott, A.M.; Simard, L.R.; Coghlan, G.; Chudley, A.E.; Chodirker, B.N.; Greenberg, C.R.; Burch, T.; Ly, V.; Hatch, G.M.; Zelinski, T. A novel mutation in KIAA0196: Identification of a gene involved in Ritscher-Schinzel/3C syndrome in a First Nations cohort. *J. Med. Genet.* **2013**, *50*, 819–822. [[CrossRef](#)]
254. Feldt, J.; Schicht, M.; Garreis, F.; Welss, J.; Schneider, U.W.; Paulsen, F. Structure, regulation and related diseases of the actin-binding protein gelsolin. *Expert Rev. Mol. Med.* **2019**, *20*. [[CrossRef](#)]
255. Lu, M.; Witke, W.; Kwiatkowski, D.J.; Kosik, K.S. Delayed retraction of filopodia in gelsolin null mice. *J. Cell Biol.* **1997**, *138*, 1279–1287. [[CrossRef](#)] [[PubMed](#)]
256. Hlushchenko, I.; Hotulainen, P. Chemical LTD, but not LTP, induces transient accumulation of gelsolin in dendritic spines. *Biol. Chem.* **2019**, *400*, 1129–1139. [[CrossRef](#)] [[PubMed](#)]
257. Khaitlina, S.; Hinssen, H. Ca-dependent binding of actin to gelsolin. *FEBS Lett.* **2002**, *521*, 14–18. [[CrossRef](#)]
258. Sahasrabudhe, A.; Ghatge, K.; Mutalik, S.; Jacob, A.; Ghose, A. Formin 2 regulates the stabilization of filopodial tip adhesions in growth cones and affects neuronal outgrowth and pathfinding in vivo. *Development* **2016**, *143*, 449–460. [[CrossRef](#)] [[PubMed](#)]
259. Law, R.; Dixon-Salazar, T.; Jerber, J.; Cai, N.; Abbasi, A.A.; Zaki, M.S.; Mittal, K.; Gabriel, S.B.; Rafiq, M.A.; Khan, V.; et al. Biallelic truncating mutations in FMN2, encoding the actin-regulatory protein formin 2, cause nonsyndromic autosomal-recessive intellectual disability. *Am. J. Hum. Genet.* **2014**, *95*, 721–728. [[CrossRef](#)]
260. Pollard, T.D. Actin and actin-binding proteins. *Cold Spring Harb. Perspect. Biol.* **2016**, *8*, a018226. [[CrossRef](#)]
261. Pollard, T.D.; Cooper, J.A. Quantitative Analysis of the Effect of Acanthamoeba Profilin on Actin Filament Nucleation and Elongation. *Biochemistry* **1984**, *23*, 6631–6641. [[CrossRef](#)]
262. Carlsson, L.; Nyström, L.E.; Sundkvist, I.; Markey, F.; Lindberg, U. Actin polymerizability is influenced by profilin, a low molecular weight protein in non-muscle cells. *J. Mol. Biol.* **1977**, *115*, 465–483. [[CrossRef](#)]
263. Tobacman, L.S.; Korn, E.D. The regulation of actin polymerization and the inhibition of monomeric actin ATPase activity by Acanthamoeba profilin. *J. Biol. Chem.* **1982**, *257*, 4166–4170. [[CrossRef](#)]
264. Borovac, J.; Bosch, M.; Okamoto, K. Regulation of actin dynamics during structural plasticity of dendritic spines: Signaling messengers and actin-binding proteins. *Mol. Cell. Neurosci.* **2018**, *91*, 122–130. [[CrossRef](#)] [[PubMed](#)]
265. Lambrechts, A.; Jonckheere, V.; Peleman, C.; Polet, D.; De Vos, W.; Vandekerckhove, J.; Ampe, C. Profilin-I-ligand interactions influence various aspects of neuronal differentiation. *J. Cell Sci.* **2006**, *119*, 1570–1578. [[CrossRef](#)]
266. Toriyama, M.; Kozawa, S.; Sakumura, Y.; Inagaki, N. Conversion of a signal into forces for axon outgrowth through pak1-mediated shootin1 phosphorylation. *Curr. Biol.* **2013**, *23*, 529–534. [[CrossRef](#)]
267. Lin, C.H.; Forscher, P. Growth cone advance is inversely proportional to retrograde F-actin flow. *Neuron* **1995**, *14*, 763–771. [[CrossRef](#)]
268. Shimada, T.; Toriyama, M.; Uemura, K.; Kamiguchi, H.; Sugiura, T.; Watanabe, N.; Inagaki, N. Shootin1 interacts with actin retrograde flow and L1-CAM to promote axon outgrowth. *J. Cell Biol.* **2008**, *181*, 817–829. [[CrossRef](#)]
269. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. *Genome Res.* **2003**, *13*, 2498–2504. [[CrossRef](#)]
270. Kang, H.J.; Kawasawa, Y.I.; Cheng, F.; Zhu, Y.; Xu, X.; Li, M.; Sousa, A.M.M.; Pletikos, M.; Meyer, K.A.; Sedmak, G.; et al. Spatio-temporal transcriptome of the human brain. *Nature* **2011**, *478*, 483–489. [[CrossRef](#)]
271. Govek, E.E.; Newey, S.E.; Van Aelst, L. The role of the Rho GTPases in neuronal development. *Genes Dev.* **2005**, *19*, 1–49. [[CrossRef](#)]
272. Ma, X.M.; Huang, J.; Wang, Y.; Eipper, B.A.; Mains, R.E. Kalirin, a Multifunctional Rho Guanine Nucleotide Exchange Factor, Is Necessary for Maintenance of Hippocampal Pyramidal Neuron Dendrites and Dendritic Spines. *J. Neurosci.* **2003**, *23*, 10593–10603. [[CrossRef](#)]
273. Ma, X.M.; Kiraly, D.D.; Gaier, E.D.; Wang, Y.; Kim, E.J.; Levine, E.S.; Eipper, B.A.; Mains, R.E. Kalirin-7 is required for synaptic structure and function. *J. Neurosci.* **2008**, *28*, 12368–12382. [[CrossRef](#)] [[PubMed](#)]
274. Satoh, A.; Nakanishi, H.; Obaishi, H.; Wada, M.; Takahashi, K.; Satoh, K.; Hirao, K.; Nishioka, H.; Hata, Y.; Mizoguchi, A.; et al. Neurabin-II/spinophilin: An actin filament-binding protein with one PDZ domain localized at cadherin-based cell-cell adhesion sites. *J. Biol. Chem.* **1998**, *273*, 3470–3475. [[CrossRef](#)] [[PubMed](#)]

275. Grossman, S.D.; Hsieh-Wilson, L.C.; Allen, P.B.; Nairn, A.C.; Greengard, P. The actin-binding domain of spinophilin is necessary and sufficient for targeting to dendritic spines. *Neuro Mol. Med.* **2002**, *2*, 61–69. [[CrossRef](#)]
276. Feng, J.; Yan, Z.; Ferreira, A.; Tomizawa, K.; Liauw, J.A.; Zhuo, M.; Allen, P.B.; Ouimet, C.C.; Greengard, P. Spinophilin regulates the formation and function of dendritic spines. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 9287–9292. [[CrossRef](#)] [[PubMed](#)]
277. Ryan, X.P.; Alldritt, J.; Svenningsson, P.; Allen, P.B.; Wu, G.Y.; Nairn, A.C.; Greengard, P. The Rho-specific GEF Lfc interacts with neurabin and spinophilin to regulate dendritic spine morphology. *Neuron* **2005**, *47*, 85–100. [[CrossRef](#)]
278. Ravindran, E.; Hu, H.; Yuzwa, S.A.; Hernandez-Miranda, L.R.; Kraemer, N.; Ninnemann, O.; Musante, L.; Boltshauser, E.; Schindler, D.; Hübner, A.; et al. Homozygous *ARHGEF2* mutation causes intellectual disability and midbrain-hindbrain malformation. *PLoS Genet.* **2017**, *13*, e1006746. [[CrossRef](#)] [[PubMed](#)]
279. Qualmann, B.; Boeckers, T.M.; Jeromin, M.; Gundelfinger, E.D.; Kessels, M.M. Linkage of the Actin Cytoskeleton to the Postsynaptic Density via Direct Interactions of Abp1 with the ProSAP/Shank Family. *J. Neurosci.* **2004**, *24*, 2481–2495. [[CrossRef](#)]
280. Duffney, L.J.; Zhong, P.; Wei, J.; Matas, E.; Cheng, J.; Qin, L.; Ma, K.; Dietz, D.M.; Kajiwar, Y.; Buxbaum, J.D.; et al. Autism-like Deficits in Shank3-Deficient Mice Are Rescued by Targeting Actin Regulators. *Cell Rep.* **2015**, *11*, 1400–1413. [[CrossRef](#)]
281. Han, K.; Holder, J.L.; Schaaf, C.P.; Lu, H.; Chen, H.; Kang, H.; Tang, J.; Wu, Z.; Hao, S.; Cheung, S.W.; et al. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. *Nature* **2013**, *503*, 72–77. [[CrossRef](#)]
282. Sarowar, T.; Grabrucker, A.M. Actin-Dependent Alterations of Dendritic Spine Morphology in Shankopathies. *Neural Plast.* **2016**, *2016*, 8051861. [[CrossRef](#)] [[PubMed](#)]
283. Bonaglia, M.C.; Giorda, R.; Mani, E.; Aceti, G.; Anderlid, B.M.; Baroncini, A.; Pramparo, T.; Zuffardi, O. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. *J. Med. Genet.* **2006**, *43*, 822–828. [[CrossRef](#)] [[PubMed](#)]
284. Bonaglia, M.C.; Giorda, R.; Borgatti, R.; Felisari, G.; Gagliardi, C.; Selicorni, A.; Zuffardi, O. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. *Am. J. Hum. Genet.* **2001**, *69*, 261–268. [[CrossRef](#)] [[PubMed](#)]
285. Soorya, L.; Kolevzon, A.; Zweifach, J.; Lim, T.; Dobry, Y.; Schwartz, L.; Frank, Y.; Wang, A.T.; Cai, G.; Parkhomenko, E.; et al. Prospective investigation of autism and genotype-phenotype correlations in 22q13 deletion syndrome and SHANK3 deficiency. *Mol. Autism* **2013**, *4*, 18. [[CrossRef](#)]
286. Shen, K.; Teruel, M.N.; Subramanian, K.; Meyer, T. CaMKII β functions as an F-actin targeting module that localizes CaMKII α/β heterooligomers to dendritic spines. *Neuron* **1998**, *21*, 593–606. [[CrossRef](#)]
287. Kürty, S.; van Woerden, G.M.; Besnard, T.; Proietti Onori, M.; Latypova, X.; Towne, M.C.; Cho, M.T.; Prescott, T.E.; Ploeg, M.A.; Sanders, S.; et al. De Novo Mutations in Protein Kinase Genes CAMK2A and CAMK2B Cause Intellectual Disability. *Am. J. Hum. Genet.* **2017**, *101*, 768–788. [[CrossRef](#)] [[PubMed](#)]
288. Lasser, M.; Tiber, J.; Lowery, L.A. The role of the microtubule cytoskeleton in neurodevelopmental disorders. *Front. Cell. Neurosci.* **2018**, *12*, 165. [[CrossRef](#)] [[PubMed](#)]
289. Conde, C.; Cáceres, A. Microtubule assembly, organization and dynamics in axons and dendrites. *Nat. Rev. Neurosci.* **2009**, *10*, 319–332. [[CrossRef](#)]
290. Witte, H.; Neukirchen, D.; Bradke, F. Microtubule stabilization specifies initial neuronal polarization. *J. Cell Biol.* **2008**, *180*, 619–632. [[CrossRef](#)]
291. Gu, J.; Firestein, B.L.; Zheng, J.Q. Microtubules in dendritic spine development. *J. Neurosci.* **2008**, *28*, 12120–12124. [[CrossRef](#)]
292. Jaworski, J.; Kapitein, L.C.; Gouveia, S.M.; Dortland, B.R.; Wulf, P.S.; Grigoriev, I.; Camera, P.; Spangler, S.A.; Di Stefano, P.; Demmers, J.; et al. Dynamic Microtubules Regulate Dendritic Spine Morphology and Synaptic Plasticity. *Neuron* **2009**, *61*, 85–100. [[CrossRef](#)] [[PubMed](#)]
293. Dent, E.W. Of microtubules and memory: Implications for microtubule dynamics in dendrites and spines. *Mol. Biol. Cell* **2017**, *28*, 1–8. [[CrossRef](#)]
294. Karabay, A.; Yu, W.; Solowska, J.M.; Baird, D.H.; Baas, P.W. Axonal growth is sensitive to the levels of katanin, a protein that severs microtubules. *J. Neurosci.* **2004**, *24*, 5778–5788. [[CrossRef](#)]
295. Akhmanova, A.; Steinmetz, M.O. Tracking the ends: A dynamic protein network controls the fate of microtubule tips. *Nat. Rev. Mol. Cell Biol.* **2008**, *9*, 309–322. [[CrossRef](#)] [[PubMed](#)]
296. Jaworski, J.; Hoogenraad, C.C.; Akhmanova, A. Microtubule plus-end tracking proteins in differentiated mammalian cells. *Int. J. Biochem. Cell Biol.* **2008**, *40*, 619–637. [[CrossRef](#)] [[PubMed](#)]
297. Neukirchen, D.; Bradke, F. Cytoplasmic linker proteins regulate neuronal polarization through microtubule and growth cone dynamics. *J. Neurosci.* **2011**, *31*, 1528–1538. [[CrossRef](#)]
298. Swiech, L.; Blazjczyk, M.; Urbanska, M.; Pietruszka, P.; Dortland, B.R.; Malik, A.R.; Wulf, P.S.; Hoogenraad, C.C.; Jaworski, J. CLIP-170 and IQGAP1 cooperatively regulate dendrite morphology. *J. Neurosci.* **2011**, *31*, 4555–4568. [[CrossRef](#)]
299. Yonekawa, V.; Harada, A.; Okada, Y.; Funakoshi, T.; Kanai, Y.; Takei, Y.; Terada, S.; Noda, T.; Hirokawa, N. Defect in synaptic vesicle precursor transport and neuronal cell death in KIF1A motor protein-deficient mice. *J. Cell Biol.* **1998**, *141*, 431–441. [[CrossRef](#)] [[PubMed](#)]
300. Hamdan, F.F.; Gauthier, J.; Araki, Y.; Lin, D.T.; Yoshizawa, Y.; Higashi, K.; Park, A.R.; Spiegelman, D.; Dobrzyniecka, S.; Piton, A.; et al. Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability. *Am. J. Hum. Genet.* **2011**, *88*, 306–316. [[CrossRef](#)]

301. Esmaeeli Nieh, S.; Madou, M.R.Z.; Sirajuddin, M.; Fregeau, B.; Mcknight, D.; Lexa, K.; Strober, J.; Spaeth, C.; Hallinan, B.E.; Smaoui, N.; et al. De novo mutations in KIF1A cause progressive encephalopathy and brain atrophy. *Ann. Clin. Transl. Neurol.* **2015**, *2*, 623–635. [[CrossRef](#)]
302. Willemsen, M.H.; Ba, W.; Wissink-Lindhout, W.M.; de Brouwer, A.P.M.; Haas, S.A.; Bienek, M.; Hu, H.; Vissers, L.E.L.M.; van Bokhoven, H.; Kalscheuer, V.; et al. Involvement of the kinesin family members *KIF4A* and *KIF5C* in intellectual disability and synaptic function. *J. Med. Genet.* **2014**, *51*, 487–494. [[CrossRef](#)]
303. Poirier, K.; Lebrun, N.; Broix, L.; Tian, G.; Saillour, Y.; Boscheron, C.; Parrini, E.; Valence, S.; Saint Pierre, B.; Oger, M.; et al. Mutations in *TUBG1*, *DYNCH1L*, *KIF5C* and *KIF2A* cause malformations of cortical development and microcephaly. *Nat. Genet.* **2013**, *45*, 639–647. [[CrossRef](#)]
304. Putoux, A.; Thomas, S.; Coene, K.L.M.; Davis, E.E.; Alanay, Y.; Ogur, G.; Uz, E.; Buzas, D.; Gomes, C.; Patrier, S.; et al. *KIF7* mutations cause fetal hydroletharus and acrocallosal syndromes. *Nat. Genet.* **2011**, *43*, 601–606. [[CrossRef](#)]
305. Kevenaer, J.T.; Bianchi, S.; Van Spronsen, M.; Olieric, N.; Lipka, J.; Frias, C.P.; Mikhaylova, M.; Harterink, M.; Keijzer, N.; Wulf, P.S.; et al. Kinesin-Binding Protein Controls Microtubule Dynamics and Cargo Trafficking by Regulating Kinesin Motor Activity. *Curr. Biol.* **2016**, *26*, 849–861. [[CrossRef](#)]
306. Hempel, M.; Cremer, K.; Ockeloen, C.W.; Lichtenbelt, K.D.; Herkert, J.C.; Denecke, J.; Haack, T.B.; Zink, A.M.; Becker, J.; Wohlleber, E.; et al. De Novo Mutations in *CHAMP1* Cause Intellectual Disability with Severe Speech Impairment. *Am. J. Hum. Genet.* **2015**, *97*, 493–500. [[CrossRef](#)] [[PubMed](#)]
307. Isidor, B.; Küry, S.; Rosenfeld, J.A.; Besnard, T.; Schmitt, S.; Joss, S.; Davies, S.J.; Roger Lebel, R.; Henderson, A.; Schaaf, C.P.; et al. De Novo Truncating Mutations in the Kinetochores-Microtubules Attachment Gene *CHAMP1* Cause Syndromic Intellectual Disability. *Hum. Mutat.* **2016**, *37*, 354–358. [[CrossRef](#)] [[PubMed](#)]
308. Tanaka, A.J.; Cho, M.T.; Retterer, K.; Jones, J.R.; Nowak, C.; Douglas, J.; Jiang, Y.-H.; McConkie-Rosell, A.; Schaefer, G.B.; Kaylor, J.; et al. De novo pathogenic variants in *CHAMP1* are associated with global developmental delay, intellectual disability, and dysmorphic facial features. *Mol. Case Stud.* **2016**, *2*, a000661. [[CrossRef](#)]
309. Larti, F.; Kahrizi, K.; Musante, L.; Hu, H.; Papari, E.; Fattahi, Z.; Bazazzadegan, N.; Liu, Z.; Banan, M.; Garshasbi, M.; et al. Erratum: A defect in the *CLIP1* gene (*CLIP-170*) can cause autosomal recessive intellectual disability. *Eur. J. Hum. Genet.* **2015**, *23*, 416. [[CrossRef](#)] [[PubMed](#)]
310. Bartholdi, D.; Stray-Pedersen, A.; Azzarello-Burri, S.; Kibaek, M.; Kirchhoff, M.; Oneda, B.; Rødningen, O.; Schmitt-Mechelke, T.; Rauch, A.; Kjaergaard, S. A newly recognized 13q12.3 microdeletion syndrome characterized by intellectual disability, microcephaly, and eczema/atopic dermatitis encompassing the *HMGB1* and *KATNAL1* genes. *Am. J. Med. Genet. Part A* **2014**, *164*, 1277–1283. [[CrossRef](#)] [[PubMed](#)]
311. Cainarca, S.; Messali, S.; Ballabio, A.; Meroni, G. Functional characterization of the Opitz syndrome gene product (midin): Evidence for homodimerization and association with microtubules throughout the cell cycle. *Hum. Mol. Genet.* **1999**, *8*, 1387–1396. [[CrossRef](#)] [[PubMed](#)]
312. Geetha, T.S.; Michealraj, K.A.; Kabra, M.; Kaur, G.; Juyal, R.C.; Thelma, B.K. Targeted Deep Resequencing Identifies *MID2* Mutation for X-Linked Intellectual Disability with Varied Disease Severity in a Large Kindred from India. *Hum. Mutat.* **2014**, *35*, 41–44. [[CrossRef](#)]
313. Barbiero, I.; Peroni, D.; Tramarin, M.; Chandola, C.; Rusconi, L.; Landsberger, N.; Kilstrup-Nielsen, C. The neurosteroid pregnenolone reverts microtubule derangement induced by the loss of a functional CDKL5-IQGAP1 complex. *Hum. Mol. Genet.* **2017**, *26*, 3520–3530. [[CrossRef](#)]
314. Baltussen, L.L.; Negraes, P.D.; Silvestre, M.; Claxton, S.; Moeskops, M.; Christodoulou, E.; Flynn, H.R.; Snijders, A.P.; Muotri, A.R.; Ulanir, S.K. Chemical genetic identification of CDKL5 substrates reveals its role in neuronal microtubule dynamics. *EMBO J.* **2018**, *37*, e99763. [[CrossRef](#)]
315. Nawaz, M.S.; Giarda, E.; Bedogni, F.; La Montanara, P.; Ricciardi, S.; Ciceri, D.; Alberio, T.; Landsberger, N.; Rusconi, L.; Kilstrup-Nielsen, C. CDKL5 and shootin1 interact and concur in regulating neuronal polarization. *PLoS ONE* **2016**, *11*, e0148634. [[CrossRef](#)] [[PubMed](#)]
316. Fehr, S.; Wilson, M.; Downs, J.; Williams, S.; Murgia, A.; Sartori, S.; Vecchi, M.; Ho, G.; Polli, R.; Psoni, S.; et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. *Eur. J. Hum. Genet.* **2013**, *21*, 266–273. [[CrossRef](#)]
317. Alberini, C.M.; Cruz, E.; Descalzi, G.; Bessières, B.; Gao, V. Astrocyte glycogen and lactate: New insights into learning and memory mechanisms. *Glia* **2018**, *66*, 1244–1262. [[CrossRef](#)] [[PubMed](#)]
318. Singh, A.; Abraham, W.C. Astrocytes and synaptic plasticity in health and disease. *Exp. Brain Res.* **2017**, *235*, 1645–1655. [[CrossRef](#)] [[PubMed](#)]
319. Suzuki, A.; Stern, S.A.; Bozdagi, O.; Huntley, G.W.; Walker, R.H.; Magistretti, P.J.; Alberini, C.M. Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell* **2011**, *144*, 810–823. [[CrossRef](#)] [[PubMed](#)]
320. Adamsky, A.; Kol, A.; Kreisel, T.; Doron, A.; Ozeri-Engelhard, N.; Melcer, T.; Refaeli, R.; Horn, H.; Regev, L.; Groysman, M.; et al. Astrocytic Activation Generates De Novo Neuronal Potentiation and Memory Enhancement. *Cell* **2018**, *174*, 59–71.e14. [[CrossRef](#)]
321. Molotkov, D.; Zobova, S.; Arcas, J.M.; Khiroug, L. Calcium-induced outgrowth of astrocytic peripheral processes requires actin binding by Profilin-1. *Cell Calcium* **2013**, *53*, 338–348. [[CrossRef](#)]

322. Ghézali, G.; Dallérac, G.; Rouach, N. Perisynaptic astroglial processes: Dynamic processors of neuronal information. *Brain Struct. Funct.* **2016**, *221*, 2427–2442. [CrossRef]
323. Renault-Mihara, F.; Mukaino, M.; Shinozaki, M.; Kumamaru, H.; Kawase, S.; Baudoux, M.; Ishibashi, T.; Kawabata, S.; Nishiyama, Y.; Sugai, K.; et al. Regulation of RhoA by STAT3 coordinates glial scar formation. *J. Cell Biol.* **2017**, *216*, 2533–2550. [CrossRef]
324. Boukhelifa, M.; Hwang, S.J.; Valtschanoff, J.G.; Meeker, R.B.; Rustioni, A.; Otey, C.A. A critical role for palladin in astrocyte morphology and response to injury. *Mol. Cell. Neurosci.* **2003**, *23*, 661–668. [CrossRef]
325. Potokar, M.; Kreft, M.; Li, L.; Andersson, J.D.; Pangršič, T.; Chowdhury, H.H.; Pekny, M.; Zorec, R. Cytoskeleton and vesicle mobility in astrocytes. *Traffic* **2007**, *8*, 12–20. [CrossRef]
326. Pillet, L.E.; Cresto, N.; Saillour, Y.; Ghézali, G.; Bemelmans, A.P.; Livet, J.; Bienvenu, T.; Rouach, N.; Billuart, P. The intellectual disability protein Oligophrenin-1 controls astrocyte morphology and migration. *Glia* **2020**, *68*, 1729–1742. [CrossRef]
327. Ali, A.A.H.; Schwarz-Herzke, B.; Rollenhagen, A.; Anstötz, M.; Holub, M.; Lübke, J.; Rose, C.R.; Schnittler, H.; Gall, C. Bmal1-deficiency affects glial synaptic coverage of the hippocampal mossy fiber synapse and the actin cytoskeleton in astrocytes. *Glia* **2020**, *68*, 947–962. [CrossRef]
328. Baumann, N.; Pham-Dinh, D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. *Physiol. Rev.* **2001**, *81*, 871–927. [CrossRef]
329. Morrison, B.M.; Lee, Y.; Rothstein, J.D. Oligodendroglia: Metabolic supporters of axons. *Trends Cell Biol.* **2013**, *23*, 644–651. [CrossRef]
330. Xin, W.; Chan, J.R. Myelin plasticity: Sculpting circuits in learning and memory. *Nat. Rev. Neurosci.* **2020**, *21*, 682–694. [CrossRef]
331. O'Rourke, M.; Gasperini, R.; Young, K.M. Adult myelination: Wrapping up neuronal plasticity. *Neural Regen. Res.* **2014**, *9*, 1261–1264. [CrossRef]
332. Zuchero, J.B.; Fu, M.M.; Sloan, S.A.; Ibrahim, A.; Olson, A.; Zaremba, A.; Dugas, J.C.; Wienbar, S.; Caprariello, A.V.; Kantor, C.; et al. CNS Myelin Wrapping Is Driven by Actin Disassembly. *Dev. Cell* **2015**, *34*, 152–167. [CrossRef]
333. Liu, A.; Muggironi, M.; Marin-Husstege, M.; Casaccia-Bonnel, P. Oligodendrocyte Process Outgrowth In Vitro Is Modulated by Epigenetic Regulation of Cytoskeletal Severing Proteins. *Glia* **2003**, *44*, 264–274. [CrossRef]
334. Zhang, Y.; Chen, K.; Sloan, S.A.; Bennett, M.L.; Scholze, A.R.; O'Keefe, S.; Phatnani, H.P.; Guarnieri, P.; Caneda, C.; Ruderisch, N.; et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J. Neurosci.* **2014**, *34*, 11929–11947. [CrossRef]
335. Ábrahám, H.; Vincze, A.; Veszprémi, B.; Kravják, A.; Gömöri, É.; Kovács, G.G.; Seress, L. Impaired myelination of the human hippocampal formation in Down syndrome. *Int. J. Dev. Neurosci.* **2012**, *30*, 147–158. [CrossRef]
336. Olmos-Serrano, J.L.; Kang, H.J.; Tyler, W.A.; Silbereis, J.C.; Cheng, F.; Zhu, Y.; Pletikos, M.; Jankovic-Rapan, L.; Cramer, N.P.; Galdzicki, Z.; et al. Down Syndrome Developmental Brain Transcriptome Reveals Defective Oligodendrocyte Differentiation and Myelination. *Neuron* **2016**, *89*, 1208–1222. [CrossRef] [PubMed]
337. Allen, K.M.; Gleeson, J.G.; Bagrodia, S.; Partington, M.W.; MacMillan, J.C.; Cerione, R.A.; Mulley, J.C.; Walsh, C.A. PAK3 mutation in nonsyndromic X-linked mental retardation. *Nat. Genet.* **1998**, *20*, 25–30. [CrossRef]
338. Gedeon, A.K.; Nelson, J.; Gécz, J.; Mulley, J.C. X-linked mild non-syndromic mental retardation with neuropsychiatric problems and the missense mutation A365E in PAK3. *Am. J. Med. Genet.* **2003**, *120 A*, 509–517. [CrossRef]
339. Cahoy, J.D.; Emery, B.; Kaushal, A.; Foo, L.C.; Zamanian, J.L.; Christopherson, K.S.; Xing, Y.; Lubischer, J.L.; Krieg, P.A.; Krupenko, S.A.; et al. A transcriptome database for astrocytes, neurons, and oligodendrocytes: A new resource for understanding brain development and function. *J. Neurosci.* **2008**, *28*, 264–278. [CrossRef]
340. Dugas, J.C.; Tai, Y.C.; Speed, T.P.; Ngai, J.; Barres, B.A. Functional genomic analysis of oligodendrocyte differentiation. *J. Neurosci.* **2006**, *26*, 10967–10983. [CrossRef]
341. Renkilaraj, M.R.L.M.; Baudouin, L.; Wells, C.M.; Doulazmi, M.; Wehrle, R.; Cannaya, V.; Bachelin, C.; Barnier, J.-V.; Jia, Z.; Oumesmar, B.N.; et al. The intellectual disability protein PAK3 regulates oligodendrocyte precursor cell differentiation. *Neurobiol. Dis.* **2017**, *98*, 137–148. [CrossRef]
342. Schafer, D.P.; Lehrman, E.K.; Kautzman, A.G.; Koyama, R.; Mardinly, A.R.; Yamasaki, R.; Ransohoff, R.M.; Greenberg, M.E.; Barres, B.A.; Stevens, B. Microglia Sculpt Postnatal Neural Circuits in an Activity and Complement-Dependent Manner. *Neuron* **2012**, *74*, 691–705. [CrossRef]
343. Kim, H.J.; Cho, M.H.; Shim, W.H.; Kim, J.K.; Jeon, E.Y.; Kim, D.H.; Yoon, S.Y. Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects. *Mol. Psychiatry* **2017**, *22*, 1576–1584. [CrossRef]
344. Paolicelli, R.C.; Bolasco, G.; Pagani, F.; Maggi, L.; Scianni, M.; Panzanelli, P.; Giustetto, M.; Ferreira, T.A.; Guiducci, E.; Dumas, L.; et al. Synaptic pruning by microglia is necessary for normal brain development. *Science* **2011**, *333*, 1456–1458. [CrossRef]
345. Molbioltools. Available online: <https://www.molbioltools.com/index.html> (accessed on 4 June 2021).
346. Zhang, Y.; Sloan, S.A.; Clarke, L.E.; Caneda, C.; Plaza, C.A.; Blumenthal, P.D.; Vogel, H.; Steinberg, G.K.; Edwards, M.S.B.; Li, G.; et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron* **2016**, *89*, 37–53. [CrossRef]
347. Contino, S.; Bertolazzi, G.; Cali, F.; Cantone, M.; Vera, J.; Romano, V. Axon Growth and Guidance in ASD: From Static Pathway Analysis to Dynamic Boolean Modeling. In *Reference Module in Biomedical Sciences*; Elsevier: Amsterdam, The Netherlands, 2020; ISBN 9780128012383.

348. Müssel, C.; Hopfensitz, M.; Kestler, H.A. BoolNet-an R package for generation, reconstruction and analysis of Boolean networks. *Bioinformatics* **2010**, *26*, 1378–1380. [[CrossRef](#)]
349. Pinto-Costa, R.; Sousa, S.C.; Leite, S.C.; Nogueira-Rodrigues, J.; da Silva, T.F.; Machado, D.; Marques, J.; Costa, A.C.; Liz, M.A.; Bartolini, F.; et al. Profilin 1 delivery tunes cytoskeletal dynamics toward CNS axon regeneration. *J. Clin. Investig.* **2020**, *130*, 2024–2040. [[CrossRef](#)] [[PubMed](#)]
350. Szikora, S.; Földi, I.; Tóth, K.; Migh, E.; Vig, A.; Bugyi, B.; Maléth, J.; Hegyi, P.; Kaltenecker, P.; Sanchez-Soriano, N.; et al. The formin DAAM is required for coordination of the actin and microtubule cytoskeleton in axonal growth cones. *J. Cell Sci.* **2017**, *130*, 2506–2519. [[CrossRef](#)]
351. Chen, B.; Chou, H.T.; Brautigam, C.A.; Xing, W.; Yang, S.; Henry, L.; Doolittle, L.K.; Walz, T.; Rosen, M.K. Rac1 GTPase activates the WAVE regulatory complex through two distinct binding sites. *eLife* **2017**, *6*, e29795. [[CrossRef](#)]
352. Carlier, M.F.; Laurent, V.; Santolini, J.; Melki, R.; Didry, D.; Xia, G.X.; Hong, Y.; Chua, N.H.; Pantaloni, D. Actin depolymerizing factor (ADF/cofilin) enhances the rate of filament turnover: Implication in actin-based motility. *J. Cell Biol.* **1997**, *136*, 1307–1322. [[CrossRef](#)]
353. Furukawa, K.; Fu, W.; Li, Y.; Witke, W.; Kwiatkowski, D.J.; Mattson, M.P. The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. *J. Neurosci.* **1997**, *17*, 8178–8186. [[CrossRef](#)]
354. Koronakis, V.; Hume, P.J.; Humphreys, D.; Liu, T.; Hørning, O.; Jensen, O.N.; McGhie, E.J. WAVE regulatory complex activation by cooperating GTPases Arf and Rac1. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 14449–14454. [[CrossRef](#)] [[PubMed](#)]
355. Schaks, M.; Döring, H.; Kage, F.; Steffen, A.; Klünemann, T.; Blankenfeldt, W.; Stradal, T.; Rottner, K. RhoG and Cdc42 can contribute to Rac-dependent lamellipodia formation through WAVE regulatory complex-binding. *Small GTPases* **2021**, *12*, 122–132. [[CrossRef](#)]
356. Kim, Y.; Sung, J.Y.; Ceglia, I.; Lee, K.W.; Ahn, J.H.; Halford, J.M.; Kim, A.M.; Kwak, S.P.; Park, J.B.; Ho Ryu, S.; et al. Phosphorylation of WAVE1 regulates actin polymerization and dendritic spine morphology. *Nature* **2006**, *442*, 814–817. [[CrossRef](#)] [[PubMed](#)]
357. Xiang, S.; Kim, E.Y.; Connelly, J.J.; Nassar, N.; Kirsch, J.; Winking, J.; Schwarz, G.; Schindelin, H. The Crystal Structure of Cdc42 in Complex with Collybistin II, a Gephyrin-interacting Guanine Nucleotide Exchange Factor. *J. Mol. Biol.* **2006**, *359*, 35–46. [[CrossRef](#)] [[PubMed](#)]
358. Backer, S.; Lokmane, L.; Landragin, C.; Deck, M.; Garel, S.; Bloch-Gallego, E. Trio gef mediates rhoa activation downstream of slit2 and coordinates telencephalic wiring. *Development* **2018**, *145*, dev153692. [[CrossRef](#)]
359. Li, Z.; Aizenman, C.D.; Cline, H.T. Regulation of Rho GTPases by crosstalk and neuronal activity in vivo. *Neuron* **2002**, *33*, 741–750. [[CrossRef](#)]
360. Fujita, Y.; Yamashita, T. Axon growth inhibition by RhoA/ROCK in the central nervous system. *Front. Neurosci.* **2014**, *8*, 338. [[CrossRef](#)]
361. Hayashi, K.; Ohshima, T.; Mikoshiba, K. Pak1 is involved in dendrite initiation as a downstream effector of Rac1 in cortical neurons. *Mol. Cell. Neurosci.* **2002**, *20*, 579–594. [[CrossRef](#)]
362. Parrini, M.C.; Lei, M.; Harrison, S.C.; Mayer, B.J. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. *Mol. Cell* **2002**, *9*, 73–83. [[CrossRef](#)]
363. Radu, M.; Rawat, S.J.; Beeser, A.; Iliuk, A.; Tao, W.A.; Chernoff, J. ArhGAP15, a rac-specific gtpase-activating protein, plays a dual role in inhibiting small GTPase signaling. *J. Biol. Chem.* **2013**, *288*, 21117–21125. [[CrossRef](#)]
364. Nikolic, M.; Chou, M.M.; Lu, W.; Mayer, B.J.; Tsai, L.H. The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity. *Nature* **1998**, *395*, 194–198. [[CrossRef](#)]
365. Cuberos, H.; Vallée, B.; Vourc'H, P.; Tastet, J.; Andres, C.R.; Bénédicti, H. Roles of LIM kinases in central nervous system function and dysfunction. *FEBS Lett.* **2015**, *589*, 3795–3806. [[CrossRef](#)]
366. Kurita, S.; Watanabe, Y.; Gunji, E.; Ohashi, K.; Mizuno, K. Molecular dissection of the mechanisms of substrate recognition and F-actin-mediated activation of cofilin-phosphatase slingshot-1. *J. Biol. Chem.* **2008**, *283*, 32542–32552. [[CrossRef](#)]
367. Kauffman, S.A. *The Origins of Order: Self-Organization and Selection in Evolution*; Oxford University Press: Oxford, UK, 1992; pp. 61–100. [[CrossRef](#)]
368. Dupraz, S.; Hilton, B.J.; Husch, A.; Santos, T.E.; Coles, C.H.; Stern, S.; Brakebusch, C.; Bradke, F. RhoA Controls Axon Extension Independent of Specification in the Developing Brain. *Curr. Biol.* **2019**, *29*, 3874–3886. [[CrossRef](#)] [[PubMed](#)]
369. Dahl, J.P.; Wang-Dunlop, J.; Gonzales, C.; Goad, M.E.P.; Mark, R.J.; Kwak, S.P. Characterization of the WAVE1 knock-out mouse: Implications for CNS development. *J. Neurosci.* **2003**, *23*, 3343–3352. [[CrossRef](#)] [[PubMed](#)]
370. Nikolic, M.; Dudek, H.; Kwon, Y.T.; Ramos, Y.F.M.; Tsai, L.H. The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation. *Genes Dev.* **1996**, *10*, 816–825. [[CrossRef](#)]
371. Korobova, F.; Svitkina, T. Arp2/3 complex is important for filopodia formation, growth cone motility, and neuritogenesis in neuronal cells. *Mol. Biol. Cell* **2008**, *19*, 1561–1574. [[CrossRef](#)] [[PubMed](#)]
372. Varshney, P.; Dey, C.S. P21-activated kinase 2 (PAK2) regulates glucose uptake and insulin sensitivity in neuronal cells. *Mol. Cell. Endocrinol.* **2016**, *429*, 50–61. [[CrossRef](#)]
373. Huang, W.; Zhou, Z.; Asrar, S.; Henkelman, M.; Xie, W.; Jia, Z. p21-Activated Kinases 1 and 3 Control Brain Size through Coordinating Neuronal Complexity and Synaptic Properties. *Mol. Cell. Biol.* **2011**, *31*, 388–403. [[CrossRef](#)]

374. Greathouse, K.M.; Boros, B.D.; Deslauriers, J.F.; Henderson, B.W.; Curtis, K.A.; Gentry, E.G.; Herskowitz, J.H. Distinct and complementary functions of rho kinase isoforms ROCK1 and ROCK2 in prefrontal cortex structural plasticity. *Brain Struct. Funct.* **2018**, *223*, 4227–4241. [CrossRef]
375. Zamboni, V.; Armentano, M.; Berto, G.; Ciraolo, E.; Ghigo, A.; Garzotto, D.; Umbach, A.; Dicunto, F.; Parmigiani, E.; Boido, M.; et al. Hyperactivity of Rac1-GTPase pathway impairs neuritogenesis of cortical neurons by altering actin dynamics. *Sci. Rep.* **2018**, *8*, 7254. [CrossRef] [PubMed]
376. Peng, Y.J.; He, W.Q.; Tang, J.; Tao, T.; Chen, C.; Gao, Y.Q.; Zhang, W.C.; He, X.Y.; Dai, Y.Y.; Zhu, N.C.; et al. Trio is a key guanine nucleotide exchange factor coordinating regulation of the migration and morphogenesis of granule cells in the developing cerebellum. *J. Biol. Chem.* **2010**, *285*, 24834–24844. [CrossRef]
377. Powell, A.D.; Gill, K.K.; Saintot, P.P.; Jiruska, P.; Chelly, J.; Billuart, P.; Jefferys, J.G.R. Rapid reversal of impaired inhibitory and excitatory transmission but not spine dysgenesis in a mouse model of mental retardation. *J. Physiol.* **2012**, *590*, 763–776. [CrossRef]
378. Belenchi, G.C.; Gurniak, C.B.; Perlas, E.; Middei, S.; Ammassari-Teule, M.; Witke, W. N-cofilin is associated with neuronal migration disorders and cell cycle control in the cerebral cortex. *Genes Dev.* **2007**, *21*, 2347–2357. [CrossRef]
379. Gombos, R.; Migh, E.; Antal, O.; Mukherjee, A.; Jenny, A.; Mihály, J. The formin DAAM functions as molecular effector of the planar cell polarity pathway during axonal development in *Drosophila*. *J. Neurosci.* **2015**, *35*, 10154–10167. [CrossRef]
380. Sapir, T.; Levy, T.; Sakakibara, A.; Rabinkov, A.; Miyata, T.; Reiner, O. Shootin1 acts in concert with KIF20B to promote polarization of migrating neurons. *J. Neurosci.* **2013**, *33*, 11932–11948. [CrossRef]
381. Albert, R.; Othmer, H.G. The topology of the regulatory interactions predicts the expression pattern of the segment polarity genes in *Drosophila melanogaster*. *J. Theor. Biol.* **2003**, *223*, 1–18. [CrossRef]
382. Hetmanski, J.H.R.; Schwartz, J.M.; Caswell, P.T. Rationalizing Rac1 and RhoA GTPase signaling: A mathematical approach. *Small GTPases* **2018**, *9*, 224–229. [CrossRef]
383. Huang, S. Gene expression profiling, genetic networks, and cellular states: An integrating concept for tumorigenesis and drug discovery. *J. Mol. Med.* **1999**, *77*, 469–480. [CrossRef]
384. Spiridigliozzi, G.A.; Keeling, L.A.; Stefanescu, M.; Li, C.; Austin, S.; Kishnani, P.S. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up. *Mol. Genet. Metab.* **2017**, *121*, 127–137. [CrossRef]
385. Costa, R.M.; Federov, N.B.; Kogan, J.H.; Murphy, G.G.; Stern, J.; Ohno, M.; Kucherlapati, R.; Jacks, T.; Silva, A.J. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. *Nature* **2002**, *415*, 526–530. [CrossRef] [PubMed]
386. Li, W.; Cui, Y.; Kushner, S.A.; Brown, R.A.M.; Jentsch, J.D.; Frankland, P.W.; Cannon, T.D.; Silva, A.J. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of Neurofibromatosis Type 1. *Curr. Biol.* **2005**, *15*, 1961–1967. [CrossRef] [PubMed]
387. Kleschevnikov, A.M.; Belichenko, P.V.; Faizi, M.; Jacobs, L.F.; Htun, K.; Shamloo, M.; Mobley, W.C. Deficits in cognition and synaptic plasticity in a mouse model of down syndrome ameliorated by GABA B receptor antagonists. *J. Neurosci.* **2012**, *32*, 9217–9227. [CrossRef]
388. Fernandez, F.; Morishita, W.; Zuniga, E.; Nguyen, J.; Blank, M.; Malenka, R.C.; Garner, C.C. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. *Nat. Neurosci.* **2007**, *10*, 411–413. [CrossRef]
389. Rueda, N.; Flórez, J.; Martínez-Cué, C. Chronic pentylentetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. *Neurosci. Lett.* **2008**, *433*, 22–27. [CrossRef]
390. Deidda, G.; Parrini, M.; Naskar, S.; Bozarth, I.F.; Contestabile, A.; Cancedda, L. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. *Nat. Med.* **2015**, *21*, 318–326. [CrossRef]
391. Pinto, B.; Morelli, G.; Rastogi, M.; Savardi, A.; Fumagalli, A.; Petretto, A.; Bartolucci, M.; Varea, E.; Catelani, T.; Contestabile, A.; et al. Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome. *Neuron* **2020**, *108*, 887–904. [CrossRef] [PubMed]
392. Peters, M.; Bletsch, M.; Stanley, J.; Wheeler, D.; Scott, R.; Tully, T. The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice. *Neuropsychopharmacology* **2014**, *39*, 2938–2948. [CrossRef] [PubMed]
393. Alarcón, J.M.; Malleret, G.; Touzani, K.; Vronskaya, S.; Ishii, S.; Kandel, E.R.; Barco, A. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. *Neuron* **2004**, *42*, 947–959. [CrossRef] [PubMed]
394. Bjornsson, H.T.; Benjamin, J.S.; Zhang, L.; Weissman, J.; Gerber, E.E.; Chen, Y.C.; Vaurio, R.G.; Potter, M.C.; Hansen, K.D.; Dietz, H.C. Histone deacetylase inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome. *Sci. Transl. Med.* **2014**, *6*, 256ra135. [CrossRef]
395. Ehninger, D.; Han, S.; Shilyansky, C.; Zhou, Y.; Li, W.; Kwiatkowski, D.J.; Ramesh, V.; Silva, A.J. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. *Nat. Med.* **2008**, *14*, 843–848. [CrossRef]
396. Meikle, L.; Pollizzi, K.; Egnor, A.; Kramvis, I.; Lane, H.; Sahin, M.; Kwiatkowski, D.J. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. *J. Neurosci.* **2008**, *28*, 5422–5432. [CrossRef] [PubMed]
397. Parker, W.E.; Orlova, K.A.; Parker, W.H.; Birnbaum, J.F.; Krymskaya, V.P.; Goncharov, D.A.; Baybis, M.; Helfferich, J.; Okochi, K.; Strauss, K.A.; et al. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. *Sci. Transl. Med.* **2013**, *5*, 182ra53. [CrossRef]
398. U.N.L. of M.C. 2017. Available online: [govhttps://clinicaltrials.gov/show/NCT0171394](https://clinicaltrials.gov/show/NCT0171394) (accessed on 27 February 2021).

399. Veenstra-Vanderweele, J.; Blakely, R.D. Networking in autism: Leveraging genetic, biomarker and model system findings in the search for new treatments. *Neuropsychopharmacology* **2012**, *37*, 196–212. [[CrossRef](#)]
400. Vinueza Veloz, M.F.; Buijssen, R.A.M.; Willemsen, R.; Cupido, A.; Bosman, L.W.J.; Koekkoek, S.K.E.; Potters, J.W.; Oostra, B.A.; De Zeeuw, C.I. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. *Genes Brain Behav.* **2012**, *11*, 325–331. [[CrossRef](#)] [[PubMed](#)]
401. Braat, S.; Kooy, R.F. Fragile X syndrome neurobiology translates into rational therapy. *Drug Discov. Today* **2014**, *19*, 510–519. [[CrossRef](#)]
402. Dziembowska, M.; Pretto, D.I.; Janusz, A.; Kaczmarek, L.; Leigh, M.J.; Gabriel, N.; Durbin-Johnson, B.; Hagerman, R.J.; Tassone, F. High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. *Am. J. Med. Genet. Part A* **2013**, *161*, 1897–1903. [[CrossRef](#)] [[PubMed](#)]
403. Bonini, S.A.; Mastinu, A.; Ferrari-Toninelli, G.; Memo, M. Potential role of microtubule stabilizing agents in neurodevelopmental disorders. *Int. J. Mol. Sci.* **2017**, *18*, 1627. [[CrossRef](#)]
404. Marchisella, F.; Coffey, E.T.; Hollos, P. Microtubule and microtubule associated protein anomalies in psychiatric disease. *Cytoskeleton* **2016**, *73*, 596–611. [[CrossRef](#)] [[PubMed](#)]
405. Lee, V.M.Y.; Daughenbaugh, R.; Trojanowski, J.Q. Microtubule stabilizing drugs for the treatment of Alzheimer's disease. *Neurobiol. Aging* **1994**, *15*, 87–89. [[CrossRef](#)]
406. Zhang, B.; Maiti, A.; Shively, S.; Lakhani, F.; McDonald-Jones, G.; Bruce, J.; Lee, E.B.; Xie, S.X.; Joyce, S.; Li, C.; et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 227–231. [[CrossRef](#)] [[PubMed](#)]
407. Zhang, B.; Carroll, J.; Trojanowski, J.Q.; Yao, Y.; Iba, M.; Potuzak, J.S.; Hogan, A.M.L.; Xie, S.X.; Ballatore, C.; Smith, A.B.; et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and alzheimer-like pathology in an interventional study with aged tau transgenic mice. *J. Neurosci.* **2012**, *32*, 3601–3611. [[CrossRef](#)]
408. Andrieux, A.; Salin, P.; Schweitzer, A.; Bégou, M.; Pachoud, B.; Brun, P.; Gory-Fauré, S.; Kujala, P.; Suaud-Chagny, M.F.; Höfle, G.; et al. Microtubule Stabilizer Ameliorates Synaptic Function and Behavior in a Mouse Model for Schizophrenia. *Biol. Psychiatry* **2006**, *60*, 1224–1230. [[CrossRef](#)] [[PubMed](#)]
409. Rowinsky, E.K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. *Annu. Rev. Med.* **1997**, *48*, 353–374. [[CrossRef](#)]
410. Gozes, I. Activity-dependent neuroprotective protein (ADNP): From autism to Alzheimer's disease. *SpringerPlus* **2015**, *4*, 1–32. [[CrossRef](#)]
411. Levine, J.; Cohen, D.; Herman, C.; Verloes, A.; Guinchat, V.; Diaz, L.; Cravero, C.; Mandel, A.; Gozes, I. Developmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation. *J. Mol. Neurosci.* **2019**, *68*, 321–330. [[CrossRef](#)]
412. Ivashko-Pachima, Y.; Sayas, C.L.; Malishkevich, A.; Gozes, I. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: A novel avenue for protection against tauopathy. *Mol. Psychiatry* **2017**, *22*, 1335–1344. [[CrossRef](#)]
413. Chua, L.; Chong, S.A.; Pang, E.; Ng, Y.; Chan, Y.H.; Chua, L. The Effect of Risperidone on Cognitive Functioning in a Sample of Asian Patients with Schizophrenia in Singapore. *Singap. Med. J* **2001**, *42*, 243–246.
414. Troost, P.W.; Lahuis, B.E.; Steenhuis, M.P.; Ketelaars, C.E.J.; Buitelaar, J.K.; Van Engeland, H.; Scahill, L.; Minderaa, R.B.; Hoekstra, P.J. Long-term effects of risperidone in children with autism spectrum disorders: A placebo discontinuation study. *J. Am. Acad. Child Adolesc. Psychiatry* **2005**, *44*, 1137–1144. [[CrossRef](#)] [[PubMed](#)]
415. Ballatore, C.; Brunden, K.R.; Trojanowski, J.Q.; Lee, V.M.Y.; Smith, A.B. Non-Naturally Occurring Small Molecule Microtubule-Stabilizing Agents: A Potential Tactic for CNS-Directed Therapies. *ACS Chem. Neurosci.* **2017**, *8*, 5–7. [[CrossRef](#)]
416. Toba, S.; Tamura, Y.; Kumamoto, K.; Yamada, M.; Takao, K.; Hattori, S.; Miyakawa, T.; Kataoka, Y.; Azuma, M.; Hayasaka, K.; et al. Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly. *Sci. Rep.* **2013**, *3*, 1224. [[CrossRef](#)]
417. Chen, Y.K.; Chen, C.Y.; Hu, H.T.; Hsueh, Y.P. CTTNBP2, but not CTTNBP2NL, regulates dendritic spinogenesis and synaptic distribution of the striatin-PP2A complex. *Mol. Biol. Cell* **2012**, *23*, 4383–4392. [[CrossRef](#)] [[PubMed](#)]
418. Ma, X.M.; Johnson, R.C.; Mains, R.E.; Eipper, B.A. Expression of Kalirin, a neuronal GDP/GTP exchange factor of the trio family, in the central nervous system of the adult rat. *J. Comp. Neurol.* **2001**, *429*, 388–402. [[CrossRef](#)]
419. Chen, Y.; Derin, R.; Petralia, R.S.; Li, M. Actinfilin, a Brain-specific Actin-binding Protein in Postsynaptic Density. *J. Biol. Chem.* **2002**, *277*, 30495–30501. [[CrossRef](#)] [[PubMed](#)]
420. Klenchin, V.A.; Allingham, J.S.; King, R.; Tanaka, J.; Marriott, G.; Rayment, I. Trisoxazole macrolide toxins mimic the binding of actin-capping proteins to actin. *Nat. Struct. Biol.* **2003**, *10*, 1058–1063. [[CrossRef](#)] [[PubMed](#)]
421. Wang, S.; Crevenna, A.H.; Ugur, I.; Marion, A.; Antes, I.; Kazmaier, U.; Hoyer, M.; Lamb, D.C.; Gegenfurtner, F.; Kliesmete, Z.; et al. Actin stabilizing compounds show specific biological effects due to their binding mode. *Sci. Rep.* **2019**, *9*, 9731. [[CrossRef](#)]
422. Moser, C.; Rüdiger, D.; Förster, F.; Von Blume, J.; Yu, P.; Kuster, B.; Kazmaier, U.; Vollmar, A.M.; Zahler, S. Persistent inhibition of pore-based cell migration by sub-toxic doses of miuraenamamide, an actin filament stabilizer. *Sci. Rep.* **2017**, *7*, 16407. [[CrossRef](#)] [[PubMed](#)]
423. Bongmba, O.Y.N.; Martinez, L.A.; Elhardt, M.E.; Butler, K.; Tejada-Simon, M.V. Modulation of dendritic spines and synaptic function by Rac1: A possible link to Fragile X syndrome pathology. *Brain Res.* **2011**, *1399*, 79–95. [[CrossRef](#)] [[PubMed](#)]

424. Gao, Y.; Dickerson, J.B.; Guo, F.; Zheng, J.; Zheng, Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 7618–7623. [[CrossRef](#)] [[PubMed](#)]
425. Montalvo-Ortiz, B.L.; Castillo-Pichardo, L.; Hernández, E.; Humphries-Bickley, T.; De La Mota-Peynado, A.; Cubano, L.A.; Vlaar, C.P.; Dharmawardhane, S. Characterization of EHOp-016, novel small molecule inhibitor of Rac GTPase. *J. Biol. Chem.* **2012**, *287*, 13228–13238. [[CrossRef](#)]
426. Zins, K.; Lucas, T.; Reichl, P.; Abraham, D.; Aharinejad, S. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. *PLoS ONE* **2013**, *8*, e74924. [[CrossRef](#)] [[PubMed](#)]
427. Shutes, A.; Onesto, C.; Picard, V.; Leblond, B.; Schweighoffer, F.; Der, C.J. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. *J. Biol. Chem.* **2007**, *282*, 35666–35678. [[CrossRef](#)]
428. Contini, A.; Ferri, N.; Bucci, R.; Lupo, M.G.; Erba, E.; Gelmi, M.L.; Pellegrino, S. Peptide modulators of Rac1/Tiam1 protein-protein interaction: An alternative approach for cardiovascular diseases. *Pept. Sci.* **2018**, *110*, e23089. [[CrossRef](#)] [[PubMed](#)]
429. Meziane, H.; Khelifaoui, M.; Morello, N.; Hiba, B.; Calcagno, E.; Reibel-Foisset, S.; Selloum, M.; Chelly, J.; Humeau, Y.; Riet, F.; et al. Fasudil treatment in adult reverses behavioural changes and brain ventricular enlargement in Oligophrenin-1 mouse model of intellectual disability. *Hum. Mol. Genet.* **2016**, *25*, 2314–2323. [[CrossRef](#)] [[PubMed](#)]
430. De Filippis, B.; Fabbri, A.; Simone, D.; Canese, R.; Ricceri, L.; Malchiodi-Albedi, F.; Laviola, G.; Fiorentini, C. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of rett syndrome. *Neuropsychopharmacology* **2012**, *37*, 1152–1163. [[CrossRef](#)]
431. Lemichez, E.; Flatau, G.; Bruzzone, M.; Boquet, P.; Gauthier, M. Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. *Mol. Microbiol.* **1997**, *24*, 1061–1070. [[CrossRef](#)]
432. Schmidt, G.; Sehr, P.; Wilm, M.; Selzer, J.; Mann, M.; Aktories, K. Gin 63 of Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. *Nature* **1997**, *387*, 725–729. [[CrossRef](#)]
433. De Viti, S.; Martino, A.; Musilli, M.; Fiorentini, C.; Diana, G. The Rho GTPase activating CNF1 improves associative working memory for object-in-place. *Behav. Brain Res.* **2010**, *212*, 78–83. [[CrossRef](#)]
434. Diana, G.; Valentini, G.; Travaglione, S.; Falzano, L.; Pieri, M.; Zona, C.; Meschini, S.; Fabbri, A.; Fiorentini, C. Enhancement of learning and memory after activation of cerebral Rho GTPases. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 636–641. [[CrossRef](#)]
435. Guy, J.; Gan, J.; Selfridge, J.; Cobb, S.; Bird, A. Reversal of neurological defects in a mouse model of Rett syndrome. *Science* **2007**, *315*, 1143–1147. [[CrossRef](#)] [[PubMed](#)]
436. Corti, S.; Faravelli, I.; Cardano, M.; Conti, L. Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery. *Expert Opin. Drug Discov.* **2015**, *10*, 615–629. [[CrossRef](#)] [[PubMed](#)]